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Acyclic nucleotide phosphonates (ANPs) have been used for years as successful anti-viral agents against 
diseases such as HIV/AIDS and hepatitis while the drug ribavirin is one of the only drugs available for the 
treatment of RNA-viral infections which mainly affect the developing world. The large and unmet need for 
anti-RNA viral treatments has prompted this study into the design and synthesis of a range of ANPs, which 
includes a series of ribavirin-based ANP derivatives. 
The series of compounds was synthesised from a diisopropyl protected phosphonomethoxyethyl (PME) 
synthon and included an arylethynyltriazole derivative which was produced via a Sonogashira palladium 
catalysed cross-coupling reaction. A selection of these compounds was then deprotected to their 
corresponding phosphonic acids via a bromotrimethylsilane mediated phosphonate ester hydrolysis. In one 
example, a bis(pivaloyloxymethyl) prodrug variant was produced in order to probe a general synthesis for 
prodrug protected ANP derivatives. All new compounds were characterised by NMR, IR, and Mass 
spectroscopic techniques. 
A selection of the new ANP derivatives was sent to a collaborator at the University of Cagliari in Italy for 







































Review of RNA Viruses 
 
1.1 Introduction 
Neglected diseases are a group of tropical infections that are especially endemic in low income populations 
in the developing regions of Africa, Asia and the Americas,1 while an emerging infection is defined as an 
infectious disease whose incidence has increased in the past twenty years and threatens to increase further 
in the near future.2 These sometimes highly pathogenic infections are often caused by RNA viruses and they 
have devastating and often fatal consequences for the people whom they afflict. They include acute 
haemorrhagic fevers such as yellow fever, Lassa fever, Crimean-Congo fever, Ebola, Argentine 
haemorrhagic fever and Marburg haemorrhagic fever.3–6 Other well known and important RNA infections 
include: severe acute respiratory syndrome (SARS),7 dengue fever,6,8,9 West Nile virus,6,8 hantavirus 
pulmonary syndrome, Japanese encephalitis and influenza (pandemic, seasonal, avian and swine flu.).3 
Many of these viruses are also classified by the CDC (Centre for Disease Control) as category A bioterrorism 
agents due to their highly infectious nature and the lack of effective treatments against them.5 On top of 
the significant risk that RNA viruses pose to human health, foot-and-mouth disease, another RNA virus has 
the potential to devastate live-stock agriculture across the world.4 Hence, RNA viral infections pose a 
significant threat to the lives and welfare of millions of people across the globe.  
Many of these diseases have very high morbidity and mortality rates in humans4,5 claiming thousands of 
lives every year and ruining many more through disability.1 Dengue fever is considered to be one of the 
most prevalent viral diseases6, 9 due to the fact that more than half of the world’s population resides in 
areas with a high risk of dengue infection (Fig. 1.1).9 Every year there are 50-100 million reported cases of 
dengue fever and of these 250,000-500,000 cases progress to dengue haemorrhagic fever, which has been 
observed to have a case fatality rate of up to 44%.9 As an extreme example, diseases such as Ebola can have 
case fatality rates of up to 89%.10 Other haemorrhagic fevers caused by RNA viruses, such as Lassa fever 
and yellow fever are also highly prevalent in many African countries. There has been a need for dedicated 
Lassa fever wards to be set up in Sierra Leone as well as other West African countries3 and although there 
exists a highly effective single dose vaccine for yellow fever, as many as 200,000 cases of the disease are 
still reported each year3 with an estimated 5000 deaths occurring annually.11 The Figure below shows the 





Fig.1.1 The global distribution of Japanese encephalitis (JE); Murray valley encephalitis (MVE); St. Louis 
encephalitis (SLE); tick borne encephalitis (TBE); West Nile encephalitis (WNV); Yellow fever (YF) and 
Dengue fever (DEN).6 
 
At present, most of the anti-viral chemotherapies available for both DNA and RNA viruses have been 
licensed for well-known diseases such as Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and 
herpes viruses.4 Of all the currently licensed anti-viral drugs, only five are specifically used to treat non-
retroviral RNA viruses, and of these, four are used to treat influenza, namely the M2 channel inhibitors 
amantadine and rimantadine (Fig. 1.2 a and b) and the neuraminidase inhibitors oseltamivir and zanamivir4 
(Fig.2 c and d). The fifth licensed drug, Ribavirin (Fig. 1.2 e), which has been licensed for use against 
Respiratory Syncytial Virus (RSV) and Hepatitis C Virus (HCV)4 has also been used experimentally against a 
wide range of other RNA viruses including Lassa fever,4,11 hantavirus4,12 and Crimean-Congo fever4,13 but 





Fig 1.2: The chemical structures of (a) Amantadine, (b) Rimantadine, (c) Oseltamivir, (d) Zanamivir and (e) 
Ribavirin. 
There are, however, many challenges involved in the development of effective medicines for RNA viral 
infections. Many of these diseases occur in low income areas with no sustainable market to incentivise the 
pharmaceutical industry to develop drugs for these illnesses.3,4 Currently, the main source of funding for 
research into these diseases is through government research grants and private organisations.3 Although 
funding is one of the major issues responsible for retarding drug-discovery efforts for RNA viral infections, 
there are many other logistical factors influencing the development and testing of new medicines. As 
discussed by Mike Bray in his article: Highly pathogenic RNA viral infections: Challenges for antiviral 
research,3 these include: i) finding research subjects as outbreaks of these illnesses are often small, spread 
over very large geographical areas and are short lived; ii) diagnosing the disease early enough in these 
patients for any experimental treatments to be effective and iii) setting up and allowing for effective 
communication between different research groups and clinicians in the fields.3 These are all significant 
factors, which are often compounded given the fact that outbreaks of these diseases often occur in areas 
where there is no running water or stable electrical power supply, let alone adequate hospitals and 
research facilities.3 A combination of all these factors has significantly hindered the drug-discovery and 
development processes for neglected and emerging RNA viral infections thus far. 
 
1.2 Virus Biology and Life-cycle. 
In all drug-discovery efforts, it is important to understand the biology of the target disease in order to 
effectively identify biological targets for potential drugs as well as the possible mechanism of action of any 
hits or leads. The rest of this chapter will serve as an introduction to the basic biology and virology of RNA 
viruses as well as to give an account of some of the successful small-molecule chemotherapies that have 
been used to treat these illnesses and how those treatments work. This sub-section aims to demonstrate 
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how the important viral interactions and processes, which are relevant to this research, fit into the overall 
life-cycle of a generalized model virus. 
All viruses are incapable of reproducing on their own and thus have to infect a host cell and commandeer 
its cellular machinery in order to replicate.14,15 The various viruses and viral families all have different 
strategies for entering their hosts in order to use the cell’s enzymes and components to replicate; however, 
most viruses share the same general life-cycle as shown below (Fig. 1.3). The first step of this process 
involves the entry of the virion into the cell. While different viruses utilise a host of different mechanisms in 
order to get their genetic material into the cell, enveloped viruses enter their hosts via the interaction of 
the viral envelope proteins with receptors on the surface of the host cell. This then leads to the fusing of 
the virus’ outer membrane (envelope) with the cell’s own membrane allowing the genetic material of the 
virus (often coated in a protein capsid) to enter the cytoplasm of the host. Non-enveloped viruses enter the 
host cell via other mechanisms as they do not possess an envelope that can fuse with the host cell. If the 
virus’s genetic material is contained in a protein capsid, then the next step is the uncoating of the capsid 
from the viral genetic information. Once the viral genetic material is free within the cell, the replication of 
the viral genome and the biosynthesis of the various viral components can begin. After the viral genome 
has been copied and the correct viral proteins have been synthesised, the assembly of the new virus capsid 
can begin. Viral envelope proteins assemble on the outer membrane of the infected cell and as the new 
progeny virus emerges from its host it tears away a piece of the cell’s membrane. This process happens 
multiple times per cell and this eventually leads to cell death. 
 
Fig. 1.3: General life-cycle of a typical virus showing: (a) initial interaction, (b) entry, (c) genome replication, 






1.3 Targets for Drug Discovery 
The viral life-cycle presents a diverse array of targets for drug-discovery and development.4 The entry of the 
viral particle into the cell, fusion of the viral membrane with the cell membrane, the uncoating and 
replication of the viral genome, the translation and processing of the viral proteins, the assembly of new 
viruses and the emergence and maturation of the progeny virus have all been considered and researched 
as potential targets for small-molecule inhibitors.4 Many of these targets have been exploited in the past by 
a whole range of successful chemotherapies that have been used to treat well-known illnesses such as 
influenza and HIV. 
The initial virus-cell interaction is an attractive although relatively newly discovered target for interfering 
with the viral life-cycle and in the case of HIV this is fairly well characterised.17 Maraviroc (Fig. 1.4) is a CCR5 
antagonist that qualifies as an entry inhibitor, and which disrupts the recognition process between HIV’s 
surface gp120 protein and the host-cell receptor CCR5.17,18 The disruption of this interaction prevents the 
next step in the entry process from taking place, whereby the virus and cell membrane fuse. Similarly 
enfuvirtide (Fig. 1.4), otherwise known as Fuzeon, has been developed to prevent the fusion process from 
taking place. Enfuvirtide is a synthetically produced 36 amino acid polypeptide based on an amino acid 
sequence in the N-domain that has been designed to complement a peptide sequence of a hydrophobic 
groove in the C-domain of the HIV gp41 protein.18,19 When bound in this position, which is only exposed 
when gp41 folds outward into the host cell’s lipid membrane, gp41 is prevented from folding back onto 
itself to form a six helix bundle, thus preventing membrane fusion from taking place.19  
 
 
Fig. 1.4: The chemical structures of Maraviroc18 and the amino acid sequence of enfuvirtide (fuzeon).18 
The next phase in the virus’ life cycle requires that the protein capsid surrounding the viral genetic material 
be removed in order for transcription and translation to take place. In the case of the influenza virus, M2 
channels allow the unidirectional passage of protons from the host cell’s cytoplasm, into the viral 
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envelope.4 The drop in pH on the inside of the viral particle causes key viral envelope protein interactions 
to become destabilized thus initiating the uncoating process and exposing the contents of the virus capsid 
to the cytoplasm of the host cell.4 The M2 channel inhibitors amantadine (fig. 1.2 a) and rimantadine (Fig. 
1.2 b) have been successfully employed to block the passage of protons into the virus, hence preventing the 
uncoating process from taking place.4 
The synthesis and subsequent modification of viral proteins from the viral genome has also been viewed as 
a potential target for anti-viral drug development.4 Unfortunately, as the actual translation process for all 
viruses makes use of cellular machinery, inhibition of the enzymes and ribosomes that perform these tasks 
may also interfere with that normal functioning of the cell.14,15 All RNA viruses, however, have polycistronic 
genomes, meaning that the single mRNA strand that is synthesised from the genome codes for multiple 
proteins.14 This causes a problem for the virus in that the ribosomes that translate the genetic information 
into proteins can only deal with monocistronic messages.14 (For every strand of mRNA that is translated 
one continuous polypeptide chain is synthesised repeatedly.) The result of this is that the viral mRNA gets 
translated into one polypeptide chain which contains the sequence information for multiple proteins. Most 
RNA viruses deal with this problem by having a protease enzyme that can selectively hydrolyse the 
polypeptide into the functional protein subunits.4,14,15 The HIV and HCV protease enzymes have been well 
studied and there are multiple licensed drugs that act as substrate transition-state analogues against these 
important enzymes.7,17,20 These include ritonavir, saquinavir, indinavir and nelfinavir.7 Lopinavir or ritonavir 
may be prescribed as the protease component of Highly Active Anti-Retroviral Treatment (HAART). 
The assembly of the progeny virus is another vital step in the virus’ reproductive pathway. There are a few 
inhibitors of this process that are currently in early development, but in the case of most RNA viruses this 
process is not well understood4. Viral assembly thus remains a potentially rich research area for future drug 
discovery efforts. 
After the viral particle has been assembled, it must leave the cell in order to infect others. There are 
numerous biochemical processes that are vital to the budding, exit and detachment of the virus from the 
cell. One of the most well understood processes of viral exit is that which involves the neuraminidase 
enzyme of the influenza virus.7 Once the Influenza virus has left the cell, viral hemagglutinin interacts with 
the N-acetylneuraminic acid (NANA)-bearing glycoprotein receptor on the cell’s surface which prevents the 
virus from breaking away from the cells surface.4 The viral neuraminidase inhibitor is responsible for 
cleaving the NANA from the host cell-surface glycoprotein, thus releasing the virus into the extracellular 
matrix in order to infect more cells. Oseltamivir (tamiflu) and zanamivir (relenza) (Fig. 1.2 c and d) are two 
widely used drugs that inhibit the action of the neuraminidase enzyme.4 They, like protease inhibitors of 
HIV, have been designed as transition-state analogues of the natural substrate.4 
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One of the most studied, most promising and currently most pharmaceutically exploited stages in the viral 
life cycle is the replication of the viral genome. This process presents many possible molecular targets for 
drug discovery;4,8 however, as different viruses all have slightly different strategies for replicating and 
transcribing their genomes, one needs to understand what differentiates the various viral classes and 
mechanisms of genome replication in order to better design and discover new drugs against them.  
 
1.4 Genome Replication as a Target for Drug-Discovery 
All viruses need to synthesize messenger RNA (mRNA) in order to use the cellular machinery for translation 
of their genetic information into viral proteins that can then assemble into thousands of new replicas of the 
original virus.14,15 mRNA is defined as positive strand [(+)RNA] as it contains the genetic information in a 
form that is directly translatable into new viral proteins.15 The Baltimore classification system categorises 
viruses based on the strategy that they use to replicate their own genomes and synthesise mRNA (Fig. 1.5). 
14,15,21 From this classification system, two broad classes of virus emerge: DNA viruses (classes I and II), 
which synthesise mRNA from a DNA genome, and RNA viruses (Classes III, IV, V and VI), which synthesise 
mRNA from an RNA genome. Retroviruses (Class VI) are often considered as a special case of RNA virus, as 
they synthesise mRNA from intermediate DNA which has been reverse-transcribed from an RNA 
genome.15,21 Retroviruses and their strategies of replication, cellular entry, construction and emergence 
have been well studied as they include the well-known and highly prevalent human immunodeficiency virus 
(HIV). 
 
Fig. 1.5: The Baltimore classification as originally reviewed by D.Baltimore.21 
 
DNA viruses exhibit a much greater diversity in size, shape and structural complexity than RNA viruses. DNA 
viruses contain their genetic information in either closed circular DNA loops or in some cases as linear DNA 
strands.14 Owing to the fact that their genomes exist in the same form that the host cell contains its genetic 
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code, the DNA virus is able to use the normal cellular machinery in order to transcribe and translate its 
genome into viral proteins. For this reason they have had to develop fewer biologically “novel” or 
“unusual” replication strategies relative to their RNA-containing counterparts.14 DNA viruses must also use 
the cell’s mechanism of DNA synthesis in order to replicate their genomes.14,15 This creates a complication 
for the virus as most cells only produce the enzymes and components required for DNA replication when 
they are about to divide naturally.14 Many DNA viruses have developed strategies to deal with this problem 
such as containing the genetic information to activate the cell-division phase or by simply producing the 
required enzymes, proteins and primers themselves.14,15 Some well-known examples of DNA viruses include 
adenovirus (conjunctivitis, tonsillitis and gastroenteritis), herpes simplex virus, hepatitis B and smallpox,14 
which killed thousands of people every year until an effective vaccine was developed against it.  
RNA viruses do not contain their genetic information in the same form as that of the host cell and, as a 
result, are unable to use the host cell’s machinery directly to synthesise mRNA or replicate their genomes. 
They have hence had to develop “novel” strategies in order to perform this task, almost always involving 
enzymes which are able to polymerise new genetic molecules from an RNA template.14 These RNA-
dependent RNA-polymerases (RdRp’s) are viral enzymes that synthesise viral RNA strands from a viral RNA 
template, and are vital to the ability of the RNA virus to reproduce. These enzymes are absent in eukaryotic 
cells8,22 and thus have to either be carried into the cell by the viral particle or, if the viral genome can act 
directly as mRNA, translated and synthesised de novo within the cell.14,15 From the Baltimore classification 
(Fig 1.5) system, Class IV [(+)ssRNA] viruses are able to use their genomes directly as mRNA and are hence 
able to synthesise their RdRps de novo.14,15 Class V [(-)ssRNA)] viruses, however, need to carry the necessary 
RdRp into the cell in order replicate and synthesise mRNA as the (-) strand RNA is not directly transcribable. 
RdRps therefore play a vital part in the life-cycle of the RNA virus, further promoting them as attractive 
targets for drug discovery.8,23 
Class VI RNA viruses, otherwise known as retroviruses, are a special case as they reproduce their genomes 
via a DNA intermediate. Unlike other RNA viruses, they use an RNA-dependent-DNA-polymerase (RdDp), 
known as a reverse transcriptase (RT) enzyme, to transcribe their genome from an RNA Template into 
DNA.14,15,24 Furthermore, reverse transcriptase can then act as a DNA-dependent DNA-polymerase, creating 
a second DNA strand to complement the first, in order to form the required double stranded DNA (dsDNA) 
that can then be integrated into the host cell’s genome and used for mRNA synthesis.24  
HIV RT has also been shown to possess RNase-H activity. Until recently, it was thought that all the effective 
drugs against HIV RT have targeted only the polymerase activity of the enzyme24 but recent evidence 
suggests that certain Non-Nucleoside Reverse-Transcriptase inhibitors do in fact interfere with the 
enzyme’s RNase-H activity.25 The HIV reverse transcriptase enzyme has been well studied and has been 
used as the target for many successful anti-retroviral drugs. Thus, the success of past drug-discovery efforts 
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against HIV reverse transcriptase and other viral polymerases continues to justify the continued exploration 
of RdRps as potential targets for new anti-viral drugs.7,8 For this reason, HIV RT acts an important model for 
understanding and manipulating other viral polynucleotide polymerases. 
 
1.5 Viral polymerases as targets for drug discovery 
RdRps produce new RNA molecules from RNA templates, a process which does not occur naturally in 
animal cells. This makes RNA virus RdRps very attractive targets for new selective drugs.23 There is still not 
the same level of structural and mechanistic understanding available for the viral polymerases of RNA 
viruses as there is for HIV and other retroviruses. However, there is an increasing amount of information 
available for different RdRps across a wide range of viral species including hepatitis C virus (HCV), dengue 
virus (DENV), West Nile Virus (WNV), poliovirus (PV) and foot and mouth disease virus (FMDV).8,20,23 The X-
ray crystal structures of HCV non-structural protein 5B (NS5B) RNA-dependent RNA-polymerase (Fig. 1.6)20 
and WNV RdRp are shown below (Fig. 1.7).8 Unlike most other polynucleotide polymerases, which possess 
an “open-hand” or U shaped structure, RdRps have a general “closed hand” structure, where the active site 
of the enzyme is completely enclosed by “thumb and finger” domains of the protein forming a channel-like 
structure in which the template RNA molecule can bind.23 This channel aids in guiding the template towards 
the active site of the enzyme. There also exists a small positively charged tunnel on the back end of the 
enzyme which helps bring the negatively charged activated nucleotides into the active site.23 Of all the 
different RdRps that are known and studied, the RdRp of HCV is one of the most understood. X-ray crystal 
structures of the HCV non-structural protein 5B (NS5B) RNA-dependent RNA-polymerase have shown the 
presence of numerous potential binding sights and pockets which may all provide potential drug-discovery 







Fig. 1.6: The structure of HCV non-structural protein 5B (NS5B) RNA- dependent RNA-polymerase as 
reviewed by De Francesco et al.20 Possible allosteric binding sites are also indicated.20 
 
 
Fig. 1.7: The Structure of West Nile Virus RNA- dependent RNA-polymerase as reviewed by Malet et al.8 
Note the formation of the “closed Hand” structure by the “thumb” and “finger domains” of the protein. 
 
As in the case of the two well-known classes of anti-retroviral drugs against HIV RT, namely Nucleoside 
Reverse Transcriptase inhibitors (NRTIs) and Non-nucleoside Reverse Transcriptase inhibitors (NNRTIs),7,25 
inhibitors of RNA viral RdRps can be largely divided into two classes based on chemical structure: 
Nucleoside Inhibitors (NIs) and Non-Nucleoside Inhibitors (NNIs) (Fig. 1.8).8,23 Generally, NIs are analogues 
of natural nucleosides that target the active site of an enzyme, either blocking a biosynthetic pathway 
involving a nucleoside, or mutating or terminating the growing strand of genetic material.8,23 Most NIs, 
especially in the case of HIV NRTIs, act as chain terminators as they lack a hydroxyl group at the 3’ position 
on the ribose ring, which is required for chain elongation.26 By comparison, NNIs are small-molecule 
inhibitors that are not nucleoside analogues, and as such, act at allosteric binding sites separate from the 
active site of a RdRp.8,23 These allosteric interactions cause (or in some cases block) a conformational 
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change in the enzyme that results in disruption of normal activity at the active site. In the case of HCV, high-
throughput screening has yielded a series of viable NNIs that are currently undergoing clinical trials (Fig. 
1.8).20,23 The rational design of nucleoside analogues, NIs, has also yielded successful candidates for clinical 







































Fig. 1.8 Nucleoside Inhibitors (NI’s) and Non-Nucleoside Inhibitors (NNIs) against HIV (AZT, 3TC, Etravirine 
and Nevirapine) and HCV (Valopicitabine, 4’-azido-cytidine, piranoindole derivative (HCV-371) and the 
pyrrolidine acid derivative).20 
 
1.6 Ribavirin and T-705 (Favipiravir) 
As was discussed earlier in this review, the number of active, approved compounds for the treatment of 
RNA viruses is disappointingly limited and all the drugs discussed thus far have been approved for a 
relatively small number of infections namely HIV, HCV and influenza. At present the only drug that has been 
approved for the treatment of RNA viruses other than influenza (not including retroviruses) is the 
nucleoside-based inhibitor Ribavirin. Owing to its particular relevance to the work described later in this 
thesis, its history, and proposed mechanism of action will be discussed in this subsection. Favipiravir, 
another potent, structurally unique nucleoside analogue, with strong, broad-spectrum activity against RNA 




The activity and structure of the nucleoside analogue ribavirin was first reported in the early 1970s and it 
was hailed as the first synthetic, non-natural nucleoside analogue to possess broad-spectrum activity 
against a large range of RNA viruses.4,27 In fact, ribavirin has over the years been shown to be active against 
virtually all RNA viruses with varying degrees of potency;28 however, overall the potency of ribavirin can be 
considered to be low, with most EC50 values above 1µM.
4 This means that any clinical treatment regime 
involves high doses of the drug with adverse side-effects.29 
 Like all cyclic nucleoside analogues, ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3- carboxamide, or virazole 
as it is less commonly known),27,28 consists of a sugar ring (in this case D-ribofuranose) coupled to a 
heterocyclic nitrogen base (Fig. 1.9). What makes ribavirin structurally unique is its non-natural, 1H-1,2,4-
triazole-3- carboxamide base, which, depending on the orientation of the amide, can be analogous to either 
of the naturally occurring purine bases, adenine or guanine (Fig. 1.9). It is also important to note the 
presence of a hydroxyl group at the 3’ position of the sugar ring, a feature which is invariably absent in 
most other chain-terminating nucleoside inhibitors (see above), suggesting that ribavirin does not act by 
































Fig. 1.9: The structure of Ribavirin27 as well as the structural relationship of its conformers to both adenine 
and guanine. 
 
Even after nearly 40 years as the main drug available for the treatment of RNA virus infection, ribavirin’s 
mechanism of action is still a topic of much debate.4 There are currently 5 main mechanisms by which it is 
thought to elicit its activity. The first is as an inhibitor of inosine monophosphate dehydrogenase (IMPDH), 
which is an important enzyme in the de novo biosynthesis of guanine nucleotides.28 The inhibition of 
IMPDH leads to the depletion of cellular guanine triphosphate (GTP), which the virus needs in order to 
replicate its genome;4,28 however, recent research involving the use of other potent IMPDH inhibitors, such 
as mycophenolic acid,29 has shown that although RNA viruses do seem to be sensitive to the depletion of 
GTP pools within the cell, this is not the main mechanism by which ribavirin shows its activity.30 
The second proposed mechanism by which ribavirin is thought to act is as an immunomodulator, where it is 
thought to maintain the T-helper type-1 response which is associated with cellular immunity.28 This 
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mechanism was proposed to explain why Lassa fever patients, who were treated with ribavirin, showed 
significantly less liver damage relative to other patients who were not, yet showed little to no decrease in 
their viral load.29 The current view is that this effect is minimal and does not account for the majority of 
ribavirin’s anti-viral activity.28,29 The third mechanism involves the inhibition of the enzymes which are 
responsible for capping and stabilizing the 5’-end of viral RNA; however, not all viruses make use of such 
capping structures and therefore this proposed mechanism of action fails to explain the broad-spectrum of 
anti-viral activity exhibited by ribavirin.28  
Ribavirin 5’-triphosphate is also thought to directly inhibit the formation of RNA viral genetic material by 
inhibiting the function of various viral RdRp’s.4,28Specifically, Ribavirin 5’-triphosphate has been shown to 
bind to, and inhibit, the active site of the both HCV and Influenza RdRP,31,32 (in order for nucleosides to 
become active metabolites of polynucleotide polymerases, they need to be converted to their 
corresponding 5’-triphosphate species. This process is described in greater depth in chapter 2.1.) The most 
current view on ribavirin’s mechanism of action is not that ribavirin 5’-triphosphate inhibits RdRps, but that 
it is rather incorporated by the RdRp into the new viral genome. The incorporation of the ribavirin 
nucleotide was always speculated, but only in 2000 did Crotty et al. produce strong evidence to determine 
that ribavirin 5’-triphosphate is indeed, although at a low rate, incorporated into the viral genome by a 
variety of different viral RdRp’s.4,28,33 More importantly, the study showed that because of ribavirin’s ability 
to mimic both adenine and guanine,29 it can be a template for both cytidine and uridine nucleic acids when 
new RNA is synthesised from the strand containing the incorporated ribavirin (Fig. 1.10).28,33 This eventually 
leads to a lethal build-up of errors in the viral RNA sequence causing the newly synthesised viral genome to 
lose its genetic fidelity, rendering the new genome useless, a process which is termed “error catastrophe” 
(Fig. 1.10).4,29,33 Through evolution most cellular organisms have developed complex mechanisms to correct 
errors in their genetic material and thus avoid error catastrophe, while viruses have not and are hence 
susceptible to mutations.29 This can be advantageous for the virus in terms of its development of resistance 
to certain drugs, as well as its general evolution, but it also makes them vulnerable to events like error 





Fig. 1.10: The left shows the hydrogen-bonding patterns of ribavirin to cytidine and uridine.28 The diagram 
on the right shows how ribavirin causes the build-up of nucleotide errors which leads to error catastrophe. 
 
1.6.2 T-705 (Favipiravir) 
The pyrazinecarboxamides T-705, T-1105 and T-1106 (Fig. 1.11) were first synthesised by the Toyama 
chemical company, Ltd., from which T-1105 was identified as a potential lead with anti-viral activity against 
influenza virus.34 Derivatives of this compound were then synthesised which led to the discovery of T-705, 
now also known as favipiravir, which shows broad spectrum anti-viral activity.6 T-705 was originally found 
to show high activity against Influenza6,34,35 and has since also been shown to posses high activity against 
various bunyaviruses and arenaviruses,36,37 as well as phlebovirus,38 West Nile virus,39 yellow fever40 and 
foot-and-mouth disease34 infections. T-705 has so far proved so effective over such a broad range of viruses 



























T-705 has been shown to be a nucleoside analogue and RNA polymerase inhibitor6,34 even though 
unmodified, on a structural level, it does not resemble the general nucleoside structure. Once it has 
entered the cell it is converted to its corresponding ribonucleotide monophosphate by a phosphoribosyl 
transferase, after which it is then further phosphorylated to its ribonucleotide triphosphate, which is the 
active species (Fig. 1.12).6 T-705 (and T-1106) have been said to be structurally analogous to ribavirin, 
especially with regard to the importance of the presence of the amide at the 3-position,6 suggesting that T-
705 could have multiple hydrogen bonding profiles, as is the case in ribavirin. These types of ambiguous 
nucleotide bases have been termed universal bases, as reviewed by Loakes,41 in that they possess the 
ability to pair with multiple natural nucleotide bases. Universal bases may hold an interesting place in the 
























Fig. 1.12: The Conversion of T-705 to T-705 ribofuranosyl triphosphate. 
 
Given the past success of nucleoside-analogues such as nucleoside-based HIV reverse transcriptase 
inhibitors, ribavirin and favipiravir and the continued promise that these types of drugs show as selective 
inhibitors against RdRps in RNA viruses, as well as their particular relevance to this project, the next chapter 
of this thesis will focus on NIs (specifically acyclic nucleotide phosphonates): their inception, development, 












Acyclic Nucleotide Phosphonates: design, development and evolution.  
2.1 Introduction 
Nucleoside analogues were first identified as potentially important chemotherapeutic agents in the 1960s 
when they where first used in the treatment of cancer and later for the treatment of viral infections.42,43 
They were seen to act as “anti-metabolites”,42 interfering with the tumour cell’s natural mechanisms of 
genome replication. All natural nucleosides, both RNA and DNA monomers, show the same basic structural 
features involving a heterocyclic base attached to an aldopentofuranose (ribose) sugar moiety (Fig. 2.1a). In 
order for the nucleoside to become an active metabolite it needs to be transformed by cellular kinases into 
its corresponding 5’-triphosphate nucleotide (nucleotides are the 5’-phosphoric acid esters of nucleosides) 
(Fig. 2.1d). Only then can it be incorporated into a growing strand of genetic material by the relevant 
nucleoside polymerases.25,42 The same process applies for nucleoside analogues, as the majority of them 
act by being incorporated into a growing strand of genetic material, either terminating its growth or 
causing it to mutate.25,29,42 The initial phosphorylation of a nucleoside to its corresponding 5’-
monophosphate (Fig. 2.1b) has been shown to be the rate-determining step in the biosynthetic pathway to 
the active 5’-triphosphate and as such, many nucleoside analogues show poor biological activity simply 
because of their lack of initial phosphorylation.42 This problem started the pursuit of phosphorous-modified 
nucleotide analogues, in which a phosphorus atom was built into the drug molecule as a way to eliminate 
the need for the initial rate-determining, intracellular phosphorylation step.42–44 
 
 
Fig. 2.1: The conversion of a nucleoside to 5’-triphosphate nucleotide. The aldopentofuranose sugar is 
shown in red, the heterocyclic base in blue and the phosphates in purple. 
 
Given the high toxicity of these nucleoside and nucleotide analogues, detailed studies on the effect of 
modification of both the heterocyclic base and sugar moieties where carried out.42 The results of these 
studies drew a number of important conclusions pertaining to the design of future nucleoside and 
nucleotide derivatives: i) The modification of the heterocyclic base has a marked effect on the relevant 
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anabolic reactions within the cell, which do not tolerate much variation in the structure of the substrates; 
however, modification of the base does not show a significant effect on catabolic processes involving the 
drug molecule.42,45 This is most likely due to the importance of strong nucleotide base-pair hydrogen-
bonding interactions in the construction of new genetic material ii) New nucleotide analogues which were 
designed to closely mimic the natural substrates were found to be catabolically unstable due to the labile 
nature of the phosphorus-oxygen bond of the phosphoric acid ester (Fig. 2.2).42–44 The overall stability of 
new nucleotide analogues needed to be increased through the modification of key linkages such as the 
phosphoric acid ester in the 5’-monophosphate.42 iii) Any phosphorus-modified derivatives had to be 
isopolar to the natural 5’-monophosphate substrates, meaning that the electronic profiles of any 
nucleotide derivatives had to be similar to those of natural nucleotides.42,43 Another goal of these studies 
was to reduce the structural features required for enzyme binding and thus a variety of acyclic nucleosides 
and nucleotides were developed (Fig. 2.3).42 These studies laid the ground work and provided a platform 
for the development of a wide range of acyclic nucleosides, which would eventually lead to the discovery of 































































































Fig. 2.3: The relationships of some well known acyclic nucleosides and nucleotides to a standard natural 
nucleoside. 
 
2.2 Acyclic Nucleotide Phosphonates 
The alkyl chain of acyclovir, one of the first and most successful acyclic nucleosides, has a clear yet 
truncated structural correlation to the carbohydrate ring in natural nucleosides.42,45 If one simply removes 
the part of the ring highlighted in red in a natural nucleotide (Fig. 2.3), one is left with the alkyl chain 
moiety that is present in acyclovir. The success of acyclovir provided a strong case for the further 
development of acyclic nucleosides, and shortly after its discovery, De Clercq et al.46 discovered the highly 
active (S)-9-(2,3-dihydroxypropyl)adenine (DHPA) (Fig. 2.3), which although having a slightly different 
mechanism of action to acyclovir, provided a strong starting point for the development of future nucleotide 
analogues.42,47 The advantage of acyclic nucleosides like acyclovir and DHPA lies in the flexibility of their 
side chains which (due to the non-constrained nature of their sp3 hybridized carbons) can easily adopt any 
conformation suitable for forming a strong interaction with the active site of the target enzyme.42 The 
disadvantage with such drugs again lies in the problem of a slow initial phosphorylation as well as the labile 
nature of the phosphate group. 
It was from this point onwards that phosphonate derivatives of bioactive molecules such as DHPA were 
investigated as a way of building a catabolically stable phosphate-like group into a drug while maintaining 
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its isopolarity with naturally occurring nucleosides.42 This led to the introduction of a completely new class 
of nucleotide analogues named Acyclic Nucleotide Phosphonates or ANPs. The key feature of ANPs, relative 
to other nucleotide analogues, is the replacement of the labile phosphoric acid ester linkage (P-O-CH2) with 
a non-cleavable phosphonate moiety (P-CH2-O),
42,44,47 circumventing the need for the drug to be mono-
phosphorylated before it is di- and then tri-phosphorylated. This has the effect of increasing the drug’s 
biological activity; and because the phosphonate group cannot be cleaved by intracellular esterases, the 
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Fig. 2.4: The key structure-activity relationships of the well-known acyclic nucleotide phosphonate, 
adefovir. 
 
ANPs act in a similar way to other nucleoside polymerase inhibitors in that once they are di-phosphorylated 
(tri-phosphorylated in the case of nucleoside inhibitors), they are used as substrate molecules by the target 
nucleotide polymerase and are incorporated into a growing chain of genetic material. The growth of the 
chain is then terminated as the drug molecule lacks the functionality required for attachments of additional 
nucleotides. The diagram shown in Fig. 2.5 has been modified from a review by de Clercq et al.42 and 
depicts this process with regard to the HIV reverse-transcriptase inhibitor adefovir. As all viruses depend on 
some form of viral polymerase in order to reproduce their genomes, the ANPs cidofovir, tenofovir and/or 
adefovir have been shown to possess broad spectrum anti-viral activity against all DNA and retroviruses,42 
making ANPs an excellent class of anti-viral agent for future drug discovery efforts against RNA viruses. Due 
to the catabolic stability that the built-in phosphonate group provides to the di- and tri-phosphorylated 
ANP derivative, the ANPs cidofovir, adefovir and tenofovir remain active within the cell for much longer 
than their acyclic nucleoside counterparts acyclovir and DHPA.42,48,49 This means that the drugs have to be 
administered to the patient much less frequently, in some cases with a dose interval of up to a week.42 It is 




Fig. 2.5: The di-phosphorylation of adefovir, its incorporation into a growing chain of genetic material and 
the method by which it terminates chain growth. Taken and modified from the 2005 review article in 
Nature by de Clercq et al.42 
 
2.3 Prodrugs of Acyclic Nucleoside phosphonates 
As summarised by Lee et al.,44 the effective overall potency of an ANP is a combination of its ease of 
phosphorylation by host phosphorylases, its catabolic stability, the metabolic stability of its mono and di-
phosphonate species, its intrinsic affinity for and activity against the viral polymerase and its overall ability 
to permeate the host cell’s membrane. The phosphonic acid nature of the acyclic nucleotide phosphonates, 
(Fig. 2.4), means that the drug molecule is very polar and unable to move easily through the membrane of 
the host cell, in fact becoming negatively charged at physiological pH.50 The drug therefore cannot 
accumulate within the target cell to a high enough concentration to become biologically effective, and also 
suffers from the problem of very low oral bioavailability.51 This unfortunately may mean that many 
potentially active, polar nucleotide analogues may have been discarded from the drug-discovery process 
due to their inability to cross the cell membrane during in vivo testing. To combat this problem, non-polar, 
degradable lipophilic prodrug moieties such as various phosphoramidate prodrugs43,51–53(Fig. 2.6) and 
various ester moieities47,54 including salicylate esters43,53, alkoxyalkyl esters43,51,55,56, acyloxyalkyl esters,51,54 
alkyloxycarbonyloxyalkyl esters51,54 and cyclosaligenyl prodrugs,50,51 have been introduced in order to 
conceal the charge of the phosphonate as a neutral phosphonate diester.44,54 Many in vitro studies have 
shown marked increases, of 10 to 100 fold, in the anti-viral activity of ANPs where there is a prodrug moiety 































Fig. 2.6: Two different acyclic nucleotide analogue phosphoramidate prodrugs.53 
In order for the prodrug to be successful, it needs to be chemically stable enough to survive passage 
through the gastrointestinal tract (GI) (in the case of orally administered drugs), absorption into the blood 
stream and then survive long enough to be distributed into the target cells.51 To achieve this, the drug 
needs to be both water soluble and yet lipophilic enough to pass through the cell membrane. Once the 
prodrug has entered the cell it must then be easily degraded to expose the active phosphonic acid for 
phosphorylation to the active species. Alkyl esters of phosphonate and phosphates have been shown to be 
relatively catabolically stable and as such cannot be used as effective prodrugs;51 therefore prodrugs need 
to be developed that are both stable in the extracellular environment and yet susceptible to degradation by 
cellular enzymes once they have entered the cell.  
One of the most commonly used classes of phosphonate prodrugs are the acyloxyalkyl and 
alkyloxycarbonyloxyalkyl phosphonate esters. These molecules feature a carboxylate or carbonate ester 
that can be easily cleaved by a cellular esterase to yield a hydroxymethyl intermediate that quickly 
degrades through the loss of formaldehyde to expose the phosphonic acid (Fig. 2.7).51,54,57 The release of 
formaldehyde during the decomposition of these drugs is of concern; however, it is thought to be a minor 
one due to the relatively large exposure to formaldehyde as a by-product from metabolised methanol 
which is present (in small quantities) in the average human diet.51 The presence of formaldehyde and other 
byproducts such as pivalic acid (generated from the degradation of pivaloyloxymethyl prodrugs) may also 
present a problem, especially when high doses of the drugs are involved; however, two well-known 
commercially available drugs fall into this class of prodrug. Adefovir dipivoxil and tenofovir disoproxil 
fumarate (Fig. 2.8), where their respective phosphonates have been converted to the 
bis(pivaloyloxymethyl) (POM) and bis(isopropyloxycarbonyloxymethyl) (POC) phosphonate esters, have 

































































Adefovir dipivoxil Tenofovir disoproxil fumarate
 
Fig. 2.8: The commercially available prodrug versions of adefovir (adefovir dipivoxil) and tenofovir 
(tenofovir disoproxil fumarate).54 
 
Another promising relatively new type of ANP prodrug that was originally applied to nucleotide phosphate 
versions of the successful nucleoside NRTI d4T,58 involves the cyclisation of 2-(hydroxymethyl)phenol on 
the phosphonate group of the ANP (Fig. 2.9). These prodrugs are referred to by their inventor, Professor 
Chris Meier of the University of Hamburg, as cyclosaligenyl or cycloSal prodrugs.58 This class of prodrug 
does not achieve degradation through the enzymatic cleavage of key bonds but rather by the optimized 
chemical decomposition of the prodrug to its phosphonic acid.51,58 The first step in the degradation process 
is the pH-sensitive, selective hydrolysis of the phosphonic acid aryl ester, which is followed by the rapid 
decomposition of the O-hydroxybenzyl intermediate to yield the active phosphonic acid (Fig. 2.9).51,58 This 
approach suffers from many disadvantages, including the degradation and clearance of most of the drug 
from the system before it can enter the cell as well as the risk that solid-state forms of the drug may 




















Fig. 2.9: The mechanism of cleavage of cycloSal-based prodrugs. 51 
Subsequent generations of cycloSal prodrugs have involved the addition of esters which may be 
enzymaticlly cleaved once in the cell in order to increase the intracellular concentration of the drug,51,59 as 
well as the modification of the rate at which the prodrug cleaves via the addition of electron-withdrawing 
groups to the aromatic ring (Fig. 2.10).51,60 CycloSal prodrugs have been successfully applied to many 
nucleotide analogues including d4T and the ANP adefovir (Fig. 2.10); however, no in vivo studies have yet 
been carried out on this class of prodrug.51 The synthesis of a generalized cycloSal ANP from a phosphonate 























































R i), ii), iii)
R = Et, i-Pr  
Fig. 2.11. The synthesis of cycloDal ANP’s: reagents and conditions: i) TMSBr, pyridine, CH3CN, rt, 16 hr; ii) 
PCl5, CH2Cl2, rt, 2.5 hr; iii) Salicyl alcohol.
50 
There is currently much ongoing research into the prodrug versions of many cyclic ANP derivatives of DHPA 
such as HPMPC, in which the phosphonate phosphorus atom is bonded with a primary alcohol present in 
the side chain that forms a six-membered ring with the remaining phosphonic acid OH group masked as an 















































Fig. 2.12: The structures of HPMPC, its cyclised version (cHPMPC) as well as phosphoramidate and salicylate 
prodrug versions of cHPMPC.53 
 
2.4 Future generations of acyclic nucleotide phosphonates 
As mentioned before, studies have shown that modification of the heterocyclic base in nucleoside and 
nucleotide analogues has a marked effect on the relevant anabolic reactions within the host cell, which do 
not tolerate much variation in the structure of the substrates involved.42,45 For this reason most of the 
successful nucleotide phosphonate analogues thus far are designed around the naturally occurring 
heterocyclic base rings, adenine, guanine and cytosine. There has, however, been relatively recent, 
promising research into subsequent generations of ANPs which feature non-natural, synthetically modified 
heterocyclic bases with good anti-viral activity. This section will focus on the introduction of variations to 






2.4.1 2,6-Diaminopurine and 2,4-diaminopyrimidine derivatives 
2,6-Diaminopurines or DAP derivatives were first reported to possess anti-viral activity against a range of 
viruses in the early 1990s.47 Since then DAP derivatives such as (R)-PMPDAP and PMEDAP (Fig. 2.13), both 
close analogues of tenofovir and adefovir respectively, have shown high antiretroviral activity as well as 
very long intracellular half-lives and high oral bioavailability.47,62 It is these features which make DAP 


























Fig. 2.13: The chemical structures of the DAP derivatives (R)-PMP-DAP and PME-DAP 
Most of the important ANP derivatives that are used to treat human patients today, like tenofovir and 
adefovir, are derived from purine ring systems, with cidofovir (a cytosine derivative) being the only 
exception.63 Pyrimidines like cytosine, thymine and uracil, show much less opportunity for substitution and 
variation than their purine counterparts; however, lately there has been a range of intriguing pyrimidine 
derivatives that have shown good to excellent anti-viral activity against a broad range of DNA and 
retroviruses (Fig. 2.14).42,47 These “second-generation” ANP derivatives, which are based on a 6-
oxysubstituted 2,4-diaminopyrimidine ring, mimic the structures of purine bases such as 2,6-diaminopurine 
and adenine (Fig. 2.14).42,63,64 They have hence been dubbed “O-linked”, “open ring” or “acyclic purine” 
ANPs,47,62,65 with their acyclic structure allowing for a much broader array of substitution patterns than was 
previously allowed, especially at position-5 on the pyrimidine ring (Fig. 2.14).63,66–69 Variation has also been 
introduced at the linking atom (Fig. 2.14, X) with the use of sulphur and nitrogen atoms being explored as 





































































Fig. 2.14: A range of DAPy derivatives,62,68 as well as the structural correlation of PMEDAP to a generalized 
DAPy structure.56,66,68 
 
2.4.2 Biaryl acyclic nucleosides and nucleotides 
Substitution onto the base ring is one of the most obvious ways of introducing variation into an acyclic 
nucleoside, thus generating novel and potentially bio-active compounds.70 Even though radical alterations 
to the structures of the heterocyclic base rings were initially considered to be detrimental to biological 
activity,42 research has shown that the substitution of various groupings onto both natural and synthetic 
nucleoside base rings can yield interesting anti-viral and anti-cancer properties. One of the best examples 
of this is the HIV NNRTI, 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio) thymine, abbreviated HEPT (Fig. 2.15). 
HEPT was originally discovered by Miyasaka et al. during an investigation into the effect of S-aryl 
substitution onto the 6-position of the thymine ring of an acyclic version of 3’-azido-3’-deoxythymidine 
(AZT).71 After carrying out biological studies against HIV, Miyasaka et al. came to the conclusion that the 
nucleoside analogue HEPT, which was shown to be much less cytotoxic than other HIV drugs at the time, 
acted via a mechanism which was very different to those of other nucleoside analogues.71 HEPT was later 
discovered, through X-ray crystal structure analysis, to bind to a hydrophobic pocket near the active site of 










Fig. 2.15: The structure of HEPT 
As discussed by Wan et al., the effect of substituting the ring of a nucleoside base not only allows for the 
introduction of new and interesting biological properties into the molecule, but also gives the drug 
molecule some level of resistance against nucleoside or nucleotide metabolizing enzymes, thus increasing 
its overall potency.70 The use of various aromatic systems in such nucleoside base ring substitutions is 
thought to aid the interactions of the drug with non-polar, and π-conjugated amino acids by providing a 
large surface for van der Vaals and π-stacking interactions to take place.70,72 The use of non-natural 
nucleoside base rings, such as the triazole-3-carboxamide moiety of ribavirin or the pyrazinecarboxamide 
base of favipiravir, is another avenue by which novel nucleoside analogues can be generated. 
A series of publications from 2005-2006, by a range of authors, explored the concept of cyclic and acyclic 
nucleosides of triazole-3-carboxamides cross-coupled with various aromatic groups to form novel biaryl 
base systems as potential anti-viral compounds.70,72–74 In this research the authors used various cross-
coupling methodologies, such as Suzuki and Sonogashira couplings (Fig. 2.16), to gain access to a range of 
aryltriazole and arylethynyltriazole nucleoside analogues (Fig. 2.16).70,72–74 Some of these biaryl compounds 
showed good anti-viral, and in some cases anticancer activity, with compound A (1-((2-
hydroxyethoxy)methyl)-5-(2-(4-fluorophenyl)ethynyl)-1H-1,2,4-triazole-3-carboxamide) (Fig 2.16) showing 
the best activity against HCV.72 Removal of the rigidity of the triple bond by reduction led to the inactive 
compound C (Fig 2.17), indicating that the rigid triple bond is important to activity.72 Zhu et al. also 
compared the crystal structure of compound A to that of HEPT, revealing a strong structural correlation 
between the two, indicating that compound A may (but not necessarily) target the RdRp of HCV (Fig. 
2.18).72 S-Aryltriazole acyclonucleotides have also been investigated as potential anti-HCV agents, as they 




























































Fig. 2.17: A range of biaryl nucleoside analogues based on the triazole moiety of ribavirin.70,72,75 
 







Chapter 3  
Aims and objectives 
 
As highlighted in Chapters 1 and 2 of part 1 of this thesis, there is a large, unmet need for new broad-
spectrum inhibitors against RNA viruses, with ribavirin, despite its relatively low potency, being the only 
one currently available for the treatment of RNA viral infections. Various acyclic nucleotide phosphonates 
have been shown to be successful against a range of viruses including HCV and HIV, while nucleoside 
analogues like ribavirin and favipiravir have also been shown to be successful in the past against a wide 
range of RNA-dependent RNA-polymerase enzymes. There are also numerous potential new avenues for 
drug design and discovery, such as biaryl, 2, 6-diaminopurine, and 2, 4-diaminopyrimidine acyclic 
nucleosides and nucleotides, which have not yet been fully explored within the context of anti-RNA virus 
research. 
 This project aimed to draw upon the success of ribavirin, in conjunction with acyclic nucleotide 
phosphonates. Using the structures of various ANPs, ribavirin and in some instances, favipiravir as starting 
points, the goal of this project was to design and synthesise a library of new potentially bioactive acyclic 
nucleotide phosphonates which can then be tested against a range of RNA viruses with the view to inhibit 
their RNA polymerases. 
The prepared compounds have been built around the simple phosphonomethoxyethyl (PME) backbone of 
adefovir, with variation being introduced via different heterocyclic bases spanning a range of different 
types including natural nucleosides, DAPy and biaryl analogues, as well triazole and pyarazine derivatives 
with a particular focus on ribavirin analogues. In some cases pivaloyloxymethyl (POM) prodrug derivatives 
were synthesised from the relevant phosphonic acid ANP derivatives in order to probe the synthesis of 









































































Fig. 3.1: Structures of the ANP derivatives synthesised. 
The work to be described in this thesis can then be broken down into the following sections and each 
section will be described in detail, including a short review of the synthesis from the relevant literature, in 
Part 2: 
i) The synthesis of the diisopropyl phosphonomethoxyethyl synthon. 
ii) The alkylation of the heterocyclic base to the PME synthon. 
iii) The synthesis of an arylethynyltriazole derivative via a Sonogashira cross-coupling reaction. 
iv) The cleavage of the diisopropyl phosphonate ester. 





































The Synthesis of the Diisopropyl phosphonomethoxyethyl Synthon 
4.1 Introduction 
The goal of the project was to synthesise a library of ANP derivatives, with variation introduced through the 
alkylation of different heterocyclic bases onto the phosphonomethoxyethyl (PME) backbone of adefovir. A 
semi convergent synthetic plan was developed with the goal of accessing a large number of derivatives 
through an advanced intermediate. A retrosynthetic analysis is shown below (Fig. 4.1). The first synthetic 
stage of this project involved the synthesis of a diisopropyl phosphonomethoxyethyl synthon (Fig. 4.2), 
from which all the other derivates could be synthesised. The next stage would involve the alkylation of the 
PME synthon with the relevant heterocyclic base moieties, after which the diisopropyl protecting group 
would be removed, and in selected cases, followed by alkylation of the phosphonic acid with a 
pivaloyloxymethyl (POM) group to yield a small series of pivaloyloxymethyl- acyclic nucleotide phosphonate 






























































Fig. 4.2. Reagents and conditions: i) Cs2CO3, Base, DMF, 100°C; ii) DCM, TMSBr: iii) MeOH; iv) TEA, 
pivaloyloxymethyl chloride, CH3CN or DMF. 
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There are two main synthetic pathways which are commonly utilised in the synthesis of different acyclic 
nucleotide phosphonates.42 The first method features the etherification of a hydroxyalkyl base-bearing 
parent molecule with an appropriate phosphonate moiety. The hydroxyalkyl parent can be readily obtained 
via alkylation of the chosen heterocyclic base with a protected hydroxyalkyl compound bearing an 
appropriate leaving group, such as a derivatized epoxide, or a halide or sulfonate (Fig. 4.3, pathways A1 and 
A2 respectively).42,56,65,76 The second method involves alkylation of the heterocyclic base directly onto an 
advanced synthon carrying the phosphonate group, built in as a protected phosphonate diester (Fig. 4.3, 
Route B). The choice of synthetic method is dictated by various factors such as the reactivity, selectivity and 
stability of the alkyl chain, phosphonate group, and/or the heterocyclic base. 42,65 As a way of generating 
further molecular variation, the resulting ANP molecule can be further modified through the manipulation 
of reactive functionalities present on the heterocyclic base ring.42 After the parent ANP compound has been 
synthesised the phosphonate esters can usually be easily cleaved and modified and this process will be 











































Fig. 4.3: Some of the various generalised methods of ANP synthesis.65 
Given the aims and objectives of this project it was deemed that alkylation of the required heterocyclic 
base onto a protected PME synthon (Fig. 4.3, Route B), would provide the most direct as well as a semi-
convergent synthetic approach, allowing a potentially large number of derivatives to be synthesised by the 
substitution of a heterocyclic base with a leaving group present in the synthon molecule. The synthesis of 
such a synthon would ideally have to be high yielding and fairly convergent so that it could be produced 
easily and in large quantities. Two synthetic routes towards the required advanced synthon were explored, 





4.2 PME synthon synthesis (Route 1) 
A synthetic route to an advanced PME synthon had been previously developed in our laboratory and used 
successfully in the synthesis of ANP-based bifunctional HIV RT inhibitors. This synthetic route (Fig. 4.4 and 
4.5), despite being relatively long, had the advantage that it allowed for variation in the side-chain to be 
easily introduced through substitution of the relevant starting materials. It also allowed for the use of 
different leaving groups at key steps in the synthesis, which would aid in optimising the alkylation step with 


































































Fig 4.5. The proposed synthetic route for the synthesis of the PME synthon, reagents and conditions: i) NaH 
(2eq), i-PrOH (3eq), THF, 0°C-rt; ii) K2CO3, paraformaldyde, i-PrOH 60°C; iii) NEt3, TsCl, DCM, DMAP, 0°C-rt; 
iv) 2-(benzyloxy)ethanol, NaH, THF, 0°C-reflux; v) Pd-C, MeOH/THF, rt; vi) NEt3, TsCl, DCM, DMAP, 0°C-rt. 
 
 
Fig. 4.6. Reagents and conditions: i) NaH, iPrOH, THF, 0°C-rt, 98%. 
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The first step involved the esterification of phosphorus trichloride with isopropanol in the presence of 
sodium hydride, to form diisopropyl hydrogen phosphonate (1) (DAHP) (Fig 4.6). Using a procedure 
outlined by Fakhraian et.al,77 isopropanol (3 equivalents relative to PCl3) was added dropwise to a stirred 
suspension of two equivalents of sodium hydride in THF after which phosphorus trichloride was slowly 
added. The mechanism of the reaction (Fig 4.7) shows that 2 equivalents of isopropoxide ion attack the 
phosphorous trichloride to form a chlorodiisopropoxy phosphite, which undergoes further substitution 
with isopropanol, resulting in the release of one equivalent of HCl which acts to protonate the resulting 
trialkyl phosphite. The protonated trialkyl phosphite then undergoes an Arbuzov-like rearrangement to 
afford the more stable pentavalent diisopropyl hydrogen phosphonate.77 The addition of more than 2 
equivalents of base results in a lower yield of 1, while three or more equivalents of base completely inhibit 
the formation of DAHP, because of the absence of HCl. The product was then extracted into ethyl acetate 
from a saturated ammonium chloride solution to yield 1 (98%) which was pure enough for use in the next 
step. Fakhraian et.al were also able to perform this reaction without the presence of a base, although this 
would have meant neutralizing all the HCl produced from the reaction during the workup.77 The 1H NMR 
spectrum of 1 showed the presence of a doublet with a very large P-H coupling at δH 6.74 (d, JHP = 687.2 Hz, 
1H, H-P=O), along with the C-H multiplet at δH 4.64 (m, 2H, CH) and 2 doublets representing the 
diastereotopic methyl hydrogens at δH 1.27 (d, J = 6.4 Hz, 6H, CH(CH3)2) and 1.26 (d, J = 6.4 Hz, 6H, 
CH(CH3)2). 
 
Fig. 4.7: The reaction mechanism for the formation of 1.77 
The next step featured the reaction of 1 with paraformaldehyde in the presence of a solid-phase base 
catalyst at 60°C to form diisopropyl hydroxymethylphosphonate in a reaction known as the Pudovik 
reaction (Fig. 4.8). The mechanism of the Pudovik reaction is shown in Fig. 4.9 and involves the 
deprotonation of DAHP after which the nucleophilic free electron-pair present on the phosphorus attacks 
the electrophilic carbonyl of formaldehyde. The resulting negatively charged and basic oxygen atom is then 







































Fig. 4.9: The proposed mechanism of the Pudovik reaction.78 
Since a non-nucleophilic, carbonate base (which is insoluble in isopropanol) is used, the Pudovik reaction 
has the practical advantage that the products can be easily isolated, simply by filtration of the solid 
potassium carbonate catalyst and the evaporation of solvent. The resulting product was pure enough for 
the next step of the synthesis without the need for further purification via extraction or column 
chromatography. The reaction had a yield of 98% and the 1H NMR spectrum of 2 showed the characteristic 
new strong doublet at δH 3.79 (d, JPH = 6.0 Hz, 2H, P-CH2) representative of the new enantiotopic methylene 
hydrogens coupled to phosphorus. The characteristic isopropyl signals were also present as expected. The 
31P spectrum of 2 also showed the presence of a single major peak at δp 22.6, which corresponds very 
closely to the data reported in the literature.78 
The next step of the synthesis involved the conversion of the hydroxyl group present in 2 to a leaving group 
via the reaction of 2 with p-toluenesulfonyl chloride in the presence of triethylamine and a small amount of 











2 3  
Fig. 4.10. Reagents and conditions: i) NEt3, TsCl, DMAP, DCM, 0°C-rt, 72%. 
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 The reaction proceeded at room temperature for 2 hours whereupon the product was extracted into ethyl 
acetate and purified via column chromatography to afford 3 in a moderate yield of 72%. The 1H NMR 
spectrum of 3 showed the presence of two new aromatic signals existing as an AB system (JAB = 8.2 Hz), 
each integrating for 2H at δH 7.76 and δH 7.33, as well as the existence of a methyl singlet at δH 2.42 
indicating the presence of the tosyl group. Also present was the strong methylene doublet at δH 4.09 (JPH = 
10.1 Hz, 2H, P-CH2), as well as all the resonances indicative of the two isopropyl groups. The 
13C NMR 
spectrum of 3 confirmed the successful attachment of the tosylate group through the presence of all the 
appropriate carbon resonances.79 The 13C NMR spectrum of 3 also showed the very large diagnostic P-C 
coupling for the carbon bonded directly to the phosphorous at δc 62.1 (d, JPC = 170.2 Hz, P-CH2), a resonance 
which is characteristic of the phosphonate bond and is present in all ANP derivatives.  
The next phase in constructing the PME synthon involved alkylation of 3 with 2-(benzyloxy)ethanol 4 which 
was readily synthesised by the reaction of ethylene glycol (excess) with 1 equivalent of benzyl bromide in 
the presence of sodium hydride (Fig 4.11). The sodium hydride was added to a stirring solution of excess 
ethylene glycol in THF to ensure mono-deprotonation, after which benzyl bromide was added as the 
limiting reagent. After refluxing for 12 hours, 4 could be extracted and isolated in a good yield of 77%, with 






Fig. 4.11. Reagents and conditions: i) BnBr, NaH, THF, reflux, 77%. 
With 3 and 4 now in hand, an alkylation of the two was attempted using sodium hydride as a base in THF at 
reflux temperature for 12 hours under a nitrogen atmosphere (Fig 4.12). This reaction produced the 
required product D but only in very low conversions of 20-30%. Isolation of the product was complicated by 
the fact that the product and the tosyl starting material 3 both had very similar Rf values, even across a 
wide range of suitable solvent systems. Preparative thin layer chromatography (TLC) with repeated 
developments in a non-polar solvent system was also unable to isolate the required product with sufficient 
purity. The low yield of this reaction was also a significant problem, since large quantities of the final 
product were required as a precursor to the advanced synthon which would be used to synthesise all future 




















Fig. 4.12. Reagents and conditions: i) NaH, THF, reflux. 
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Numerous attempts to optimize and improve the reaction of 3 with 4 were attempted, which included the 
investigation of different solvents, different ratios of starting materials and reagents, reaction 
temperatures and in some cases the introduction of catalytic iodide (formation of iodide in situ) and 
alternative bases (Table 4.1). Various solvents were investigated including THF, acetonitrile (CH3CN), and 
dimethoxyethane (DME). Caesium carbonate was used as an alternative base in CH3CN but this did not yield 
any conversion of starting materials to products. The reaction was also performed over a wide range of 
temperatures to rule out the concern that some product was being lost to thermal decomposition. In some 
cases catalytic amounts of sodium iodide or tetrabutyl ammonium iodide (TBAI) were introduced to the 
reaction to increase the rate of alkylation via the formation of a more reactive iodinated intermediate. 
Compound 4 was always used in excess relative to 3 (with a minimum ratio of 2:1) in order to make the 
chromatography easier by reducing the amount of starting material. Unfortunately this was in vain as the 
reaction never reached completion in any experiment. 
Table 4.1. The various reaction conditions used in the attempted alkylation of 4 and 3 to produce D. 
Reaction Base Solvent Temperature Time Iodide Approx. Conversion (by tlc) 
1 NaH THF reflux 18hrs none 20-30% 
2 Cs2CO3 CH3CN reflux 48hrs none No reaction 
3 NaH THF 40°C 48hrs TBAI 20% 
4 NaH THF rt 1 week NaI 10% 
5 NaH CH3CN reflux 48 hrs TBAI 10% 
6 NaH DME reflux 48 hrs TBAI no reaction 
 
To further investigate the alkylation of 4 and 3, different combinations of leaving groups were explored. 
Tosyl, mesyl and iodo variants were synthesised from compounds 4 and 2 (Fig 4.13), and used as starting 
materials in the synthesis of D. The alkylation reaction was performed on the new substrates in the 



































Fig. 4.13. Reagents and conditions: i) MsCl, NEt3, DCM, DMAP, rt; ii) I2, PPh3, imidazole, rt; iii) TsCl, NEt3, 
DCM, DMAP, rt. 
The syntheses of compounds 2a, 4a and 4b were carried out under the standard mesylation and tosylation 
conditions which were broadly discussed above for the synthesis of the tosyl derivative 3. The iodinations 
of 4 and 2 were carried out at room temperature with use of iodine, triphenylphosphine and imidazole as a 
base. In this case the reaction mixture was worked up with a saturated sodium thiosulfate solution to 
remove any iodine, and extracted with ethyl acetate, after which the iodinated products were isolated by 
column chromatography. The mechanism of this reaction proceeds via the formation of a phosphonium salt 




























Fig 4.14: The mechanism of formation of 2b. 
 
Table. 4.2: The various reaction conditions used as well as the nucleophile / electrophile combinations used 
in the attempted synthesis of D. 
Reaction Base Nucleophile electrophile Solvent Temperature Time Observation 
1 NaH 4 2a THF reflux 48 hrs no reaction 
2 NaH 4 2b THF reflux 48 hrs no reaction 
3 NaH 2 4a THF reflux 48 hrs no reaction 
4 NaH 2 4b THF reflux 48 hrs no reaction 




Owing to the very low yields of the reactions of 4 and 3 and the failure of all other attempts to find better 
leaving groups, the decision was made to abandon this particular synthetic route, despite the fact that it 
had been previously completed with relative success in our laboratory. A possible explanation is that the 
electron-withdrawing phosphonate group destabilises the partial positive charge in the SN2 transition state. 
In addition, the alkoxide species is a basic, poorly nucleophilic species. 
 
4.3 PME synthon synthesis (Route 2) 
After the failure of the first route to produce the required PME synthon, our attention turned to a synthetic 
route which had been used and published by Holý et al. in 1999.81 This route makes use of an Arbuzov 
reaction as its key step in which triisopropyl phosphite reacts chemoselectively with chloro-2-
(chloromethoxy)ethane to produce a diisopropyl phosphonomethoxyethyl synthon bearing a chlorine atom 
as a leaving group. This route has the advantage that it comprises only two steps and can be performed on 
a relatively large scale. The main disadvantages of this particular synthesis are all associated with the 
synthesis of 1-chloro-2-(chloromethoxy)ethane, which is synthesised from highly toxic 2-chloroethanol and 
paraformaldehyde using large quantities of hydrogen chloride gas. Another disadvantage to this approach 
is that it limits the possibility of easily introducing variation in the PME side chain and also restricts the 


















Fig. 4.15: The synthesis of the final PME synthon. Reagents and conditions: i) paraformaldehyde, HCl(g), 
DCM, 0°C, 61%; ii) triisopropyl phosphite, 100°C, 83%. 
The procedure for the synthesis of 5 was adapted from procedures described by Liu et al.82 and Powell et 
al.83 and began with formation of a rapidly stirring suspension of paraformaldehyde and 2-chloroethanol in 
dry dichloromethane (DCM) at 0°C in a sealed two-necked flask fitted with a rubber septum. HCl gas, 
generated from the reaction of stirring solid NaCl with concentrated H2SO4 in a separate two-necked flask, 
was constantly bubbled into the reaction mixture via a piece of rubber tubing and a long steel needle, for 6 
hours at 0°C after which the mixture was refrigerated overnight. The next day, HCl gas was again bubbled 
through the mixture to ensure complete saturation of the solution. Due to the highly non-polar and toxic 
nature of the products and starting materials, it was impossible to use tlc to monitor the reaction, thus 
NMR analysis of the crude material was used to follow the reaction’s progress. One was able to observe the 
appearance of new product peaks in the 1H NMR spectrum at δH 5.52 (s, 2H, H-1) and δH 3.95 (t, J = 5.6 Hz, 
2H, H-2) while the integrations of the starting material peaks decreased over time. When NMR analysis had 
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revealed a 75% conversion of starting materials to products, the reaction was stopped and the solution 
dried with calcium chloride. Product 5 was then distilled off from the less volatile, excess 2-chloroethanol 
under reduced pressure with the product boiling at 64°C under 20 mmHg. Both the spectral and boiling 
point data for this compound were found to correspond to the data reported in the literature.82,83  
The mechanism of this reaction begins with the protonation of the formaldehyde oxygen which increases 
the electrophilicity of the carbonyl carbon thus aiding the addition of the poorly nucleophilic oxygen of the 
2-chloroethanol. The hydroxyl group on the resulting hemiacetal picks up a further proton through a proton 
transfer and is expelled as water to form an oxocarbenium ion, which then undergoes addition with a 
chloride ion to produce 5. (Fig 4.16). 
 
Fig. 4.16: The mechanism of the formation of 5 
The final PME synthon was synthesised in good yield via a chemoselective Arbuzov reaction of 5 with 
triisopropyl phosphite. The Arbuzov reaction involves an SN2 reaction between the phosphorus of a trialkyl 
phosphite and an alkyl halide to form a phosphonium intermediate which reacts with the displaced halide 
ion to yield a phosphonate and a new alkyl halide via a dealkylation step (Fig 4.17).84 From the procedure by 
Holý et al.,81 neat triisopropyl phosphite was heated to 100°C in a reaction flask fitted with a Vigreux 
column, still-head, condenser and thermometer. Chloride 5 was slowly added to the stirring solution at 
such a rate that the resulting 2-chloropropane by-product could be distilled off. It was observed that the 
triisopropyl phosphite reacts chemoselectively with carbon 1 over carbon 3 of compound 5, since this is the 
most electrophilic carbon in the molecule due to stabilization of the incipient positive charge in the 
transition state by the adjacent oxygen (Fig 4.17). This level of chemoselectivity suggests that side reactions 
with the 2-chloropropane by-product are unlikely, aside from the fact that the 2-chloropropane is being 
constantly removed from the reaction. After the reaction was complete and 2-chloropropane was no longer 
being evolved, the product PME synthon could then be isolated directly from the reaction mixture by 
distillation under high vacuum, with the product boiling at 120°C at 0.1 mmHg, which corresponds exactly 




























Fig. 4.17: The mechanism of the formation of 6 via an Arbuzov reaction. 
The 1H NMR spectrum of 6 revealed the expected triplets at δH 3.85 (t, J = 5.8 Hz, 2H, H-2) and δH 3.63 (t, J = 
5.8 Hz, 2H, H-3), as well as the diagnostic doublet at δH 3.79 (d, JPH = 8.4 Hz, 2H) which is formed from the 
strong J2 coupling of the phosphorus with the hydrogens on C-1, confirming the formation of the P-C bond. 
The doublet of heptets at δH 4.76 (dhept, JHP, HH = 7.7, 6.3 Hz, 2H) is representative of the CH(CH3)2 
hydrogens on the isopropyl groups of the phosphonate and arises first from the large coupling of the 
phosphorus to the hydrogens (JHP = 7.7 Hz) and then from the slightly smaller couplings associated with the 
six hydrogens on the adjacent isopropyl methyls (JHH = 6.3 Hz). The isopropyl methyl groups are 
diastereotopic and are therefore non-equivalent. They might have been present in the 1H NMR spectrum as 
two doublets, each with a coupling constant of JHH ≈ 6-7 Hz. However they did not resolve and were instead 
visible as one doublet with a coupling constant of JHH = 6.3 Hz. The 
13C NMR spectrum did however resolve 
the diastereotopic methyl carbons into 2 doublets at δc 24.3 and δc 24.1, each with a small coupling (JCP = 
4.2 Hz) due to J3 coupling with phosphorus (Fig 4.17, CH3). The CH isopropyl carbon was represented as a 
doublet with a J2 PC coupling at δc 71.4 (d, JPC = 6.7 Hz, CH(CH3)2) (Fig 4.18), while C-2 appeared as a doublet 
with a J3 PC coupling at δc 73.2 (d, JPC = 10.6 Hz)(Fig 4.18, resonance 2), which is counterintuitive as one 
would expect the resonance with a larger coupling constant to have a closer proximity to the phosphorus. 
(These assignments were confirmed by the HSQC in conjuction with the 13C NMR data of other ANP 
derivatives later on in this work and will be discussed in detail in chapter 5 of this thesis.) C-3 appeared as a 
singlet at δc 42.5 as it is too far away from the phosphorus for PC coupling. By comparison C-1 appeared as 
a doublet with a very large coupling constant at δc 66.3 (d, JPC = 167.6 Hz) (Fig 4.18, resonance 1) arising 
from a J1 P-C coupling, a resonance characteristic of the P-C bond of a phosphonate. 
 




Alkylation of the PME synthon with heterocycles 
5.1 Introduction 
With an advanced PME synthon in hand, the next phase in the project was to introduce selected 
heterocycles via alkylation. A large variety of both natural and synthetic basic heterocyclic rings were 
selected with a particular interest in derivatives of the 5-membered triazole ring of ribavirin. Most bases 
were available commercially; however, a number of bases need to be synthesised de novo or prepared via 
modification of a commercially available precursor and the synthesis of these compounds will also be 

















Fig. 5.1. Reagents and conditions: i) Cs2CO3, DMF, 100°C 
The general procedure for these reactions was derived from various works by Holý et al.,66,81 in which they 
explored the use of various inorganic bases such as sodium hydride, caesium carbonate, as well as organic 
amine bases such as diisopropylethylamine (Hünig’s base), 1,8-bis(dimethylamino)naphthalene (proton 
sponge) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in dimethylformamide (DMF).81 The results of these 
studies showed that sodium hydride and DBU were both suitable bases for these alkylation reactions, 
although caesium carbonate was shown to be a superior base overall, both in terms of yield and reaction 
time. Thus, despite being a rather expensive reagent, caesium carbonate was selected as the base for our 
purposes.  
A typical experimental procedure follows: The relevant heterocyclic base was suspended with the PME 
synthon 6 and caesium carbonate in dry DMF and warmed to 100°C. Reaction times varied from 6 – 48 
hours depending on the heterocycle involved. After tlc analysis had revealed reaction completion, the DMF 
was distilled off from the reaction mixture under high vacuum and the organic material extracted from 
aqueous sodium bicarbonate into chloroform/methanol (2:1). The presence of DMF was shown to pull the 
organic product into the aqueous layer as well as interfere with the subsequent chromatography, thus it 
was removed by distillation early so as to avoid these problems. Acetonitrile was investigated as an 
alternative solvent for these alkylation reactions as it is much easier to work with and remove but, in most 
cases, it was found to be an inferior solvent to DMF, resulting in much lower yields and much longer 
reaction times. In most, but not all cases, ethyl acetate and DCM were found to be too non-polar to 
properly extract the highly polar ANP products from the inorganic layer in the work-up step and it was for 
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this reason that a methanol/chloroform extraction was used. After the dried crude product was obtained 
from the work-up, the desired product was then isolated in all cases by column chromatography. 
 
5.2 The synthesis of ANP derivatives with heterocycles of natural nucleosides. 
A series of ANP analogues were synthesised containing the naturally occurring pyrimidine bases of uracil, 





























Fig. 5.2. Reagents and conditions: i) Cs2CO3, DMF, 100°C, 41%. 
The first ANP derivative to be synthesised was the uracil derivative 13 which was synthesised from the 
general procedure described above (Fig 5.2). The crude material, which displayed only one dominant 
product, was isolated via column chromatography to yield 13 in a modest yield of 41%. The reaction was 
found to be 1N-chemoselective as expected, with alkylation occurring on the more reactive 1N-anion as 
opposed to the less nucleophilic, more resonance-stabilised 3N-anion. The 1H NMR spectrum of 13 
confirmed the alkylation of the uracil ring through the slight downfield shift of the triplet for the H-3 
protons from δH 3.63 (t, J = 5.7 Hz, 2H) in the chloride 6, to δH 3.96 (t, J = 5.0 Hz, 2H). Other diagnostic 
signals in the 1H NMR spectrum included the broad N-H singlet at δH 10.13 (H-3’), the uracil hydrogen AB 
paired doublets at δH 7.55 (d, J = 7.9 Hz, 1H, H-6’) and at δH 5.53 (d, J = 7.9 Hz, 1H, H-5’), the phosphonate P-
H coupled doublet at δH 3.79 (d, JPH = 8.2 Hz, 2H, H-1) and the two diasterotopic methyl doublets at δH 1.29 
(d, J = 6.0 Hz, 6H, CH(CH3)2) and δH 1.26 (d, J = 6.0 Hz, 6H, CH(CH3)2). The 
13C NMR spectrum showed both 
carbonyl resonances at δC 164.4 (C-2’) and δC 151.9 (C-4’). All 
1H and 13C assignments were confirmed with 
the use of HSQC NMR spectroscopy but, owing to the very close nature of the 13C NMR resonances at δC 
71.4 (d, JPC = 10.4 Hz, C-2) and δC 71.2 (d, JPC = 6.4 Hz, CH(CH3)2 ) in the HSQC spectrum of 13, C-2 and 
CH(CH3)2 were assigned based on the coupling constants of those signals in the HSQC spectra of analogous 
ANP derivatives (discussed in greater detail below). These assignments were confirmed by the 13C NMR 
































Fig. 5.3. Reagents and conditions: i) Cs2CO3, DMF, 100°C, 45%. 
The next ANP derivative to be synthesised was the 5-methyluracil (thymine) derivative 14 (Fig 5.3). The 
compound was produced in much the same way as 13 with column chromatography being used to isolate 
14 in a yield of 45%. Again, 1N-chemoselectivity was observed. IR spectroscopy showed the presence of the 
two carbonyls with absorptions at 1709 cm-1(C=O) and 1688 cm-1 (C=O), while the presence of the 
phosphonate group was confirmed by peaks at 1237 cm-1 (P=O) and 993 cm-1 (P-O). The 1H NMR spectrum 
of 14 showed all the resonances associated with the diisopropyl PME moiety and also confirmed the 
presence of the thymine ring by virtue of an N-H singlet at δH 9.88 (s, 1H, H-3’), the H-6’ singlet at δH 7.40 (s, 
1H, H-6’), and the methyl singlet at δH 1.82 (s, 3H, H-7’). The 
13C NMR spectrum showed the presence of the 
two carbonyl peaks at δC 165.2 (C-2’) and δC 152.0 (C-4’) as well as a weak singlet at δC 109.5 indicative of 
the quaternary centre at C-5’. The large P-C coupled doublet at δC 66.2 (d, JPC = 166.5 Hz, C-1) and the two 
diastereotopic methyl doublets at δC 24.3 (d, JPC = 4.2 Hz, CH(CH3)2) and δC 24.1 (d, JPC = 4.2 Hz, CH(CH3)2) 




























Fig. 5.4. Reagents and conditions: i) Cs2CO3, DMF, 100°C, 66%. 
Finally the cytosine derivative 15, which had previously been synthesised by Holý et al. during research 
towards new anti-retroviral agents,81 was prepared. In this case Cs2CO3 was used as the limiting reagent 
with cytosine (2 eq.) and 6 (2.2 eq.) in excess to ensure the selective formation of the anion at 1N over the 
primary amine at position 4 on the cytosine ring. Tlc analysis of the reaction mixture showed the formation 
of several new products with very similar Rf values but, with careful repeated chromatography, the major 
product spot could be isolated in a yield of 66%. The 1H NMR spectrum corresponded closely with the 1H 
NMR data reported in the literature,81 showing the AB doublet system indicative of H-6’and H-5’ with peaks 
at δH 7.52 (d, J = 7.2 Hz, 1H, H-6’) and δH 5.75 (d, J = 7.2 Hz, 1H, H-5’). A broad singlet at δH 6.49, integrating 
for 2H, showed the presence of the free amine on C-4’, indicating this family of reactions to again be 1N-
chemoselective. The 13C NMR spectrum again showed all the diagnostic resonances typical of the 
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diisopropyl PME chain. Also present were the carbon resonances representative of C-6’ and C-5’ at δC 146.8 
and δC 92.4 respectively. The quaternary centre at C-4’ was revealed by the presence of a very weak singlet 
δC 145.7 due to the fact that the weak quaternary C-4’ signal is further weakened by the presence of two 
adjacent nitrogen atoms. The proton-decoupled 31P NMR spectrum showed a single peak at δP 24.1 
representing the single phosphorus atom in the phosphonate moiety. 




























Fig. 5.5: The structures of T-705, T-1105 and the proposed T-1105 ANP Derivative. 
As discussed in Part 1, Chapter 1, of this thesis, T-1105 and T-705 (favipiravir) have been shown to have 
potent broad spectrum anti-viral activity (Fig 5.5). In an effort to probe the synthesis of ANP derivatives of 
T-1105, a model synthesis of the parent pyrazine compound, 2-hydroxypyrazine 7, was performed using the 
cheap and easily obtainable starting materials, glycinamide and glyoxal. The resulting 2-hydroxypyrazine 
ring was then alkylated onto the PME synthon 6 under the standard conditions. It was envisioned that a 
similar strategy would be used to synthesise 3-hydroxypyrazine-2-carboxamide (T-1105), using 2-














Fig. 5.6: Reagents and conditions: i) NaOH, MeOH, 39% 
For 7, the condensation reaction between glycinamide hydrochloride and glyoxal using sodium hydroxide 
as base was carried out in accordance with the procedure described by Jones (Fig 5.6).85 According to Jones, 
condensation in the presence of a hydroxide base increases the reaction rate and yield and results in the 
formation of target hydroxypyrazine as a sodium salt.85 The hydroxide helps drive the reaction by aiding 
aromatization of the pyrazine ring (Fig 5.7). The reaction yielded the required product 7 in a modest yield of 
39%, sufficiently pure for use in the next step. The 1H NMR spectrum showed the presence of 3 aromatic 
resonances at δH 8.07 (d, J = 1.4 Hz, 1H, H-2), δH 7.44 (d, J = 4.1 Hz, 1H, H-4) and δH 7.38 (dd, J = 4.1, 1.4 Hz, 
1H, H-3), consistent with the pyrazine ring system. The resonance at δH 8.07 (H-2) couples to the doublet of 
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doublets at δH 7.38 via a long range aromatic coupling (JHH = 1.4 Hz). The doublet of doublets also showed 
coupling to the doublet at δH 7.44 (d, J = 4.1 Hz, 1H, H-4), revealing H-3 and H-4 as an AB pair. The 
13C NMR 
spectrum showed three resonances at δC 149.6 (C-4), δC 128.6 (C-2) and δC 125.9 (C-3), as well as a weak 
peak at δC 158.8 indicative of the quaternary centre at C-1. IR spectroscopy showed the presence of a 
carbonyl absorbance at max 1650 cm



















































Fig. 5.7: The mechanism of the formation of 7. The two tautomers of 2-hydroxypyrazine 7a and 7b. 7a’ and 






































Fig. 5.8: Reagents and conditions: i) Cs2CO3, DMF, 100°C, 16a 21%, 16b 47% 
Tlc analysis of the alkylation reaction of 7 with synthon 6, again using Cs2CO3 in DMF (Fig 5.8), showed the 
formation of two major product spots. Careful chromatography using a DCM/MeOH solvent system (2: 98) 
allowed separation of the two isomers affording the N-alkylated 16a (21% yield) and the O-alkylated 16b ( 
47% yield) which were assigned by NMR and IR spectroscopy (vide infra). Deprotonation of 7 results in the 
formation of a resonance stabilized anion shown as resonance structures 7a’ and 7b’ (Fig 5.7). The O-anion, 
7b’, is the most favoured resonance structure as it allows the bulk of the negative charge to rest on the 
more electronegative oxygen atom while also preserving the aromaticity of the pyrazine ring. This accounts 
for the formation of the O-alkylated 16b as the major reaction product over 16a. 
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The 1H NMR spectra of both 16a and 16b showed the presence of the CH(CH3)2 multiplets at δH 4.68 and δH 
4.70 respectively, the P-H coupled phosphonate doublets at δH 3.69 (J = 8.4 Hz) and δH 3.81 (J =8.2 Hz), as 
well as the diastereotopic methyl doublets between δH 1.29 and δH 1.26, confirming the presence of the 
diisopropyl phosphonate group. The distinction between 16a and 16b was made based on the 1H and 13C 
NMR data as well as the IR spectroscopic data for each compound. The infrared spectroscopic data of 16a 
confirmed it as the N-alkylated product through the presence of a strong carbonyl stretch at max 1662 cm
-1 
as no such absorbance was seen in the IR data of 16b. The diagnostic differences between the two 1H NMR 
spectra of 16a and 16b lie in their aromatic regions, as well as in the relative chemical shifts of the triplets 
representing H-3. The H-3 triplet of the N-alkylated 16a at δH 4.09 (t, J = 4.8 Hz, 2H) lies significantly upfield 
to that of the O-alkylated 16b, which can be found at δH 4.52 (t, J = 4.8 Hz, 2H), due to the fact that oxygen 
is a more electronegative, and hence a more deshielding atom than nitrogen (Fig 5.9). This is also seen in 
the 13C NMR spectra in which C-3 of 16a resonates at δC 49.1 while C-3 of 16b appears significantly 
downfield at δC 65.2. The second piece of supporting evidence for 16b as the O-alkylated product could be 
found in the 1H and 13C NMR aromatic signals of the aromatic region. The signals found at δH 8.22 (d, J = 1.4 
Hz, 1H, H-3’), δH 8.15 (d, J = 2.8 Hz, 1H, H-6’) and δH 8.13 (dd, J = 2.8, 1.4 Hz, 1H, H-5’), and at δC 160.1 (C-2’), 
δC 140.5 (C-3’), δC 136.9 (C-6’) and δC 136.2 (C-5’),
 correspond very closely to both the 1H and 13C NMR data 
available for the aromatic signals of the analogous, commercially available compound, 2-
methoxypyrazine.86,87  
 
Fig. 5.9: The expanded and superimposed NMR spectra of 16a and 16b 
The HSQC NMR of both 16a and 16b confirmed the 1H and 13C NMR assignments made for each compound 
(Fig 5.10). The HSQC spectrum of 16a showed the CH(CH3)2 multiplet at δH 4.68 coupling to the P-C J
2 
coupled doublet at δC 71.3 (d, JPC = 6.7 Hz, CH(CH3)2). This means that the resonance at δC 70.3 (d, JPC= 11.0 
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Hz) must be assigned to C-2, an unexpected result as one would usually expect to assign the resonance with 
the larger coupling (JPC) constant to the carbon as the closest in proximity to the phosphorus atom. 
 
Fig. 5.10: The expanded HSQC spectrum of 16a. 
5.4 The synthesis of pyrimidine-based ANP derivatives. 
The next series of derivatives which were synthesised were based on the open ring diaminopyrimidine 
(DAPy) ANP variants discussed in Part 1, Chapter 2.4.2. The first derivative, which was formed from the 
alkylation of 2,4-diaminopyrimidine with synthon 6, resembles an acyclic analogue of the naturally 
































Fig 5.11. Reagents and conditions: i) Cs2CO3, DMF, 100°C, 40%. 
The reaction was performed and worked up according to the same general procedure as described above, 
with an excess of 2,4-diaminopyrimidine used to ensure the formation of the mono-alkylated product. 
Although the formations of different regioproducts were possible through the alkylation of either of the 
51 
 
two amino groups, only one product could be distinguished from the tlc or spectroscopic data. However, 
the exact structure of the resulting product as either the 2’-amino or 4’-amino variant could not be 
assigned from the available data. Isolation of the major product of the crude reaction mixture via column 
chromatography with MeOH/DCM (6:94) afforded 17 in a yield of 40%. The 1H NMR spectrum of 17 showed 
all the expected diisopropyl phosphonate resonances at δH 4.69 (m, 2H, CH(CH3)2), δH 3.77 (d, JPH = 8.0 Hz, 
2H, H-1), δH 1.29 (d, J = 6.0 Hz, 6H, CH(CH3)2) and δH 1.27 (d, J = 6.0 Hz, 6H, CH(CH3)2) as well as an aromatic 
AB coupled pair of doublets at δH 7.66 (d, J = 5.9 Hz, 1H, H-6’) and δH 5.84 (d, J = 5.9 Hz, 1H, H-5’). A broad 
singlet at δH 6.40, integrating for 1H showed the presence of the alkylated amine group, while the broad 
singlet at δH 5.56 integrating for 2H, represented the un-alkylated amine, confirming the structure as the 
mono-alkylated product. The resonances indicative of H-2 and H-3 appeared upfield of the phosphonate 
doublet at δH 3.77 (d, JPH = 8.0 Hz, 2H, H-1). The resonance indicative of H-2 appeared at δH 3.74 (t, J = 5.5 
Hz, 2H, H-2), while the signal for H-3 appeared as a quartet at δH 3.52 (q, J = 5.5 Hz, 2H,), showing H-H 
coupling with H-2 and the hydrogen on the adjacent nitrogen. The 13C NMR spectrum of 17 showed all the 
expected signals including the phosphonate doublet at δC 66.4 (d, JPC = 166.6 Hz, C-1) and the diastereotopic 
methyl doublets at δC 24.4 (d, JPC = 4.0 Hz, CH(CH3)2) and δC 24.3 (d, JPC = 4.0 Hz, CH(CH3)2). Further evidence 
for the structure of 17 was given by mass spectroscopy, HRMS (ES): 333.1697 (M+ + H), which corelated 
with the molecular formula C13H26N4O4P (expected value (M


























Fig. 5.12: Reagents and conditions: i) Cs2CO3, DMF, 100°C, 64%. 
The next compound, 18, was formed from the alkylation of 2-amino-4-cyano-pyrimidine and synthon 6 
under the standard reaction conditions (Fig 5.12). Product 18 was found to be much less polar than the 
structurally similar 17 due to the presence of a cyano group instead of an amino group at position 4’ on the 
pyrimidine ring. For this reason the compound could be isolated relatively easily by column 
chromatography using 100% ethyl acetate as the solvent system. The 13C NMR spectrum of 18 showed a 
resonance at δC 117.1 typical of a nitrile carbon. The IR spectroscopy confirmed the presence of the cyano 
group with a C≡N absorbance at max 2246 cm
-1. The 1H NMR spectrum showed an AB pair for H-6’and H-5’ 
at δH 8.41 (d, J = 5.0 Hz, 1H, H-6’) and δH 6.80 (d, J = 5.0 Hz, 1H, H-5’). The N-H signal could be observed at 
δH 6.07 (s, 1H, NH) along with the quartet at δH 3.63 (q, J = 5.3 Hz, 2H, H-3) for H-3 which again coupled to 
both the N-H and H-2. HSQC NMR of 18 again showed the carbon resonance of C-2 (δC 72.8 (d, JPC = 12.1 Hz, 
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C-2)) to have a larger P-C coupling constant than the CH(CH3)2 signal at δC 73.2 (d, JPC = 6.7 Hz, CH(CH3)2), (Fig 
5.13). 
 
Fig. 5.13: The expanded HSQC NMR of 18. 
5.5 The synthesis of ribavirin-like ANP derivatives. 
The next family of derivatives to be synthesised were all analogues of the well-known anti-viral nucleoside 
analogue, ribavirin. The derivatives described all feature a 5-membered heterocycle containing 2 or 3 
nitrogen atoms in various arrangements. An amide group, as discussed above in Chapter 1, is thought to be 
vital to the drug’s ability to form multiple hydrogen-bonding profiles, a trait believed to be a possible 
source of ribavirin’s broad spectrum anti-viral activity. The first derivative was designed to exclude the 
amide in order to test this hypothesis, which involved the reaction of 1,2,4-triazole with 6 under standard 

























Fig. 5.14: Reagents and conditions: i) Cs2CO3, DMF, 100°C, 58%. 
Although the formation of three alkylation products, one for alkylation of each triazole nitrogen were 
theoretically possible, the substitution reaction afforded only one major observable product in a 58% yield, 
as revealed by tlc as well as 1H and 13C NMR spectroscopy. The exact structure of the major regio-product, 
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19, as either the 1,2 or 4-alkyl variant could not be determined from the available data. Surprisingly, 19, 
was found to be non-UV active, thus the tlc plate could only be visualised with various stain reagents, the 
most successful being anisaldehyde which showed the product as a strong white spot. The 1H NMR 
spectrum of 19 featured two aromatic singlets at δH 8.36 (s, 1H, H-5’) and δH 7.84 (s, 1H, H-3’), each 
integrating for 1H, confirming the presence of the triazole ring within the molecule. The 13C NMR spectrum 
showed the corresponding triazole carbon signals at δC 151.9 (C-5’) and δC 144.1 (C-3’). The other signals 
typical of the diisopropyl PME chain were also present in both the 1H and 13C NMR spectra. A relatively 
deshielded triplet for H-3 at δH 4.43 (t, J = 6.8 Hz, 2H, H-3) was noted, demonstrating the electron-
withdrawing nature of the triazole ring. HSQC NMR of 19 was again used to confirm the 1H and 13C NMR 
assignments, specifically the carbon assignments of the P-C coupled doublets at δH 71.3 (d, JPC = 6.8 Hz, 
CH(CH3)2) and δH 70.8 (d, JPC = 10.0 Hz, C-2).  
The next set of derivatives were ANP derivatives of ribavirin, obtained from the reaction of synthon 6 and 
1H-1,2,4-triazole-3-carboxamide. 1H-1,2,4-triazole-3-carboxamide (8) was not commercially available and 


















Fig. 5.15. Reagents and conditions: i) SOCl2, DMF, Reflux, N2; ii) NH3, 50°C 
A patent was found which outlined a procedure for its synthesis from 1H-1,2,4-triazole-3-carboxylic acid in 
neat thionyl chloride with a catalytic quantity of DMF under inert atmospheric conditions.88 This was 
carried out resulting in the formation of a reactive but stable and isolatable dimeric ketene of 1,2,4-
triazole-3-carboxylic acid (Fig 5.16).88 After 3hrs, once the intermediate dimer had formed, the thionyl 
chloride and DMF were removed under high vacuum to yield the intermediate as a dry white powder. 
Saturated ammonia solution was then added to the intermediate at 0°C, after which the stirring suspension 
was warmed to 50°C to drive the ammonolysis of the intermediate dimer to afford 8 (Fig 5.16). The 
ammonia solution was then evaporated under reduced pressure to afford 8, which could be recrystallised 
from a solution of water and methanol (1:10). IR spectroscopy of the dried product showed absorptions at 
max 3327 cm
-1, 3155 cm-1 and 1699 cm-1 representing the two amide N-H bands and C=O stretch 
respectively. The 1H NMR spectrum in DMSO-d6 showed one aromatic signal at δH 8.38 (s, 1H, H-5) as well 
as two broad singlets at δH 7.61 (s, 1H, NH2) and δH 7.85 (s, 1H, NH2) representing the amide hydrogens. The 
structure was further confirmed with mass spectroscopy, showing HRMS (ES): 113.0448 (M+ + H), which 
corresponded to the molecular ion C3H5N4O (M



































































Fig. 5.16: The reaction mechanism for the formation of 8. 
With 8 in hand, the next task was its alkylation with PME synthon 6, which was again achieved using Cs2CO3 
in DMF at 100°C (Fig 5.17). Three possible products (20a, 20b and 20c) were expected from the reaction as 
each triazole nitrogen could act as a nucleophile and point of alkylation. However, tlc analysis of the 
reaction mixture after 12 hours of stirring at reflux showed the formation only of 2 distinguishable product 
spots, both with very similar Rf values. Repeated and careful chromatography was, however, able to 



























































The IR spectra, recorded in DCM in a sodium chloride solution cell, revealed the presence of the primary 
amide in both cases with the presence of strong bands at νmax 3516 (N-H) cm
-1, 3398 (N-H), cm-1 and 1704 
(C=O) cm-1 for 20a; and νmax 3512 (N-H) cm
-1, 3393 (N-H), cm-1 and 1704 (C=O) cm-1 for 20b, confirming the 
successful alkylation of 8 and 6. The 1H NMR spectra of 20a and 20b revealed the only real spectroscopic 
differences between the 2 compounds to be the difference in chemical shift of the H-5’ and H-3 hydrogen 
signals, suggesting their existence as regioisomers of each other. The H-5’ hydrogen singlet in 20a appeared 
at δH 8.51 while in 20b it appeared at δH 7.92. The H-3 triplets of 20a and 20b showed the most obvious 
difference in chemical shift which, at δH 4.52 (t, J = 4.0 Hz, 2H, H-3) and δH 4.90 (t, J = 5.5 Hz, 2H, H-3) 
respectively, and suggested the points of attachments on the triazole ring to have markedly different 
electronic environments in each case (Fig 5.18). HSQC NMR was used to confirm the 13C NMR assignment of 
the H-5’ resonance at δC 146.2 in 20a and δC 150.4 in 20b, as well as the 
1H and 13C NMR assignments 
associated with PME chain, including the assignments of the ambiguous P-C coupled doublets of C-2 and 
the i-Pr CH(CH3)2. 
 
Fig. 5.18: The expanded and superimposed NMR spectra of 20a and 20b 
The 1H, 13C and HSQC NMR data was, however, inconclusive regarding assignment of regiochemistry as 
either 20a or 20b. HMBC (Heteronuclear Multiple Bond Correlation) NMR spectroscopy was used to solve 
this problem as this NMR technique shows only J2 and J3 C-H cross-coupling. The HMBC spectrum of 20a 
showed the diagnostic J3 C-H cross coupling of the H-3 triplet at δH 4.52 (t, J = 4.0 Hz, 2H, H-3) with the C-5’ 
carbon resonance at δC 146.2 (Fig 5.19), a cross-coupling relationship which is not possible in 20b. The 




Fig. 5.19: The expanded HMBC of 20a showing the cross-coupling of H-3 with C-5’. 
The third isomer, 20c, was not detected as a major product by tlc and was only revealed later as an 
inseparable minor impurity in the 1H and 13C NMR spectra of 20a (Fig 5.20). Unfortunately there is no way 
to distinguish 20a from 20c structurally from the NMR data, even if they could be separated, as the 
quaternary carbon resonance at C-3’ is too weak to be seen in the HMBC NMR spectra. The exact structure 




Fig. 5.20: The 1H NMR of 20a, showing the peaks of “20c” as an un-isolatable minor product. 
The next derivative featured a 1H-pyrazole-3-carboxamide base in place of ribavirin’s 1H-triazole-3-
carboxamide. Once again 9 was unavailable commercially and had to be made from 1H-pyrazole-3-















Fig. 5.21: Reagents and conditions: i) MeOH, H2SO4, reflux, ii) MeOH/NH3, 40°C 
The same procedure which was used to produce 8, was unsuccessful with 1H-pyrazole-3-carboxylic acid. 
Thus, 9 had to be synthesised in 2 steps, with the methyl ester as an intermediate. Refluxing 1H-pyrazole-3-
carboxylic acid in methanol with 1.2 equivalents of H2SO4 quantitatively produced the methyl ester. 1.2 
Equivalents (as opposed to a catalytic quantity) of acid had to be used, due to the basic character of the 
pyrazole ring. After isolating the methyl ester by extraction with ethyl acetate from a saturated sodium 
carbonate solution, the methyl ester was warmed in a solution of methanol and ammonia to afford 9 in an 
overall yield of 86%. The 1H NMR spectrum of 9 in DMSO showed the presence of an AB doublet pair at δH 
7.71 (d, J = 2.0 Hz, 1H, H-5’) and δH 6.67 (d, J = 2.0 Hz, 1H, H-4’) as well as two broad singlets at δH 7.54 (s, 
1H, N-H) and δH 7.19 (s, 1H, N-H), indicative of the amide hydrogens. A minor impurity was also observed 
and thought to be a possible tautomer of 9, but the product was deemed to be sufficiently pure for use in 
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the next step. IR spectroscopy also showed the presence of the new primary amide with absorptions at max 
3405 (N-H), 3266 (N-H), 1698 (C=O) cm-1, while mass spectroscopy confirmed the structure with HRMS (ES): 
112.0494 (M+ + H), correlating closely to expected value for the molecular formula C4H6N3O (M








































Fig. 5.22: Reagents and conditions: i) Cs2CO3, DMF, 100°C, 21a: 42%, 21b: trace 
With 9 in hand, the reaction with 6 under the usual conditions was performed to produce 21a in a modest 
yield of 42% (Fig 5.22). Although formation of both 21a and its regioisomer 21b were expected, the tlc 
profile of the reaction showed only one spot, even when developed across a range of different solvent 
systems. The 1H NMR spectrum of 21a showed the presence of an inseparable impurity, which given the 
nature and chemical shifts of the impurity peaks (Fig 5.23), suggested the formation of the regioisomer, 
21b, in trace quantities. The structural distinction between 21a and 21b was made based on analogy with 
compounds 20a and 20b, specifically by the relative position of the H-3 triplet in each case. The N1-
alkylated product, 20a, showed a triplet at δH 4.52 (t, J = 4.0 Hz, 2H, H-3), relatively upfield of the 
corresponding peak in the spectrum of its regioisomer 20b which appeared at δH 4.90 (t, J = 5.5 Hz, 2H, H-
3). This relationship was applied by analogy to assign the H-3 resonances in the spectrum of 21a and 21b 
(Fig 5.23), thus the major H-3 resonance in the spectrum was assigned to 21a. 
The other dominant peaks in the 1H NMR spectrum showed the amide hydrogens at δH 6.79 (s, 1H, NH2) 
and δH 5.79 (s, 1H, NH2), as well as the aromatic AB pair of H-4’coupling to H-5’ at δH 7.50 (d, J = 2.4 Hz, 1H, 
H-5’) and δH 6.76 (d, J = 2.4 Hz, 1H, H-4’). All the expected resonances indicative of the PME backbone were 
also present in the 1H NMR spectrum. 13C NMR spectroscopy again revealed the presence of minor impurity 
peaks throughout the spectrum, with both their splitting patterns and chemical shifts shadowing the 
dominant product peaks assigned to 21a. The 13C NMR spectrum, like the 1H NMR spectrum, showed all the 
relevant PME backbone peaks, as well as the aromatic carbon resonances at δC 146.4 (C-3’), δC 132.1 (C-5’) 
and δC 107.1 (C-4’) and the amide carbonyl resonance at δC 164.1 (C=O). The 
1H decoupled 31P NMR 




Fig. 5.23: The 13C and 1H NMR spectra of 21a, showing the proposed minor product 21b as an impurity. 
The final analogue in this series featured an amide-bearing imidazole ring, which, as in the case of the 
pyrazole derivative discussed above, had to be synthesised from the relevant carboxylic acid. This was again 
achieved thorough the formation and subsequent ammonolysis of the methyl ester of 1H-imidazole-4-
carboxylic acid. The same procedure used to form pyrazole 9 was used in the formation of the imidazole 















Fig. 5.24: Reagents and conditions: i) MeOH, H2SO4, reflux, ii) MeOH/NH3, 40°C. 
Following ammonolysis, the 1H NMR spectrum of 10 revealed H-2 and H-5 as singlets at δH 7.70 (s, 1H, H-2) 
and δH 7.61 (s, 1H, H-5) respectively, while the amide hydrogens resolved as two broad singlets at δH 7.39 
and δH 7.07, each integrating for 1H. The 
13C NMR spectrum showed four resonances at δC 164.3 (C=O), δC 
137.9 (C-2), δC 136.4 (C-5), δC 121.6 (C-4), with the weak, downfield resonace at δC 164.3 indicative of the 
carbonyl carbon. With 10 in hand, an alkylation with the PME synthon 6, was performed under the usual 
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reaction conditions (Fig 5.25) and despite the presence of two nucleophilic triazole nitrogens (hence two 
possible alkylation products),the formation of only one major reaction product was observed (by both tlc 




























Fig. 5.25: Reagents and conditions: i) Cs2CO3, DMF, 100°C, 42% 
The 1H NMR spectrum of 22 showed all the standard PME resonances such as the diastereotopic methyl 
doublets at δH 1.27 (d, J = 6.2 Hz, 6H, CH(CH3)2) and δH 1.24 (d, J = 6.2 Hz, 6H, CH(CH3)2), the isopropyl CH 
multiplet at δH 4.65 (m, 2H, CH(CH3)2) and the strong P-H doublet at δH 3.79 (d, JPH = 8.3 Hz, 2H, C-1). The 
more deshielded H-3 triplet appears at δH 4.30 (t, J = 5.2 Hz, 2H, C-3). The imidazole ring showed the two 
expected diagnostic singlets at δH 7.69 (s, 1H, H-5’) and δH 7.64 (s, 1H, H-2’), as well as the amide hydrogens 
as broad singlets at δH 7.14 (s, 1H) and δH 6.56 (s, 1H). The 
13C NMR showed all the expected resonances 
including the three imidazole ring signals at δC 138.4 (C-5’), δC 138.0 (C-4’) and δC 123.4 (C-2’), as well as the 
carbonyl carbon resonance δC 165.1. All the 


















Synthesis of an arylethynyltriazole ANP derivative via a Sonogashira cross-coupling reaction. 
6.1 Introduction 
Arylethynyltriazole acyclic nucleoside derivatives were discussed in Chapter 2 as a new class of anti-viral 
agent, with the 4-fluorophenylethynyl triazole-3-carboxamide acyclic nucleoside derivative, A (Fig 6.1), 
shown to possess a high level of activity against HCV and other RNA viruses.72 Compound A, which was 
conceptualised from the cyclic nucleoside E,70 features an acyclic nucleoside chain, suggesting that its 
mechanism of action is in some way related to other acyclic nucleoside analogues. As of yet acyclic 
nucleotide analogues of these biaryl type derivatives have not been explored. This chapter will discuss the 
synthesis and analysis of the ANP derivative 24’ through a Sonogashira palladium (0) catalysed cross-
























E 24'A  
Fig. 6.1: The structures of the cyclic nucleoside analogue E, the acyclic nucleoside analogue A, and the 
target ANP arylethynyltriazole derivative 24’. 
 
6.2 Overview of the Sonogashira reaction. 
The Sonogashira cross-coupling reaction was developed by Kenkichi Sonogashira in 1975, and has been 
widely applied within the field of nucleoside and nucleotide synthesis.89 The reaction, along with other 
palladium catalysed reactions, has over the years become of great importance to medicinal chemists as a 
means of generating complex structures through the formation of new C-C bonds under relatively mild 
reaction conditions. This reaction had been previously used in our research group as a key coupling reaction 
in the synthesis of bifunctional HIV RT inhibitors,90 and this work served as a starting point for the 
exploration of Sonogashira cross-coupling reactions in the context of arylethynyltriazole-based ANPs. 
The mechanism of the Sonogashira reaction involves firstly the oxidative insertion of Pd(0)(PPh3)2 (a 14e
- 
species) into an appropriate aryl-leaving group bond to form an aryl-Pd(II)-halide complex (a 16e- species.) 
A copper-activated acetylide, formed from the reaction of a terminal alkyne with CuI in the presence of a 
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base, then undergoes transmetallation with the palladium complex to form a new alkynyl-Pd-aryl species, 
which reductively eliminates to form the required product and the regenerated catalyst.89 The mechanism 






















Fig. 6.2: The mechanism of the Sonogashira cross-coupling reaction.89 
Practically, Sonogashira reactions may be carried out under a large range of reaction conditions involving 
many different solvents as well as bases either inorganic or organic. In such a way, the reaction conditions 
can be optimized for any given substrate.70,72,73,89,90 The solvent used has been shown to have a large 
influence on reaction yields as well as product specificity. The Sonogashira reaction is also very oxygen-
sensitive when using Pd(PPh3)4 and all solvents and reactants need to be thoroughly degassed with an inert 
gas such as nitrogen or argon before the oxygen-sensitive palladium catalyst is introduced. 
6.3 The synthesis of ANP arylethynyltriazole derivative 24’. 
The literature premise for the synthetic work towards the target arylethynyltriazole ANP 24’, came from 2 
articles from 2007 and 2008 by Zhu et al.,72,73 in which the authors described their synthesis of A through a 
Sonogashira cross-coupling. They started by converting the commercially available methyl 5-amino-1H-
1,2,4-triazole-3-carboxylate to methyl 5-bromo-1H-1,2,4-triazole-3-carboxylate 11 via a Sandmeyer 
diazotization reaction. Subsequent ammonolysis, alkylation with an acyclic side chain and deprotection 
yielded precursor P73 (Fig 6.3) which was then used to synthesise a large library of aryltriazole73 and 
arylethynyltriazole72 acyclic nucleoside analogues that included the promising compound A.72 Their 




























































































ii) ii) ii) ii)
H I
A
 Fig. 6.3: The synthesis of 1f via the intermediate P, as described by Zhu et al.72,73 Reagents and conditions: 
i) NaH, CH3CN, RT; ii) NH3, MeOH. 
The first step of their synthesis involved the transformation of methyl 5-amino-1H-1,2,4-triazole-3-
carboxylate to methyl 5-bromo-1H-1,2,4-triazole-3-carboxylate (11) through a Sandmeyer reaction, which 
was then alkylated with a protected side chain group (Fig 6.3).72 This reaction gave four products as the two 
anticipated regioisomers, methyl 5-bromo-1H-1,2,4-triazole-3-carboxylate and methyl 5-bromo-2H-1,2,4-
triazole-3-carboxylate derivatives F and H, as well as two 5-chloro derivatives G and I, which formed as the 
result of a halide exchange with the chloride ion generated from the alkylation reaction.72 According to the 
paper, the methyl esters F and G could not be separated by chromatography and the distinction between 
the two compounds could only be seen in the different chemical shifts of the anomeric carbons in the 13C 
NMR spectra; however, after ammonolysis (which resulted in the transformation of the methyl esters to 
the amides and removal of the benzoyl protecting groups), P and G’ could be separated through 
recrystallization, after which their structures were confirmed by X-Ray crystallography. The 5-chloro 
derivatives G’ and I’ were found to be poor substrates for the Sonogashira reaction and a method was 
eventually developed which avoided its formation.72 
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Given these results,72,73 the exact synthetic route towards the synthesis of 24’ was initially unclear. 
Retrosynthetic analysis identified a choice regarding the timing of the alkylation step in view of the halide 
exchange issue discussed above. It was thus decided to carry out the Sonogashira reaction first in order to 




































































Fig. 6.4: The retrosynthetic analysis of 24’ via the two possible initial disconnections. 
The synthesis, as shown in Fig 6.5, began with a Sandmeyer reaction of the commercially available methyl 
5-amino-1H-1,2,4-triazole-3-carboxylate, the mechanism of which is shown in Fig 6.6. The reaction 
proceeds via an aromatic diazonium salt formed from reaction of the aromatic amine with nitrous acid 
formed in situ. In the presence of a copper(I) halide catalyst, the diazonium salt then transforms through a 
radical-nucleophilic aromatic substitution to an aromatic halide while eliminating nitrogen gas, which helps 


























Fig. 6.5. The synthetic strategy for the synthesis of 24’ developed from the retrosynthetic route X. Reagents 
and conditions: i) NaNO2, H2SO4, KBr (2 eq), CuI (5 mol%), rt; 75%; ii) NH3, MeOH; 98% iii) 1-ethynyl-4-









































Fig. 6.6: The reaction mechanism of the Sandmeyer reaction. 
The aromatic diazonium salt of methyl 5-amino-1H-1,2,4-triazole-3-carboxylate was formed at 0°C, after 
which a solution of potassium bromide (2 eq., large excess relative to catalyst) and a catalytic amount of 
Cu(I)I (5 mol%) was slowly added to the solution. The ideal catalyst to use for this reaction would have been 
Cu(I)Br, but due to its unavailability at the time, Cu(I)I was used as a substitute source of Cu(I) ions to 
catalyse the reaction , while the overwhelming excess of bromide ions provided the nucleophile. Upon the 
addition of the CuI and potassium bromide solution, nitrogen gas rapidly evolved and the solution was 
allowed to stir at room temperature for 3hrs to ensure complete conversion of the diazonium salt to the 
bromide 11, which could be readily extracted from the aqueous reaction mixture with ethyl acetate and 
purified by column chromatography, in a good yield of 75%. 1H NMR analysis, as expected, only revealed a 
resonance for the methyl ester, which in DMSO appeared as a singlet a δH 3.89. The 
13C NMR spectrum was 
unable to reveal the two quaternary carbons contained in the triazole ring and was only able to show the 
carbonyl and methyl resonances at δC 157.4 and δC 52.7. The only true confirmation of structure was 
obtained through the use of high resolution mass spectroscopy which gave HRMS (EI): 204.9483 (M+) 
correlating closely with the molecular formula C4H4BrN3O2 (expected, 204.9487 (M
+)). 
Stirring 11 in the presence of ammonia and methanol generated the amide 12 in a yield of 98%. The 1H 
NMR spectrum of 12 showed two new broad N-H singlets at δH 8.25 (brs, 1H, N-H) and 7.96 (brs, 1H, N-H), 
indicating the expected restriction of rotation around the amide C-N bond. The 13C NMR spectrum 
successfully resolved the three carbon resonances at δC 157.4 (C=O), δC 150.9 (C-1) and δC 150.0 (C-2). 
Again, the structure was confirmed with the use of mass spectroscopy with HRMS (ES): 190.9568 (M+ + H), 
which correlated exactly with the molecular formula C3H4BrN4O (expected M
+ + H, 190.9568). 
With 12 in hand, a Sonogashira reaction was attempted with 1-ethynyl-4-fluorobenzene, using 
triethylamine as base. The solvent system of THF/DMF (2:1) was chosen, as this combination had been used 
in our laboratory in the past with great success;90 however, the reaction failed (Fig 6.5). The failure of the 
reaction was thought to be due to the fact that the triazole was being deprotonated and that this was in 
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some way interfering with the formation of the aryl-Pd(II)-halide complex or the formation of the copper-
activated acetylide species. In order to counteract this problem, it was decided to N-protect the triazole 




















Fig. 6.7: The strategy for the synthesis of protected derivatives of 12. Reagents and conditions: i) acyl 
chloride, NaH, DMF; ii) benzoyl chloride, NaH, DMF. 
An attempt was made to protect the triazole ring of 12 by acylation of the triazole nitrogen with both acyl 
chloride and benzoyl chloride in DMF. The reaction of 12 with benzoyl chloride showed no progress even 
after 12 hours at reflux while the formation of the acyl-protected derivative of 12 was also unsuccessful. 
Instead of trying additional N-protecting groups, despite the concerns surrounding the halide exchange 
mentioned previously, and the worry that the presence of the bulky phosphonate group would sterically 
hinder the Sonogashira reaction, it was decided to N-alkylate first with synthon 6 to form the precursor to 
the Sonogashira reaction, 23’ (Fig 6.8). This would solve the problem of protecting the triazole ring and 



































Fig. 6.8. The synthetic strategy for the synthesis of 24’ developed from the retrosynthetic route Y. Reagents 
and conditions: i) Cs2CO3, DMF, 100°C 65%. ii) 1-ethynyl-4-fluorobenzene, Pd(PPh3)4, CuI, NEt3, THF/DMF, rt-
reflux. 
Thus, 12 was reacted with the synthon 6 with Cs2CO3 as a base under the same reaction conditions used in 
the general procedure which was described in Chapter 5. In this case the reaction took 48 hours to reach 
completion, which was much longer than the other reactions. This could possibly be attributed to the 
strong electron-withdrawing groups present on the triazole ring, which would decrease the nucleophilicity 
of the triazole nitrogen, resulting in a much lower reaction rate. Isolation of the major reaction product 
afforded 23 in a moderate yield of 65%. Its IR spectrum showed the presence of the amide and 
phosphonate moieties with bands at max 3508 (N-H) cm
-1, 3390 (N-H) cm-1, 1708 (C=O) cm-1, 1284 (P=O) 
cm-1 and 999 (P-O) cm-1. The 1H NMR spectrum of 23 confirmed the presence of the amide hydrogens at δH 
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7.27 (s, 1H, N-H) and δH 6.54 (s, 1H, N-H), as well as all the resonances typical of the side chain and 
phosphonate groups at δH 4.65 (m, 2H, CH(CH3)2), δH 3.98 (t, J = 5.4 Hz, 2H, H-2), δH 3.71 (d, JPH = 8.3 Hz, 2H, 
H-1), δH 1.26 (d, J = 6.2 Hz, 6H, CH(CH3)2) and δH 1.23 (d, J = 6.2 Hz, 6H, CH(CH3)2). The 
13C NMR spectrum 
also displayed all the expected resonances typical of the ANP triazole-3-carboxamide family of compounds. 
Interestingly, H-3 appeared downfield δH 4.83 (t, J = 5.4 Hz, 2H, H-3) analagous to the example of the 
triazole-3-carboxamide compound 20b which was disscused in Chapter 5. 20b featured a downfield H-3 
triplet at δH 4.90 (t, J = 5.5 Hz, 2H, H-3), a similar chemical shift to that possessed by 23. This suggests the 
structure of 23 (and hence 24) is akin to that of 20b rather than 20a (Fig 6.9). Given the analogy with 20b, 
the structure of the alkylation product was assigned as 23 and not 23’. Unfortunately an HMBC spectrum of 
23 was unavailable, while the HMBC spectrum of 24 was inconclusive (discussed below). Thus the exact 








































































Fig. 6.9: The structures of 20a and 20b and the most likely structures of 23 and 24.  
The 1H and 13C NMR and mass spectra of the isolated product, 23, did not show any evidence of the 5-
chlorotriazole derivative. If the 5-chlorotriazole had been formed as an inseparable impurity as discussed 
by Zhu et al.,73 one might have expected to see a residual H-3 peak in the NMR spectra with a slightly 
different chemical shift to that possessed by the target bromide derivative. No residual by-product peak 
could be observed implying that an aromatic substitution of the bromine did not take place under these 
specific reaction conditions. 
With 23 in hand, work began on the Sonogashira cross coupling reaction using the conditions that had 
previously been used in our laboratory.90 Tetrakis(triphenylphosphine)palladium(0), copper(I) iodide and 1-
ethynyl-4-fluorobenzene were added to a thoroughly degassed solution of 23 and triethylamine in 
THF/DMF (2:1), under an inert argon atmosphere. After stirring at room temperature for 2 hours, no 
reaction was observed so the temperature of the solution was increased to allow the reaction mixture to 
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reflux overnight. This still did not yield a result and after further review of the literature, an approach 




































Fig. 6.10: Reagents and conditions i) 1-ethynyl-4-fluorobenzene, Pd(PPh3)4, CuI, Li2CO3, Dioxane/water (3:1), 
100°C MW, 82%. 
According to the method by Zhu et al.,72 a solution of 23 in dioxane and water (3:1) was prepared and 
thoroughly degassed by bubbling argon gas through it for 30 minutes. Lithium carbonate, 1-ethynyl-4-
fluorobenzene, copper (I) iodide, and tetrakis(triphenylphosphine)palladium(0) (weighed out under argon) 
was then added to the reaction vessel which was flushed with argon gas. The reaction mixture was then 
irradiated under pressure in a microwave reactor for 30 min and worked up with a disodium 
ethylenediaminetetraacetate (EDTA) solution in order to remove any copper ions. Tlc analysis of the 
resulting mixture revealed the product spot to have an Rf value almost identical to that of the starting 
material. The only indication that it was a new product was that it now possessed a dark blue semi-
fluorescent tint under UV light, which was attributed to the extensive conjugated arylethynyltriazole 
system. The product could be readily isolated by column chromatography by first removing the 
tetrakis(triphenylphosphine)palladium(0) by flushing with petroleum ether (100%) and then eluting the 
product with ethyl acetate (80%-100%) to afford 24 in an 82% yield (Fig 6.10). 
IR spectroscopy showed the presence of a primary amide with bands at max 3508 (N-H) cm
-1, 3390 (N-H) 
cm-1 and 1705 (C=O) cm-1. The phosphonate could be seen at max 1234 (P=O) cm
-1 and 994 (P-O) cm-1, while 
the new triple bond showed an absorbance at max 2231 (C≡C) cm
-1. The 1H NMR spectra of 24 (Fig 6.11) 
showed the amide resonances at δH 7.27 (s, 1H, N-H) and δH 6.14 (s, 1H, N-H), while again the peaks 
associated with the diisopropyl phosphonate were displayed δH 4.68 (m, 2H, CH(CH3)2), δH 3.74 (d, JHP = 8.3 
Hz, 2H, H-1), δH 1.29 (d, J = 6.2 Hz, 6H, CH(CH3)2) and δH 1.27 (d, J = 6.2 Hz, 6H, CH(CH3)2). As in the 
1H NMR 
spectrum of 23 the H-3 resonance was observed to be relatively upfield at δH 4.90 (t, J = 5.4 Hz, 2H, H-3), 
which is analogous to the H-3 resonance in 20b. The aromatic region of the 1H NMR spectrum revealed H-
4’’ as a doublet of doublets at δH 7.56 (dd, JHH; HF = 8.4, 5.3 Hz, 2H, H-4’’) which arises from an H-H coupling 
(JHH = 8.4) and a long range J
4 H-F coupling (JHF = 5.3). A second aromatic signal, interpreted as a doublet of 
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doublets with two equal coupling constants, was assigned to H-5’’ at δH 7.05 (dd, JHH; HF = 8.4, 8.4 Hz, 2H, H-
5’’) and displayed a J3 H-F coupling (JHF = 8.4), as well as an H-H coupling (JHH = 8.4) which resulted in the 
formation of an AB doublet pair with H-4’’. 
 
Fig. 6.11: The 1H NMR spectrum of 24. 
The 13C NMR spectrum (Fig 6.12) displayed all the PME side chain resonances at δC 71.4 (d, JCP = 6.6 Hz, 
CH(CH3)2), δC 70.9 (d, JCP = 10.6 Hz, C-2), δC 65.9 (d, JCP = 167.2 Hz, C-1), δC 50.6 (C-3), δC 24.2 (d, JCP = 3.7 Hz, 
CH(CH3)2 ) and δC 24.1 (d, JCP = 4.5 Hz, CH(CH3)2) as expected. The diagnostic triple bond carbon’s C-1” and 
C-2” were revealed at δC 79.3 (C-1’’) and δC 89.1 (C-2’’). The carbon resonances at δC 134.3 (d, JCF = 8.6 Hz, C-
4’’) and δC 116.0 (d, JCF = 22.3 Hz, C-5’’) were assigned based on their C-F coupling constants and their 
proximity to the fluorine atom. All of the above assignments were confirmed through the use of HSQC and 
HMBC NMR. A large J1 C-F coupling was observed for the resonance at δC 163.4 (d, JCF = 251.6 Hz, C-6’’), 
while a small long range J4 C-F coupling was observed for the resonance indicative of C-3’’ at δC 117.5 (d, JCF 
= 3.4 Hz, C-3’’). Further evidence for the overall structure of 24 was provided by high resolution mass 
spectroscopy, with HRMS (ES): m/z found as 453.1712 (M+ + H), which corelated closely with the molecular 
formula C20H27FN4O5P (expected (M




Fig. 6.12: The 13C NMR spectrum of 24. 
The HMBC NMR spectrum was inconclusive with regard to assignment of the exact structure as either 24 or 
24’ (Fig 6.9). The 13C chemical shifts of the carbon resonances of C-3’and C-5’ at δC 146.5 (C-3’) and δC 146.1 
(C-5’) were very close together and the resulting cross-peak could not be distinguished as a C-5’: H-3 or C-
3’: H-3 cross coupling. Thus, the assignment of the structure of 24 was made based on analogy with the 















Cleavage of the diisopropyl phosphonate ester. 
7.1 Introduction 
As discussed in Chapter 2, the activity of acyclic nucleotide phosphonates in general lies in their ability to 
readily undergo intracellular phosphorylation to active di-phosphorylated species, which is a requirement 
for attachment onto the growing chain of genetic material through a substitution reaction on the 
phosphonate phosphorus. Such activation proceeds via the di-phosphonic acid, and as studies have shown 
the enzymatic hydrolysis of the isopropyl protecting group is slow enough to decrease the overall potency 
of the drug,43 a selection of the diisopropyl protected derivatives discussed in chapter 5 were converted to 














Fig. 7.1. Reagents and conditions: i) TMSBr, DCM or CH3CN, 0°C-rt; ii) MeOH or H2O. 
The reaction mechanism (Fig 7.2) involves the phosphonate oxygen reacting with TMSBr to form a 
phosphonium salt with the expulsion of a bromide ion.91 This then promotes an Arbuzov-like 
rearrangement, releasing isopropyl bromide, resulting in the isopropyl trimethylsilyl protected 
intermediate. The process repeats itself to afford the bis(trimethylsilyl) protected intermediate, which can 


































































7.2 Synthesis of phosphonic acid ANP derivatives. 
The reaction described above has been widely used in the field of ANP synthesis56,66,81,92 as an efficient, high 
yielding way to access phosphonic acids from isopropyl esters. Generally, the reaction is performed in 
either DCM or CH3CN at room temperature with an excess of TMSBr, usually between 3 or 6 equivalents. 
Practically, the most difficult aspect of the reaction is the purification of the highly polar products and 
various techniques such as aqueous extraction, recrystallization or ion-exchange chromatography, have 
been used.56,66,81,92 
Where possible, deprotection of the diisopropyl protected ANP’s discussed in Chapter 5 was carried out 
under the general reactions conditions described above. The first deprotection involved the uracil 





























Fig. 7.3. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) H2O, 84% 
A highly polar tlc solvent system (used for all the phosphonic acid derivatives discussed in this chapter) 
consisting of water, acetic acid, 1-butanol and acetone (1:1:1:1), was able to lift the product off the 
baseline of the tlc plate which confirmed the reaction to be complete. A small amount of water was added 
to hydrolyse the bis-silyl phosphonate esters, after which all solvents were removed under high vacuum. 
Toluene was used to azeotropically aid the removal of water and the resulting residue could then be 
dissolved in hot methanol. The product was then precipitated out of this solution by adding cold DCM to 
afford 25 as a fine white powder in an 84% yield. 
IR spectroscopy from a potassium bromide pellet showed absorption corresponding to the phosphonic acid 
moiety at max 3020 cm
-1 (O-H), 1250 cm-1 (P=O) and 1013 cm-1 (P-O). The 1H NMR spectrum of 25, as in the 
spectrum of 13, showed the AB doublet pair of H-6’ and H-5’ at δH 7.58 (d, J = 7.9 Hz, 1H, H-6’) and δH 5.61 
(d, J = 7.9 Hz, 1H, H-5’). The resonances indicative of H-3, H-2 and H-1 could be observed, as expected, at δH 
3.96 (t, J = 4.9 Hz, 2H, H-3), δH 3.80 (t, J = 4.9 Hz, 2H, H-2) and δH 3.74 (d, J = 8.8 Hz, 2H, H-1) while the 
absence of CH(CH3)2 multiplet and the diastereotopic methyl doublets confirmed the successful removal of 
the isopropyl groups. The uracil N-H exchanged with the deuterated methanol NMR solvent and was not 
observed. The 13C NMR spectrum showed all the expected resonances indicative of the uracil ring and side 
chain. Since the CH(CH3)2 had been eliminated the only remaining resonance in that region of the spectrum, 




11.6 Hz of C-2 in the 13C NMR spectrum of 25, correlated with the chemical shift and coupling constant of 
the resonance assigned to C-2 (and not CH(CH3)2) in the 
13C NMR spectrum of 13 (Chapter 4). High 
resolution mass spectroscopy provided further evidence of the successful deprotection of the phosphonate 
showing: HRMS (ES) for 25 of 251.0423 (M+ + H), which correlated with the molecular formula C7H12N2O6P 






























Fig. 7.4. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) H2O, 83% 
The same procedure used to prepare and isolate 25 was also used to form the thymine derivative 26 in a 
yield of 83%. The 1H NMR spectrum of 26 again revealed the resonances associated with the PME side chain 
at δH 3.93 (t, J = 5.0 Hz, 2H, H-3), δH 3.79 (t, J = 5.0 Hz, 2H, H-2) and δH 3.74 (d, JPH = 8.9 Hz, 2H, H-1). The 
thymine hydrogen H-6’ resonated as a singlet at δH 7.43 (s, 1H, H-6’) while the thymine methyl H-7’ was 
observed at δH 1.86 (s, 3H, H-7’). The 
13C NMR spectrum revealed the expected resonances of the thymine 
ring, thymine methyl and the PME side chain including the P-C coupled doublet at δC 71.9 (d, JPC = 11.7 Hz, 
C-2), which through the same process of elimination discussed above, helped confirm the C-2 assignment in 
the 13C NMR spectrum of the precursor 14. Similarly, mass spectroscopy confirmed the correct structure 
with an HRMS (ES) peak at 265.0581 (M+ + H), with C8H14N2O6P requiring 265.0584 (M
+ + H). 
The next derivatives, 27-36, could not be crystallized or precipitated, and attempts to purify them via 
anion-exchange chromatography also proved unsuccessful, probably due to excessively strong ionic 
interactions with the positively charged ion exchange resin. Any attempts to dislodge the compound from 
the resin with sufficiently concentrated hydrochloric acid resulted in degradation of the target molecule.  
Topalis et al.92 discussed an alternative method for isolating phosphonic acid derivates whereby the silyl 
phosphate esters, generated from the reaction of the protected phosphonate and TMSBr, were hydrolysed 
by methanol to release the target phosphonic acid and methoxytrimethylsilane (TMSOMe), a volatile by-
product which could be evaporated off under high vacuum with mild heating. The polar phosphonic acid 
could then be extracted into an aqueous medium while any other residual organic impurities were 
removed. Removal of the water by evaporation, in most cases gave the final product as an amorphous solid 
or thick oil. The first product to be purified in this way was the cytosine derivative 27 which was formed 
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Fig. 7.5. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 91%. 
Compound 27 was isolated as an amorphous solid in a yield of 91%, with a melting point range of 164-
166°C which is similar to the melting-point range reported in the literature [lit Mp: 167-168°C].81 The IR 
spectrum of 27, recorded from a potassium bromide pellet, showed absorptions at max 3483 cm
-1 (O-H), 
3313 cm-1 (N-H stretch), 1684 cm-1 (C=O), 1660 cm-1 (N-H bend), 1250 cm-1 (P=O) and 998 cm-1 (P-O), 
indicating the presence of the amine, the cytosine carbonyl and the phosphonate moiety. The 1H NMR 
spectrum (Fig 7.6) was diagnostic by virtue the absence of the two isopropyl peaks. H-6’and H-5’ were 
revealed as an AB doublet pair at δH 7.93 (d, J = 7.6 Hz, 1H, H-6’) and δH 6.04 (d, J = 7.6 Hz, 1H, H-5’). In the 
13C NMR spectrum, the four cytosine carbon resonances were observed at δC 161.6 (C-2’), δC 152.3 (C-6’), δC 
149.1 (C-4’) and δC 93.8 (C-5’), while the PME side chain resonances were present at δC 71.0 (d, JPC = 11.2 
Hz, C-2) and δC 50.3 (C-3), with a strong P-C phosphonate doublet at δC 67.3 (d, JPC = 163.9 Hz, C-1). Mass 
spectroscopy gave further evidence for the structure showing (ES): 250.0581 (M+ + H), which corresponded 
to the molecular formula of C7H13N3O5P (expected 250.0587 (M
+ + H)). 
 
Fig. 7.6: The 1H NMR spectrum of 27. 
After the successful synthesis of 27, deprotection of the diisopropyl phosphonate 2-hydropyrazine 
derivatives 16a and 16b was then attempted with little success. Tlc of each reaction mixture showed the 
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conversion of starting material to a possible product; however, all attempts to isolate the new phosphonic 
acid derivatives of 16a and 16b failed, suggesting the products to be degrading during the isolation step. 
Although the exact reason for the degradation was not clear, it was postulated that the presence of HBr, 
generated from the reaction of methanol and residual TMSBr, was able to protonate the pyrazine ring, 
activating it as a leaving group. 
The next derivative, 28, was prepared from the 2,4-diaminopyrimidine derivative 17 using the same 






























Fig. 7.7. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 93%. 
As compounds 28-33 were formed as thick oils only soluble in methanol, water and DMSO, acquisition of 
their IR spectra from a standard potassium bromide pellet, sodium chloride nujol plate or solution cell was 
impossible. The IR spectra of 28-33 were thus recorded using an ATR-IR (Attenuated total reflectance- 
Infrared) spectrometer, whereby the spectrum was recorded directly from the neat, unprepared sample 
placed on a diamond crystal. Infrared radiation passed through the crystal generates an evanescent wave, 
which penetrates the sample before being reflected back into the crystal and collected by a sensor. The IR 
spectrum of 28 displayed absorptions at max 3361 cm
-1 (O-H), 3087 cm-1 (N-H stretch), 3023 cm-1 (N-H 
stretch), 1670 cm-1 (N-H bend), 1659 cm-1 (N-H bend), 1222 cm-1 (P=O) and 1076 cm-1 (P-O), again indicating 
the presence of the aromatic amine, and the phosphonic acid. 
The 1H NMR spectrum of 28 did not show any signals relating to the isopropyl groups, confirming their 
removal. The PME side chain resonances were all present at δH 3.78 (d, JPH = 8.4 Hz, 2H, H-1), δH 3.76 (t, J = 
4.9 Hz, 2H, H-2) and δH 3.68 (t, J = 4.9 Hz, 2H, H-3) with H-2 and H-3 appearing relatively upfield, as was the 
case in the 1H NMR spectrum of 17. H-6’ and H-5’ were observed as an AB coupled doublet pair with 
resonances at δH 7.56 (d, J = 7.3 Hz, 1H, H-6’) and δH 6.13 (d, J = 7.3 Hz, 1H, H-5’). The 
13C NMR spectrum 




















Fig. 7.8. The unsuccessful dealkylation of 18. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH. 
A dealkylation of the 2-amino-4-cyanopyrimidine derivative 18 using TMSBr in DCM before quenching with 
methanol, was also attempted but as with the case of 16a and 16b, all attempts to workup and purify the 
reaction product were unsuccessful (Fig 7.8). This was again thought to be due to a side reaction with HBr, 
possibly involving the cyano group. Work then began on deprotection of the ribavirin analogues 19, 20a, 
20b, 21 and 22. The first of these derivatives was formed from the dealkylation of 19 via the same 






















Fig. 7.9. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 99%. 
The 1H NMR spectrum of 29 revealed the triazole hydrogens as two singlets at δH 9.82 (s, 1H, H-4’) and δH 
8.90 (s, 1H, H-3’), while the PME hydrogens were observed at δH 4.70 (t, J = 4.9 Hz, 2H, H-3), δH 4.08 (t, J = 
4.9 Hz, 2H, H-2) and δH 3.81 (d, JPH = 8.8 Hz, 2H, H-1). The resonances typical of the isopropyl groups were 
again absent in both the 13C and 1H NMR spectra confirming successful dealkylation. The 31P decoupled 
spectrum displayed a single phosphorus peak at δP 18.6. Mass spectroscopy confirmed the structure 
showing a protonated molecular ion (M+ + H) of 208.0479 which corresponds very closely to the molecular 
formula of C5H11N3O4P which requires 208.0482. 
The next derivative, 30, was synthesised from ribavirin mimic 20a using the standard dealkylation 


























20a 30  
Fig. 7.10. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 89%. 
The 1H NMR spectrum of 30 did not show the two distinct N-H amide singlets as those hydrogens were able 
to exchange with the deuterium from the deuterated methanol solvent. However, ATR-IR spectroscopy 
showed the N-H amide bands at max 3337 cm
-1 and 3112 cm-1; a region which is known to display primary 
amide peaks in ATR-IR spectra,93 while the 13C NMR showed the resonance associated with the amide 
carbonyl carbon at δC 160.4 (C=O). The
 1H NMR showed all the expected PME resonances at δH 4.64 (t, J = 
4.9 Hz, 2H, H-3), δH 4.06 (t, J = 4.9 Hz, 1H, H-2) and δH 3.81 (d, JPH = 8.8 Hz, 1H, H-1), as well as a minor 
unknown impurity (10%) in the aromatic region of the spectrum. The impurity was also reflected as minor 
peaks in the aromatic region of the 13C NMR spectrum. Despite repeated attempts with conventional 
purification methods such as recrystallization and extraction, it could not be removed. Electrospray mass 
spectroscopy revealed a protonated molecular ion peak of 251.0535, which corresponded to the expected 
value of 251.0540 (M+ + H) for a compound with a molecular formula of C6H12N4O5P. 
The same reaction was repeated using the N2-alkylated regioisomer 20b to afford the ribavirin ANP 
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Fig. 7.11. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 89%. 
The 1H NMR spectrum of 31 showed the aromatic H-5’ resonance at δH 8.25 (s, 1H, H-5’) and also revealed 
the PME side chain signals at δH 4.88 (t, J = 5.3 Hz, 2H, H-3), δH 4.04 (t, J = 5.3 Hz, 2H, H-2) and δH 3.78 (d, JPH 
= 8.7 Hz, 2H, H-1). 1H NMR spectrum showed, through the absence of both isopropyl related resonances, 
that the compound had been successfully dealkylated. The 13C NMR spectrum confirmed this conclusion as 
only the PME side chain peaks at δC 72.0 (d, JPC = 11.7 Hz, C-2), δC 66.8 (d, JPC = 163.4 Hz, C-1) and δC 51.4 (C-
3), and the triazole and carbonyl carbon resonances at δC 159.6 (C=O), δC 149.3 (C-5’) and δC 147.7 (C-3’), 
could be observed. IR spectroscopy showed the amide bands at max 3376 cm
-1(N-H), 3123 cm-1 (N-H) and 
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1688 cm-1 (C=O), while phosphonate absorptions were observed as expected at 1249 cm-1 (P=O) and 995 
cm-1 (P-O). Electrospray mass spectroscopy again provided evidence for the structure, showing m/z found 
to be 251.0535 (M+ + H) which corresponded closely to the expected value of 251.0540 for the molecular 
formula C6H12N4O5P. 
The pyrazole derived diisopropyl protected ANP, 21, was reacted with TMSBr via the standard reaction 
procedure to afford the phosphonic acid 32 as an oil in a yield of 97% (Fig 7.12). Unfortunately, 32 was 
found to be relatively impure with impurity peaks present in all spectra. Preparative reverse phase high 
performance liquid chromatography (HPLC) could have possibly been used to purify the highly polar 
product but these facilities were unavailable and any attempts to purify 32 using conventional purification 
methods met with failure. It is important to note that the starting material, 21, also contained an impurity 

























Fig. 7.12. Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 97%. 
The 1H NMR spectrum of 32 showed the AB doublet pair indicative of H-5’ and H-4’ at δH 7.79 (d, J = 2.3 Hz, 
1H, H-5’) and δH 6.77 (d, J = 2.3 Hz, 1H, H-4’) as well as the PME side chain resonances at δH 4.42 (t, J = 4.9 
Hz, 2H, C-3), 3.96 (t, J = 4.9 Hz, 2H, C-2), 3.73 (d, JPH = 8.9 Hz, 2H, C-1). The 
13C NMR spectrum showed 
aromatic carbon resonances at δC 146.5 (C-3’), δC 133.8 (C-5’) and δC 107.6 (C-4’) as well as the amide 
carbonyl signal at δC 167.0 (C=O), all of which corresponded in chemical shift to the aromatic resonances in 
the 13C NMR spectrum of the parent molecule 21. The amide N-H bands in the ATR-IR spectrum were not 
resolved due to a high level of baseline noise present in the spectrum, which may have been due to high 
levels of water or methanol in the sample, despite being dried under high vacuum for well over 48 Hours. 
Mass spectroscopy showed a peak at 250.0587 (M+ + H) corresponding with the expected value 250.0587 
(M+ + H) for the molecular formula of 32 (C7H13N3O5P). 
The final derivative to be successfully dealkylated under the standard deprotection conditions was the 



























Fig. 7.13: Reagents and conditions: i) TMSBr, DCM, 0°C-rt; ii) MeOH, 94% 
ATR-IR spectroscopy revealed the presence of the amide in 33 with absorption at max 3325 cm
-1 (N-H), 
3131 cm-1 (N-H) and 1680 cm-1 (C=O), while the peaks at max 1232 cm
-1 (P=O) and 997 cm-1 (P-O) indicated 
the presence of the phosphonic acid. 1H NMR spectroscopy revealed the aromatic hydrogens, H-2’and H-5’, 
at δH 9.09 (s, 1H, H-2’) and δH 8.25 (s, 1H, H-5’), while as usual the PME side chain peaks were observed as 
two triplets and a doublet at δH 4.55 (t, J = 4.8 Hz, 2H, H-3), δH 4.02 (t, J = 4.8 Hz, 2H, H-2) and δH 3.83 (d, JPH 
= 8.8 Hz, 2H, C-1). The 13C NMR spectrum showed the amide carbonyl at δC 160.2 (C=O), while the three 
aromatic carbons were observed at δC 138.4 (C-4’), δC 129.2 (C-2’) and δC 124.7 (C-5’). The two P-C coupled 
doublets indicative of C-2 and C-1 could be observed at δC 71.6 (d, JPC = 11.7 Hz, C-2), 67.2 (d, JPC = 163.5 Hz, 
C-1), while C-3 was revealed as a singlet at δC 51.0 (C-3).
 The assignments in both the 1H and 13C NMR 
spectra of 33 corresponded with those in the spectra of 22, apart from the isopropyl peaks, whose absence 
again confirmed that dealkylation had taken place. A single resonance was observed in the 31P spectrum at 
δC 18.7. Electrospray mass spectroscopy gave further evidence for the existence of 33 by showing a 
protonated molecular ion peak of 250.0591 (M+ + H), which corresponded closely with the expected value 
of 250.0587 (M+ + H) required by the molecular formula C7H13N3O5P. 
Finally, a dealkylation reaction of the Sonogashira cross coupled product, 24 (Fig 7.14), was also attempted 
but as was the case in the reactions involving compounds 16a, 16b and 18, the product could not be 
isolated. The production of the dealkylated variant of 24 was thus abandoned due to time constraints; 
however, as its structure is particularly interesting, future work should be performed so that the effect of 





























The synthesis of a bis(pivaloyloxymethyl) ANP prodrug 
8.1 Introduction 
Research carried out into the use of prodrug variants of acyclic nucleotide phosphonates as a means of 
increasing the in vivo activity of the drug were discussed in Chapter 2. Since ANPs are generally highly polar 
molecules, especially in their phosphonic acid form, they are often unable to effectively cross cell 
membranes to enter infected cells. Protection of the phosphonic acid moiety through the use of readily 
hydrolysable non-polar protecting groups has been well explored as a way of easily increasing an ANP 
drug’s ability to permeate cell membranes, hence increasing its overall anti-viral activity. This Chapter will 
discuss our own exploratory efforts into the general synthesis of acylmethyloxy ANP prodrugs, through the 


























Fig. 8.1: The structures of 26 and its bis(pivaloyloxymethyl) derivative, 34. 
The alkylation of various phosphonic acids with a range of different non-polar protecting groups, through a 
range of different synthetic procedures has been reported in the literature.54,56,57,61,92 Two dominant 
synthetic approaches exist: The first involves activation of the phosphonic acid to a phosphonic acid halide 
that can undergo attack by an appropriate nucleophilic protecting group (Fig 8.2 A). This has the 
disadvantage that it requires an extra synthetic step to form an air and water-sensitive acid halide, which 
can often be difficult and dangerous to work with; however, this approach is often faster and higher 
yielding due to the use of a reactive intermediate. The second approach uses an electrophilic protecting 
group, with the phosphonate conjugate base as a nucleophile generated from the acid with base (Fig 8.2 B). 
This reaction is much slower and lower yielding than the first approach, often requiring elevated reaction 
















































Fig. 8.2: The two dominant synthetic approaches used in the synthesis of ANP prodrugs. 
Use of approach (A) has seen limited use in the reported literature. The reactive intermediate, I, can readily 
react with nucleophilic centres on the heterocyclic base ring, resulting in undesired by-products. During 
their investigation of bis(trifluoroethyl) phosphonic ester prodrugs, Krecmerová et al.61 attempted to 
circumvent this problem by producing a tosylmethylphosphonate prodrug synthon (the (diisopropyl) 
tosylmethylphosphonate synthon 4 discussed in chapter 4), which could then be alkylated with an 
appropriate heterocycle-bearing hydroxyethyl synthon (Fig 8.3). These alkylation reactions (as discussed in 
Chapter 4) often require highly alkaline conditions which are not suitable for use with the relatively 






















Fig. 8.3. Reagents and conditions: i)TMSBr, CH3CN, Rt ; ii) (COCl)2, DMF, DCM; iii) CF3CH2OH, NEt3, DCM; iv) 
NaH, THF, reflux.61 
The second approach (B) has seen much wider use as it avoids many of the issues associated with approach 
(A) such as cross-reactivity, harsh reaction conditions and extra steps. Tang et al.54 used relatively mild 
reaction conditions to synthesise a range of alkoxycarbonyloxymethyl prodrugs of phosphonomethylethyl 
adenine (PMEA) (Fig 8.4). They reacted a range of chloromethyl alkyl carbonates with the phosphonic acid 
of PMEA in the presence of a mild organic amine base such as triethylamine, to afford bis-protected 
prodrug derivatives of PMEA (Fig 8.4 1). Krecmerová et al.57 also reported a similar strategy whereby they 
reacted a tetrabutyl ammonium salt of a cyclic phosphonate monoester with pivaloylmethyl chloride 
(POMCl) in dioxane at 100°C to from a mono pivaloylmethyl cyclic phosphonate ester (Fig 8.4 2). Similarly 
Starrett et al.94 discussed the synthesis of bis(pivaloylmethyl) phosphonate esters using pivaloylmethyl 
chloride with a hindered base such as N,N-dicylohexylmorpholinecarboxamidine or triethylamine in DMF 
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(Fig 8.4 3). These examples, which in most cases use fairly standard alkylation conditions, formed the 












































































Fig. 8.4. Reagents and conditions: i) NEt3, N-methyl-2-pyrrolidinone, 80-60°C; ii) tetrabutylammonium 
hydroxide; iii) POMCl, dioxane, 100°C; iv) POMCl, N,N-dicylohexylmorpholinecarboxamidine or 
triethylamine, DMF, 100°C.54,57,94 
8.2 Synthesis of the ANP pivaloylmethyl prodrug, 34. 
The aim of this part of the project was to gain an understanding into some of the challenges involved in the 
synthesis of acyclic nucleotide prodrugs. The thymine derivative, 26, was chosen as the model to work on 
simply because it was an easy-to-handle solid and was in good supply as a product from earlier 
experiments. POMCl was chosen as the prodrug group as it was also readily accessible and its use is well 
published in the literature. Triethylamine was chosen as a base, since it was readily obtained and easy to 
use.  
The reaction was initially performed in DMF at 100°C over a period of 48hrs. Some conversion of starting 
material was observed by tlc but the presence of DMF made the reaction difficult to monitor and greatly 
hindered the isolation of the product. The product was found to thermally degrade in the heat required to 
remove the DMF, even under vacuum, and if an extraction was attempted directly, the DMF had a 
tendency to pull the product into the aqueous layer. Acetonitrile was then investigated as an alternative 
solvent as it was both polar and relatively volatile, making it easy to work with. After heating all the 
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reactants together in acetonitrile at reflux temperature, the reaction mixture became homogeneous after 
30 minutes. The reaction was allowed to stir for 48 hours at reflux, after which the only product, by tlc, was 
extracted and purified with chromatography to afford 34 as a white solid with a melting point range of 111-





































Fig. 8.5: Reagents and conditions: i) Pivaloylmethyl chloride (POMCl), NEt3, CH3CN, reflux, 48hrs, 75% 
The IR spectrum of 34, collected from an NaCl DCM solution cell, showed key absorptions at max 3384 cm
-1 
(N-H), 2965 cm-1 (C-H), 1754 cm-1 (C=O), 1708 cm-1 (C=O), 1689 cm-1 (C=O), 1239 cm-1 (P=O) and 967 cm-1 (P-
O). The 1H NMR spectrum (Fig 8.6) revealed the PME side chain signals at δH 3.88 (t, J = 4.6 Hz, 2H, C-3), δH 
3.85 (d, JHP = 7.7 Hz, 2H, C-1) and δH 3.79 (t, J = 4.6 Hz, 2H, C-2), while the thymine N-H, methyl and H-6’ 
could be seen at δH 9.09 (s, 1H, N-H), δH 1.89 (s, 3H, CH3) and δH 7.13 (s, 1H, H-6’) respectively. These 
assignments were made by analogy with the spectra of compounds 26 and 14. The resonances diagnostic 
for the attachment of the pivaloylmethyl groups were the t-butyl singlet at δH 1.21 (s, 18H, H-3’’) and the 
two doublet of doublets at δH 5.68 (dd, Jgem = 9.5, J HP = 5.1 Hz, 2H, H-1”) and δH 5.65 (dd, Jgem = 9.5, JHP = 5.1 
Hz, 2H, H-1”) for the two pairs of diastereotopic hydrogens at H-1”. Each of the H-1” resonances integrated 
for 2H and featured an H-H geminal coupling (J2= 9.5 Hz) as well as a smaller H-P coupling (J3= 5.1 Hz).  
The 13C NMR spectrum showed all the resonances for the PME side chain as well as the thymine ring at 
their expected chemical shifts. The 13C NMR spectrum also revealed the new POM diastereotopic tert-butyl 
groups as a singlet at δC 26.9 (C-3’’), the t-butyl quaternary carbon as a singlet at δC 38.8 (C(CH3)3) and the 
pivaloyl carbonyl carbon at δC 176.9 (C-2’’), while the resonance associated with the C-1’’ methylene carbon 
was observed as a P-C J3 coupled doublet at δC 81.8 (d, JCP = 6.1 Hz, C-1’’), providing further evidence for the 
attachment of the POM groups. Mass spectroscopy showed a peak at 493.1946 (M+ + H), which 





Fig. 8.6: The 1H NMR spectrum of 34. 
With the synthesis of 34 successfully completed, the synthesis of further POM protected derivatives was 
attempted using the pyrazole-3-carboxamide and triazole-3-carboxamide derivatives 30 and 32, which 
were chosen for their relevance to the project. The reactions with the two new starting materials were 
carried out under the same conditions as for 26 but they never became homogeneous and only a small 
amount of product formation was observed by tlc. The reactions were also attempted in DMF but this 
change had little effect. Finally, the use of caesium carbonate was also investigated in both DMF and 
CH3CN, as an alternative base to triethylamine, but this too failed to increase the amount of product 
formed. Unfortunately, this meant that the synthesis of the two POM protected derivatives of 30 and 32 









Results and discussion of the biological evaluations 
A selection of the compounds discussed above was sent to Prof Paolo La Colla at the Department of 
Virology, University of Cagliari in Italy for biological testing. Although the intracellular cleavage of the 
isopropyl ester has been shown to be slow, these derivatives were sent for testing regardless, in order 
ensure that no active compounds were missed in the screening process. The compounds shown below (Fig 
9.1) were tested against a range of RNA and retroviral infections, including: HIV, bovine viral diarrhoea virus 
(BVDV), yellow fever virus (YFV), Coxsackie B-5 virus (CBV), respiratory syncytial virus (RSV) and vesicular 
stomatitis virus (VSV), as well as the dsDNA viruses: herpes simplex virus-1 (HSV-1) and vaccinia virus (VV). 
Compounds 13, 14, 19, 20a, 20b, 25, 26, 30 and 31 were found to be non-cytotoxic and to posses no 
significant activity against the viruses tested (Table 9.1). Unfortunately at the time of printing this thesis, 
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Fig. 9.1: A diagram showing the compounds sent for biological evaluation.
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Table 9.1. Cytotoxicity and anti-viral activity of selected ANPs, and reference compounds, against representatives of ssRNA+ (HIV-1, BVDV, YFV, CBV-5, Sb-1), ssRNA- (RSV, VSV), 






BHK YFV Reo-1 
 






























               
20b >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
13 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
20a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
19 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
25 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
26 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
14 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
31 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
30 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
               
Reference 
Compounds 




36 >36 10 >10 >10 20 >20 >20 >20 >20 >20 >20 
2’-C-methyl-
guanosine 






 >100 55 50 >100 >100 >100 >100 











>100 >100 >100 >100 
6-Aza-uridine 0.3± 0.1 >0.3 >100 >100 >100 >100 >100 12.5 >12.5 >12.5 
1.4±0.2 
(9) 
>12.5 >12.5 >12.5 








               
° Data represent mean values + SD for three independent determinations. For values where SD is not shown, variation among duplicate samples was less than 15%.  
a Compound concentration (µM) required to reduce the proliferation of mock-infected MT-4 cells by 50%, as determined by the MTT method. 
b Compound concentration (µM  required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity, as determined by the MTT method. 
c Compound concentration (µM) required to reduce the viability of mock-infected MDBK cells by 50%, as determined by the MTT method. 




e Compound concentration (µM) required to reduce the viability of mock-infected BHK cells by 50%, as determined by the MTT method. 
f Compound concentration (µM) required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by the MTT method. 
g Compound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced cytopathogenicity, as determined by the MTT method. 
h Compound concentration (µM) required to reduce the viability of mock-infected Vero-76 cells by 50%. as determined by the MTT method. 
I Compound concentration (µM) required to reduce the plaque number of CVB-5 by 50% in Vero-76 monolayers. 
j Compound concentration (µM) required to reduce the plaque number of Sb-1 by 50% in Vero-76 monolayers. 
k Compound concentration (µM) required to reduce the plaque number of RSV by 50% in Vero-76 monolayers. 
l Compound concentration (µM) required to reduce the plaque number of VSV by 50% in Vero-76 monolayers. 
m Compound concentration (µM) required to reduce the plaque number of VV by 50% in Vero-76 monolayers. 
n Compound concentration (µM) required to reduce the plaque number of HSV-1 by 50% in Vero-76 monolayers. 




Conclusion and Future work 
A range of acyclic nucleotide phosphonates were synthesised and characterised based on a diisopropyl 
phosphonomethylethyl synthon. Amongst these derivatives was a series of ribavirin-based analogues which 
may show interesting biological properties due to their ability to act as “universal bases” through their 
possession of multiple hydrogen-bonding profiles.42 Acyclic nucleoside ribavirin-like analogues were 
previously explored by Beauchamp et al.,46 but to our knowledge no investigations have thus far been 
conducted on acyclic nucleotide phosphonate analogues of ribavirin.  
A Sonogashira palladium catalysed cross-coupling reaction was used to synthesise an arylethynyltriazole 
ANP derivative. Acyclic nucleoside arylethynyltriazole analogues have also been previously explored as 
potential anti-viral and anti-cancer agents by other authors,71,73,74 however, the inclusion of the 
phosphonate moiety into such drug candidates seems to be, to the best of our knowledge, novel to this 
work. Future work in this area may include the synthesis of additional arylethynyltriazole and aryltriazole 
ANP derivatives through the use of palladium mediated cross-coupling reactions, in order to further probe 
the mechanism of action of such compounds and increase their potency if they are found to be biologically 
active. 
Some of these products were then converted to their corresponding phosphonic acids through a TMSBr-
mediated phosphonic ester hydrolysis. In one example, a bis(pivaloyloxymethyl) prodrug variant was 
produced in order to probe a general synthesis which could be used to produce future prodrug derivatives 
of other interesting ANP analogues. Any future work featuring the compounds discussed in this thesis, as 
well as other future ANP derivatives should involve the formation of their phosphonic acids in order to 
maximize the possibility of intracellular phosphorylation to an active di-phosphate species. The synthesis of 
future prodrug derivatives is also of high importance as the presence of the prodrug moiety aids the drug 
molecule to cross the cell membrane, thus allowing it to enter the cell and elicit its activity, indirectly 
increasing its potency. 
Once the results of the biological activity studies have been released, conclusions and new hypotheses as to 
the structural activity relationships of the selected candidate molecules can be formed. Work may then 
begin on optimizing and improving the active structures, ultimately aiding in the discovery and 
























Experimental section  
 
General instrumentation used 
 
All starting materials were obtained from Sigma-Aldrich and all solvents were freshly distilled. 
 
Reactions were monitored by TLC using aluminium-backed Merck silica-gel 60 F245 plates and spots were 
observed using UV light (254 nm) as well as iodine vapour, a 2.5% mixture of anisaldehyde in ethanol and 
sulphuric acid (1:1) or a solution of potassium permanganate, potassium carbonate and sodium hydroxide 
in water. 
 
Nuclear Magnetic Resonance spectra were recorded on a Varian Mercury 300 MHz (75.5 MHz for 13C, 121 
MHz for 31P), Bruker 400 MHz (100.6 MHz for 13C, 162 MHz for 31P) or a Varian Unity 400 MHz (100.6 MHz 
for 13C, 162 MHz for 31P) machine and were carried out in chloroform-d unless otherwise stated. Chemical 
shifts (δ) were recorded relative to residual chloroform (δ 7.26 in 1H NMR and δ 77.16 in 13C NMR), acetone 
(δ 2.05 in 1H NMR and δ 29.84 in 13C NMR), methanol (δ 3.31 in 1H NMR and δ 49.00 in 13C NMR) and DMSO 
(δ 2.50 in 1H NMR and δ 39.52 in 13C NMR). All chemical shifts (δ) are reported in ppm and J values are 
reported in Hz. 
 
Mass spectra were recorded on a JEOL GCmatell in electron ionization mode. High resolution mass spectra 
were recorded on a VG70 SEQ micromass spectrometer electrospray positive mode. Infrared (IR) 
absorptions were measured on a Perkin Elmer Spectrum One FT-IR spectrometer in which peaks are 
reported in cm-¹. Melting points and decomposition temperatures were determined using a Reichert-Jung 












Diisopropyl hydrogen phosphonate77 (1) 
 
Isopropanol (5.26 ml, 68.8 mmol) was added dropwise to a stirring suspension of sodium hydride (60% 
mineral oil, 2.29 g, 57.30 mmol) in THF (40 ml) at 0°C and the resulting mixture was allowed to stir for 15 
minutes. Phosphorus trichloride (2.0 ml, 22.9 mmol) dissolved in THF (10 ml) was added dropwise to the 
vigorously stirring solution. The reaction mixture was then allowed to stir at room temperature for 1,5 
hours before being quenched with saturated ammonium chloride solution (10 ml) upon which the resulting 
mixture was transferred to a separating funnel containing ammonium chloride solution (40 ml). The 
product was then extracted with ethyl acetate (3 x 50 ml) and the pooled organic fractions were dried with 
magnesium sulphate and evaporated. The resulting residue was purified with column chromatography 
(ethyl acetate / hexane= 3:7) to afford 1 as a colourless oil (3.60 g, 95%). 
δH (400 MHz, CDCl3) 6.74 (d, JHP = 687.2 Hz, 1H, H-P=O), 4.64 (m, 2H, CH), 1.27 (d, J = 6.4 Hz, 6H, CH(CH3)2), 
1.26 (d, J = 6.4 Hz, 6H, CH(CH3)2); δp (162 MHz, CDCl3) 4.3.  
 
Diisopropyl hydroxymethyl phosphonate77 (2) 
 
A solution of paraformaldehyde (0.74 g, 24.8 mmol), potassium carbonate (0.27 g, 1.96 mmol) and 
diisopropyl hydrogen phosphonate 1 (3.26 g, 19.62 mmol) in Isopropanol (20 ml) was prepared. The 
mixture was then warmed to 60°C and allowed to stir for 2 hours. The mixture was then filtered through a 
pad of Celite, which was washed with ethyl acetate (20 ml). The solvent was then removed under reduced 
pressure to give 2 as a colourless oil (3.76 g, 98%), which was pure enough for use in the next step. 
δH (400 MHz, CDCl3) δ 4.69 (m, 2H, CH(CH3)2), 3.89 (br s, 1H, OH), 3.79 (d, JPH = 6.0 Hz, 2H, P-CH2), 1.30 (d, J 
= 6.0 Hz, 6H, CH(CH3)2), 1.28 (d, J = 6.0 Hz, 6H, CH(CH3)2); δP (162 MHz, CDCl3) δ 22.6. 
 
















Diisopropyl hydroxymethyl phosphonate 2 (1.22 g, 6.20 mmol) was dissolved in DCM (10 ml) with 
triethylamine (1.04 ml, 7.44 mmol). A solution of p-toluenesulfonyl chloride (1.42 g, 7.44 mmol) and 4-
Dimethylaminopyridine (0.038 g, 0.31 mmol) in DCM (10 ml) was prepared and added dropwise to the 
reaction mixture at 0°C. The reaction mixture was then allowed to warm to room temperature and left to 
stir for 2 hours, after which it was extracted with ethyl acetate (3 x 50 ml) from a saturated solution of 
ammonium chloride (30 ml). The pooled organic fractions were then dried with magnesium sulphate, 
evaporated under reduced pressure, and the resulting residue chromatographed (ethyl acetate: hexane = 
1:1) to yield 3 as a clear oil (1.57 g, 72 %). 
δH (300 MHz, CDCl3) 7.76 (d, J = 8.2 Hz, 2H, H-2), 7.33 (d, J = 8.2 Hz, 2H, H-3), 4.69 (m, 2H, CH(CH3)2), 4.09 (d, 
JPH = 10.1 Hz, 2H, P-CH2), 2.42 (s, 3H, ArCH3), 1.29 (d, J = 6.2 Hz, 6H, CH(CH3)2), 1.26 (d, J = 6.2 Hz, 6H, 
CH(CH3)2); δc (101 MHz, CDCl3) 145.5 (C-1) , 132.0 (C-4), 130.0 (C-3) , 128.3 (C-4), 72.4 (d, JPC = 6.6 Hz, 
CH(CH3)2), 62.09 (d, JPC = 170.2 Hz, P-CH2), 24.0 (d, JPC = 4.9 Hz, CH(CH3)2), 23.9 (d, J PC= 4.9 Hz, CH(CH3)2), 




A suspension of sodium hydride (60% mineral oil, 2.800 g, 70.40 mmol) in THF (20 ml) was added dropwise 
to a stirred solution of ethylene glycol (10.7 ml, 192 mmol) in THF (20 ml) at 0°C and the reaction mixture 
was left to stir at room temperature for 15 minutes. Benzyl bromide (7.6 ml, 64 mmol) was then slowly 
added to the reaction mixture which was allowed to reflux for 12 hours. Saturated ammonium chloride 
solution (20 ml) was then added to the resulting mixture, and the organic material was extracted with ethyl 
acetate (3 x 80 ml), which was washed once with distilled water (50 ml). The combined organic fractions 
were then dried with magnesium sulphate, the solvent removed under reduced pressure and the residue 
then purified by column chromatography (ethyl acetate/ Hexane= 1: 1) to afford 4 as a colourless oil (7.52 
g, 77 %). 
δH (400 MHz, CDCl3) 7.35 (m, 5H, Ph), 4.56 (s, 2H, PhCH2), 3.74 (t, J = 6.4, 6.4 Hz, 2H, CH2), 3.58 (t, J = 6.4, 6.4 









HCl gas, generated from the dropwise addition of concentrated sulphuric acid (98 %, 50 ml) to solid sodium 
chloride (10 g) in a sealed two-necked flask, was bubbled through a suspension of paraformaldehyde (8.740 
g, 291.0 mmol) and 2-chloroethanol (15.0 ml, 224 mmol) in DCM (30 ml) for 6 hours at 0°C. The reaction 
was then stored at 4°C in a refrigerator for 12 hours after which HCl gas was then bubbled through the 
mixture for a further 8 hours stored again at 4°C for 12 hours. The reaction mixture was then dried using 
CaCl2, filtered through a pad of Celite, and solvent was removed under reduced pressure to yield the crude 
product (9.49 g). The 1H NMR spectrum of the crude material revealed a starting material to product 
conversion of 75%. The product was then purified by distillation (bp 64°C at 20 mm Hg) to yield 5 as a 
colourless liquid (17.7 g, 61 %). 
δH (300 MHz, CDCl3) 5.52 (s, 2H, H-1), 3.95 (t, J = 5.6 Hz, 2H, H-2), 3.68 (t, J = 5.6 Hz, 2H, H-3); δc (101 MHz, 
CDCl3) δ 82.5 (C-1), 70.4 (C-2), 42.0 (C-3). 
 










Triisopropyl phosphite (29.4 ml, 119 mmol) was heated in a round-bottomed flask fitted with a Vigreux 
column, still-head and condenser. 1-Chloro-2-(chloromethoxy) ethane 5 (18.43 g, 143.0 mmol) was then 
added dropwise and the resulting 2-chloropropane was distilled off at atmospheric pressure. The reaction 
was then allowed to stir at 100°C for a further 4 hours, after which it was distilled under high vacuum (bp 
120°C, 0.1 mm Hg); [lit. 120oC/0.1 mm Hg]81 to yield 6 as a colourless liquid (25.52 g, 83 %). 
δH (300 MHz, CDCl3) 4.76 (dhept, JHP, HH = 7.7, 6.3 Hz, 2H, CH(CH3)2), 3.85 (t, J = 5.7 Hz, 2H, H-2), 3.79 (d, JPH = 
8.4 Hz, 2H, H-1), 3.63 (t, J = 5.7 Hz, 2H, H-3), 1.34 (2 x d, J = 6.3 Hz, 2 x 6H, 2 x CH(CH3)2); δc (101 MHz, CDCl3) 
73.2 (d, JPC = 10.6 Hz, C-2), 71.4 (d, JPC = 6.7 Hz, CH(CH3)2), 66.3 (d, JPC = 167.6 Hz, C-1), 42.5 (C-3), 24.3 (d, JPC 














A solution of sodium hydroxide (10M, 3.40 ml, 33.7 mmol) and methanol (10 ml) was prepared and cooled 
to -10°C using a methanol and ice bath, after which glycinamide (1.00 g, 13.5 mmol) in methanol (10 ml) 
was added to the solution. Glyoxal (40% in water, 2.94 g, 20.3 mmol) was added slowly to the solution, with 
stirring, while the temperature of the reaction was maintained at -10°C. The reaction mixture was allowed 
to stir at room temperature for 3 hours, after which an excess of acetic acid (10 ml) was added. The mixture 
was then evaporated to dryness under reduced pressure and the resulting solid residue was then 
exhaustively extracted with boiling acetone (4 x 100 ml). The acetone was removed under reduced pressure 
to afford 7 as a dark brown powder which was found to be pure enough for use in the next step. (0.50 g, 39 
%) 
Mp: 190-191°C [lit Mp: 187°C]; IR (KBr): max 3435 (O-H), 3085 (C-H ), 1650 (C=O), 1255 (C-N); δH (400 MHz, 
MeOD) 8.07 (d, J = 1.4 Hz, 1H, H-2), 7.44 (d, J = 4.1 Hz, 1H, H-4), 7.38 (dd, J = 4.1, 1.4 Hz, 1H, H-3); δC (101 












1H-1,2,4-triazole-3-carboxylic acid (500.0 mg, 4.42 mmol) was suspended in thionyl chloride (2.9 ml, 39.8 
mmol) and a catalytic amount of dimethylformamide (0.03 ml, 0.4 mmol, 10 mol %) was added. The 
reaction mixture was then refluxed under a nitrogen atmosphere for 3 hours to give a clear solution after 
which all the thionyl chloride was removed under reduced pressure to yield the reaction intermediate as a 
white powder. This was then warmed to 50°C in 25% aqueous ammonia (5 ml), after which the majority of 
the ammonia and water were removed under vacuum and the residue triturated with acetone, to initiate 
the precipitation of the final product (491 mg, 99 %), which was found to be pure enough for use in the 
next step. The final amide was recrystallised from water and methanol (1: 10) for analysis. 
Mp: 205°C (dec); IR (KBr): max 3327 (N-H), 3155 (N-H),2926 (C-H), 1715 (C=O), 1699 (C=O); δH (400 MHz, d6-
DMSO) 8.38 (s, 1H, H-5), 7.85 (s, 1H, NH2), 7.61 (s, 1H, NH2);
 δc (101 MHz, d6-DMSO) 160.3 (C=O), 147.7 (C-
3), 146.8 (C-5); HRMS (ES): m/z found 113.0448 (M+ + H), C3H5N4O requires 113.0463 (M












1H-Pyrazole-3-carboxylic acid (300.0 mg, 2.86 mmol) was suspended in a solution of methanol (5 ml) and 
concentrated sulphuric acid (0.28 ml, 5.35 mmol) and the mixture refluxed for 12 hours. The methanol was 
then removed and saturated sodium bicarbonate (ca. 10 ml) was added to bring the pH of the solution to 
above 7. The aqueous solution was extracted with ethyl acetate (3 x 30ml) and the pooled organic fractions 
were collected and dried with magnesium sulphate after which the solvent was removed under reduced 
pressure to afford pyrazole-3-carboxylic acid methyl ester. The latter was then warmed at 40°C in the 
presence of aqueous ammonia (5 ml) for 6 hours after which the excess ammonia and water were 
evaporated off under reduced pressure to afford 9 (256 mg, 86 %) as an off-white amorphous solid pure 
enough for use in the next step. 
Mp: 122-128°C; IR (KBr): max 3405 (N-H), 3266 (N-H), 2961 (C-H), 1699 (C=O), 1668 (C=O); δH (400 MHz, d6-
DMSO) 7.71 (d, J = 2.0 Hz, 1H, H-5’), 7.54 (s, 1H, N-H), 7.19 (s, 1H, N-H), 6.67 (d, J = 2.0 Hz, 1H, H-4’); δc (101 
MHz, d6-DMSO) 163.0 (C=O), 132.0 (C-5’), 107.2 (C-3’), 105.3 (C-4’); HRMS (ES): m/z found 112.0494 (M
+ + 
H), C4H6N3O requires 112.0511 (M











1H-Imidazol-3-carboxylic acid (300.0 mg, 2.86 mmol) was suspended in a solution of methanol (5 ml) and 
concentrated sulphuric acid (0.28 ml, 5.35 mmol) and the mixture refluxed for 12 hours. The methanol was 
then removed and saturated sodium bicarbonate (ca. 10 ml) was added to bring the pH of the solution 
above 7. The aqueous solution was extracted with ethyl acetate and the pooled organic fractions were 
collected and dried with magnesium sulphate after which the solvent was removed under reduced pressure 
to afford the imidazole-3-carboxylic acid methyl ester as an intermediate. The methyl ester was then 
warmed in the presence of aqueous ammonia (5 ml) for 6 hours after which the excess ammonia and water 
were removed under reduced pressure to afford the product 1H-imidazol-3-carboxamide (290 mg, 98 %) as 
an off-white amorphous solid pure enough for use in the next step. 
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Mp: 184-189; IR (KBr): max 3397 (N-H), 3172 (N-H), 2676 (C-H), 1655 (C=O), 1400; δH (400 MHz, d6-DMSO) 
7.70 (s, 1H, H-2), 7.61 (s, 1H, H-5), 7.39 (brs, 1H, N-H), 7.07 (brs, 1H, N-H); δc (101 MHz, d6-DMSO) 164.3 
(C=O), 137.9 (C-2), 136.4 (C-5), 121.6 (C-4); HRMS (ES): m/z found 112.0492 (M+ + H), C4H6N3O requires 
112.0511 (M+ + H). 
 








Methyl 5-amino-1H-1,2,4-triazole-3-carboxylate (500.0 mg, 3.52 mmol) was suspended in an aqueous 
solution of sulphuric acid (0.2 ml in 5 ml of water) at 0°C after which an aqueous solution of sodium nitrite 
(364.0 mg, 5.280 mmol) was add dropwise with constant stirring. After 30 minutes at 0°C an aqueous 
solution of potassium bromide (837 mg, 7.04 mmol) and copper iodide (33.5 mg, 0.176 mmol) was then 
added to the solution. The reaction solution was left to stir at room temperature for 3 hours after which it 
was extracted with ethyl acetate (4 x 30 ml). The organic fractions were then pooled, dried with magnesium 
sulphate and evaporated under reduced pressure. The remaining residue was then purified with column 
chromatography (MeOH: DCM = 4 : 96) to yield 11 as an off white solid, (541 mg; 75 %). 
Mp: 134-137 °C; IR (KBr): max 1741 (C=O), 1708, 1481, 1236; δH (400 MHz, d6-DMSO) 3.89 (s, 3H, CH3); δc 
(101 MHz, d6-DMSO) 157.4 (C=O), 52.7 (CH3); HRMS (EI): m/z found 204.9483 (M











Methyl 5-bromo-1H-1,2,4-triazole-3-carboxylate (125 mg, 0.607 mmol) was suspended in a solution of 
methanol (2 ml) and aqueous ammonia (25 %, 3 ml) and stirred for 12 hours at 40°C. The solvent was then 
removed by gentle warming under reduced pressure to yield 12 as an off white solid pure enough for use in 
the next step. (113 mg, 98 %) 
Mp: 175-180°C; IR (KBr): max 3374 (N-H), 3250 (N-H), 2924, 1686 (C=O), 1610, 1441, 1291;
 δH (400 MHz, d6-
DMSO) 8.25 (brs, 1H, N-H), 7.96 (brs, 1H, N-H); δc (101 MHz, d6-DMSO) 157.4 (C=O), 150.9 (C-1), 150.0 (C-2); 
HRMS (ES): m/z found 190.9568 (M+ + H), C3H4BrN4O requires 190.9568 (M
+ + H). 
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General procedure for the alkylation of a nucleotide heterocyclic base with diisopropyl (2-chloroethoxy) 
methylphosphonate.81 (GP1) 
 
The heterocyclic base and caesium carbonate were suspended in DMF (2-3ml) and diisopropyl(2-
chloroethoxy)methylphosphonate 6 was then added to the mixture. The mixture was allowed to stir for 12 
hours at 100 °C. The DMF was then removed under high vacuum and the remaining residue dissolved in a 
saturated sodium bicarbonate solution (20 ml) and extracted with a methanol/ chloroform mixture (1:3, 3 x 
20 ml). The organic phase was dried using magnesium sulphate and the solvent removed to give a residue 
which was chromatographed to afford the final purified product. 
 

















According to GP1: Uracil (78.0 mg, 0.67 mmol), caesium carbonate (113 mg, 0.35 mmol) and diisopropyl(2-
chloroethoxy)methylphosphonate 6 (200 mg, 0.77 mmol) in DMF. Chromatography (MeOH : DCM = 3 : 97) 
afforded 13 as a white solid (105 mg, 41%). 
Mp: 66-68°C; IR (CH2Cl2): max 3685, 3384 (N-H), 2977 (C-H), 1690 (C=O), 1269 (P=O), 994 (P-O); δH (400 
MHz, d6-acetone) 10.13 (s, 1H, H-3’), 7.55 (d, J = 7.9 Hz, 1H, H-6’), 5.53 (d, J = 7.9 Hz, 1H, H-5’), 4.68 (m, 2H, 
CH(CH3)2), 3.96 (t, J = 5.0 Hz, 2H, H-3), 3.84 (t, J = 5.0 Hz, 2H, H-2), 3.79 (d, JPH = 8.2 Hz, 2H, H-1), 1.29 (d, J = 
6.0 Hz, 6H, CH(CH3)2), 1.26 (d, J = 6.0 Hz, 6H, CH(CH3)2); δc (101 MHz, d6-acetone) 164.4 (C-2’), 151.9 (C-4’), 
146.9 (C-6’), 101.5 (C-5’), 71.4 (d, JPC = 10.4 Hz, C-2), 71.2 (d, JPC = 6.4 Hz, CH(CH3)2 ), 66.4 (d, JPC = 166.2 Hz, 
C-1), 48.5 (C-3), 24.3 (d, JPC = 4.2 Hz, CH(CH3)2), 24.3 (d, JPC = 4.2 Hz, CH(CH3)2); δp (162 MHz, d6-acetone) 
18.5; HRMS (ES): m/z found 335.1372 (M+ + H), C13H24N2O6P requires 335.1366 (M


























According to GP1: Thymine (195 mg, 1.55 mmol), caesium carbonate (252 mg, 0.77 mmol) and 
diisopropyl(2-chloroethoxy)methylphosphonate 6 (200 mg, 0.77 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 2 : 98) afforded 14 product as a white solid (120.0 mg, 45 %). 
Mp: 76-79°C; IR (CH2Cl2): max 3387 (N-H), 2982 (C-H), 1709 (C=O), 1688 (C=O), 1237 (P=O), 993 (P-O); δH 
(400 MHz, d6-acetone) 9.88 (s, 1H, H-3’), 7.40 (s, 1H, H-6’), 4.67 (m, 2H, CH(CH3)2), 3.92 (t, J = 4.9 Hz, 2H, H-
3), 3.82 (t, J = 4.9 Hz, 2H, H-2), 3.77 (d, JPH = 8.3 Hz, 2H, H-1), 1.82 (s, 3H, H-7’), 1.28 (d, J = 6.8 Hz, 6H, 
CH(CH3)2), 1.26 (d, J = 6.8 Hz, 6H, CH(CH3)2); δc (101 MHz, d6-acetone) 165.2 (C-2’), 152.0 (C-4’), 143.0 (C-6’), 
109.5 (C-5’), 71.5 (d, JPC = 6.1 Hz, CH(CH3)2), 71.4 (d, JPC = 10.1 Hz, C-2), 66.2 (d, JPC = 166.5 Hz, C-1), 48.3 (C-
3), 24.3 (d, JPC = 4.2 Hz, CH(CH3)2), 24.1 (d, JPC = 4.2 Hz, CH(CH3)2), 12.3 (C-7’); δp (162 MHz, d6-acetone) 18.4; 
HRMS (ES): m/z found 349.1523 (M+ + H), C14H26N2O6P requires 349.1523 (M
+ + H). 
 
















According to GP1: Cytosine (170 mg, 1.53 mmol), caesium carbonate (249 mg, 0.77 mmol) and 
diisopropyl(2-chloroethoxy)methylphosphonate 6 (495 mg, 1.91 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 4 : 96) afforded 15 as a yellow solid (167 mg, 66 %). 
Mp: 143-146°C [lit Mp: 151°C]; IR (CH2Cl2): max 3685, 3525 (N-H), 3409 (N-H), 2983 (C-H), 1655 (C=O), 1249 
(P=O), 993 (P-O); δH (400 MHz, d6-acetone) 7.52 (d, J = 7.2 Hz, 1H, H-6’), 6.49 (s, 2H, NH2), 5.75 (d, J = 7.2 Hz, 
1H, H-5’), 4.66 (m, 2H, CH(CH3)2), 3.91 (t, J = 5.1 Hz, 2H, H-3), 3.80 (t, J = 5.1 Hz, 2H, H-2), 3.75 (d, JPH = 8.4 
Hz, 2H, H-1), 1.28 (d, J = 6.3 Hz, 6H, CH(CH3)2 ), 1.25 (d, J = 6.3 Hz, 6H, CH(CH3)2); δC (101 MHz, d6-acetone) 
166.5 (C-2’), 146.8 (C-6’), 145.7 (C-4’), 92.4 (C-5’), 70.7 (d, JPC = 11.0 Hz, C-2), 70.1 (d, JPC = 6.4 Hz, CH(CH3)2), 
65.4 (d, JPC = 166.6 Hz, C-1), 48.8 (C-3), 23.3 (d, JPC = 4.2 Hz, CH(CH3)2), 23.2 (d, JPC = 4.2 Hz, CH(CH3)2); δP 
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(121 MHz, d6-acetone) 24.1; HRMS (ES): m/z found 334.1531 (M




Diisopropyl (2-(2-oxopyrazin-1(2H)-yl)ethoxy)methylphosphonate (16a) 




























According to GP1: 2-Hydroxypyrazine (100 mg, 1.04 mmol), caesium carbonate (339 mg, 1.04 mmol) and 
diisopropyl (2-chloroethoxy)methylphosphonate 6 (296.0 mg, 1.15 mmol) in DMF. Chromatography (MeOH 
: DCM = 2 : 98) gave 16a (71 mg, 21 %) and 16b (155 mg, 47 %) as clear yellow oils. 
16a) IR (CH2Cl2): max 3682, 2978 (C-H), 1662 (C=O), 1237 (P=O), 995 (P-O); δH (400 MHz, CDCl3) 8.12 (d, J = 
1.1 Hz, 1H, H-3’), 7.27 (d, J = 4.4 Hz, 1H, H-6’), 7.25 (dd, J = 4.4, 1.1 Hz, 1H, H-5’), 4.68 (m, 2H, CH(CH3)2), 
4.09 (t, J = 4.8 Hz, 2H, H-3), 3.86 (t, J = 4.8 Hz, 2H, H-2), 3.69 (d, JPH = 8.4 Hz, 2H, H-1), 1.29 (d, J = 6.2 Hz, 6H, 
CH(CH3)2), 1.26 (d, J = 6.2 Hz, 6H, CH(CH3)2); δc (101 MHz, CDCl3) 156.3 (C-2’), 149.4 (C-3’), 130.2 (C-6’), 123.5 
(C-5’), 71.3 (d, JPC = 6.7 Hz, CH(CH3)2), 70.3 (d, JPC= 11.0 Hz, C-2), 66.2 (d, JPC = 168.5 Hz, C-1), 49.1 (C-3), 24.2 
(d, JPC = 4.0 Hz, CH(CH3)2), 24.1 (d, JPC = 4.0 Hz, CH(CH3)2); δp (162 MHz, CDCl3) 18.43; HRMS (ES): m/z found 
319.1417 (M+ + H), C13H24N2O5P requires 319.1419 (M
+ + H). 
16b) IR (CH2Cl2): max 3682, 3427, 2978 (C-H), 1248 (P=O), 1007 (P-O); δH (400 MHz, d6-acetone) 8.22 (d, J = 
1.4 Hz, 1H, H-3’), 8.15 (d, J = 2.8 Hz, 1H, H-6’), 8.13 (dd, J = 2.8, 1.4 Hz, 1H, H-5’), 4.70 (m, 2H, CH(CH3)2), 
4.52 (t, J = 4.8 Hz, 2H, H-3), 3.97 (t, J = 4.8 Hz, 2H, H-2), 3.81 (d, JPH = 8.2 Hz, 2H, H-1), 1.29 (d, J = 4.3 Hz, 6H, 
CH(CH3)2), 1.27 (d, J = 4.2 Hz, 6H, CH(CH3)2); δc (101 MHz, CDCl3) 160.1 (C-2’), 140.5 (C-3’), 136.9 (C-6’), 136.2 
(C-5’), 71.3 (d, JPC = 7.1 Hz, C-2), 71.2 (d, JPC = 4.4 Hz, CH(CH3)2)), 66.3 (d, JPC = 167.3 Hz, C-1), 65.2 (C-3), 24.2 
(d, JPC = 4.4 Hz, CH(CH3)2), 24.1 (d, J = 4.4 Hz, CH(CH3)2); δp (162 MHz, CDCl3) 18.9; HRMS (ES): m/z found 
319.1417 (M+ + H), C13H24N2O5P requires 319.1419 (M
+ + H).  
 

















According to GP1: 2, 4-Diaminopyrimidine (94.0 mg, 0.85 mmol), caesium carbonate (126 mg, 0.39 mmol) 
and diisopropyl (2-chloroethoxy)methylphosphonate 6 (100 mg, 0.39 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 6 : 94) gave 17 as a yellow oil (51 mg, 40 %). 
IR (CH2Cl2): max 3685, 3522 (N-H), 3409 (N-H), 2989 (C-H), 1599, 1236 (P=O), 994 (P-O); δH (400 MHz, d6-
acetone) 7.66 (d, J = 5.9 Hz, 1H, H-6’), 6.40 (s, 1H, NH), 5.84 (d, J = 5.9 Hz, 1H, H-5’), 5.56 (s, 2H, NH2), 4.69 
(m, 2H, CH(CH3)2), 3.77 (d, JPH = 8.0 Hz, 2H, H-1), 3.74 (t, J = 5.5 Hz, 2H, H-2), 3.52 (q, J = 5.5 Hz, 2H, H-3), 
1.29 (d, J = 6.0 Hz, 6H, CH(CH3)2), 1.27 (d, J = 6.0 Hz, 6H, CH(CH3)2); δc (101 MHz, d6-acetone) 164.3 (C-2’), 
164.1 (C-4’), 155.6 (C-6’), 96.6 (C-5’), 72.5 (d, JPC = 9.9 Hz, C-2), 71.3 (d, JPC = 6.4 Hz, CH(CH3)2), 66.4 (d, JPC = 
166.6 Hz, C-1), 40.9 (C-3), 24.4 (d, JPC = 4.0 Hz, CH(CH3)2), 24.3 (d, JPC = 4.0 Hz, CH(CH3)2); δp (162 MHz, d6-
acetone) δ 19.2; HRMS (ES): m/z found 333.1697 (M+ + H), C13H26N4O4P requires 333.1686 (M
+ + H). 
 
















According to GP1: 2-Aminopyrimidine-4-carbonitrile (102 mg, 0.85 mmol), caesium carbonate (126 mg, 
0.39 mmol) and diisopropyl(2-chloroethoxy)methylphosphonate 6 (100.0 mg, 0.39 mmol) were reacted in 
DMF. Chromatography (hexane: ethyl acetate = 2 : 8) gave 18 as a yellow oil (84 mg, 64 %). 
IR (CH2Cl2): max 3435 (N-H), 2883 (C-H), 2246 (C≡N), 1580, 1235 (P=O), 992 (P-O); δH (400 MHz, CDCl3) 8.41 
(d, J = 5.0 Hz, 1H, H-6’), 6.80 (d, J = 5.0 Hz, 1H, H-5’), 6.07 (s, 1H, NH), 4.76 (m, 2H, CH(CH3)2), 3.81 – 3.71 (m, 
4H, H-1, H-2), 3.63 (q, J = 5.3 Hz, 2H, H-3), 1.34 (d, J = 5.4 Hz, 6H, CH(CH3)2), 1.31 (d, J = 5.4 Hz, 6H, 
CH(CH3)2); δc (101 MHz, CD3OD) δ 163.9 (C-2’), 161.6 (C-6’), 159.6 (C-4’), 117.1 (C≡N), 113.9 (C-7’), 73.2 (d, 
JPC = 6.7 Hz, CH(CH3)2 ), 72.8 (d, JPC = 12.1 Hz, C-2), 66.2 (d, JPC = 168.0 Hz, C-1), 41.7 (C-3), 24.3 (d, JPC = 4.0 
Hz, CH(CH3)2), 24.2 (d, JPC = 4.0 Hz, CH(CH3)2); δp (121 MHz, Acetone) 24.7; HRMS (ES): m/z found 343.1527 
(M+ + H), C14H24N4O4P requires 343.1530 (M





















According to GP1: Triazole (111.0 mg, 1.61 mmol), caesium carbonate (525.0 mg, 1.61 mmol) and 
diisopropyl(2-chloroethoxy)methylphosphonate 6 (500.0 mg, 1.93 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 1 : 99) afforded 19 as a clear oil (273 mg, 58 %). 
IR (CH2Cl2): max 3686, 2979 (C-H), 1241 (P=O), 994 (P-O); δH (300 MHz, d6-acetone) 8.36 (s, 1H, H-4’), 7.84 
(s, 1H, H-3’), 4.64 (m, 2H, CH(CH3)2), 4.43 (t, J = 6.8 Hz, 2H, H-3), 3.99 (t, J = 6.8 Hz, 2H, H-2), 3.75 (d, JPH = 8.7 
Hz, 2H, H-1), 1.27 (d, J = 6.1 Hz, 6H, CH(CH3)2), 1.23 (d, J = 6.1 Hz, 6H, CH(CH3)2); δC (101 MHz, CDCl3) 151.9 
(C-4’), 144.1 (C-3’), 71.3 (d, JPC = 6.8 Hz, CH(CH3)2), 70.8 (d, JPC = 10.0 Hz, C-2), 66.4 (d, JPC = 167.9 Hz, C-1), 
49.8 (C-3), 24.1 (d, JPC = 4.9 Hz, CH(CH3)2), 24.1 (d, JPC = 4.9 Hz, CH(CH3)2);
 δP (162 MHz, CDCl3) 18.1; HRMS 
(ES): m/z found 292.1417 (M+ + H), C11H23N3O4P requires 292.1421 (M
+ + H). 
 
Diisopropyl (2-(1H-1,2,4-triazol-1-yl-3-carboxamide)ethoxy)methylphosphonate (20a) 




























According to GP1: 1H-1,2,4-triazole-3-carboxamide (100 mg, 0.89 mmol), caesium carbonate (291 mg, 0.89 
mmol) and diisopropyl(2-chloroethoxy)methylphosphonate 6 (256 mg, 0.99 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 2 : 98) afforded 20a (80 mg, 24 %) and 20b (150 mg, 45 %) as clear oils. 
20a) IR (CH2Cl2): max 3516 (N-H), 3398 (N-H), 2935 (C-H), 1704 (C=O), 1236 (P=O), 994 (P-O); δH
 (400 MHz, 
d6-acetone) 8.51 (s, 1H, H-5’), 7.40 (s, 1H, NH2), 6.95 (s, 1H, NH2), 4.62 (m, 2H, CH(CH3)2), 4.52 (t, J = 4.0 Hz, 
2H, H-3), 4.04 (t, J = 4.0 Hz, 2H, H-2), 3.80 (d, JPH = 8.3 Hz, 2H, H-1), 1.26 (d, J = 6.2 Hz, 6H, CH(CH3)2), 1.22 (d, 
J = 6.2 Hz, 6H, CH(CH3)2); δC (101 MHz, d6-acetone) 161.5 (C=O), 158.0 (C-3’), 146.2 (C-5’), 71.3 (d, JPH = 6.4 
Hz, CH(CH3)2), 71.2 (d, JPH = 10.8 Hz, C-2), 66.3 (d, JPH = 166.4 Hz, C-1), 50.6 (C-3), 24.3 (d, JPH = 3.7 Hz, 
CH(CH3)2), 24.2 (d, JPH = 4.5 Hz, CH(CH3)2); δP (162 MHz, d6-acetone) δ 18.4; HRMS (ES): m/z found 335.1474 
(M+ + H), C12H24N4O5P requires 335.1479 (M
+ + H). 
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20b) IR (CH2Cl2): max 3512 (N-H), 3393 (N-H), 2932 (C-H), 1704 (C=O), 1239 (P=O), 994 (P-O); δH (400 MHz, 
d6-acetone) 7.92 (s, 1H, H-5’), 7.67 (s, 1H, NH2), 7.20 (s, 1H, NH2), 4.90 (t, J = 5.5 Hz, 2H, H-3), 4.63 (m, 2H, 
CH(CH3)2), 4.03 (t, J = 5.5 Hz, 2H, H-2), 3.74 (d, JPH = 8.3 Hz, 2H, H-1), 1.25 (d, J = 6.2 Hz, 6H, CH(CH3)2), 1.22 
(d, J = 6.2 Hz, 6H, CH(CH3)2); δC (101 MHz, d6-acetone) 159.8 (C=O), 150.4 (C-5’), 147.7 (C-3’), 71.7 (d, JPC = 
11.2 Hz, C-2), 71.2 (d, JPC = 6.4 Hz, CH(CH3)2), 66.2 (d, JPC = 166.0 Hz, C-1), 50.4 (C-3), 24.3 (d, JPC = 3.7 Hz, 
CH(CH3)2), 24.2 (d, JPC = 3.7 Hz, CH(CH3)2); δP (162 MHz, d6-acetone) 18.1; HRMS (ES): m/z found 335.1479 
(M+ + H), C12H24N4O5P requires 335.1479 (M
+ + H). 
 
Diisopropyl (2-(1H-pyrazol-1-yl-3-carboxamide)ethoxy)methylphosphonate (21) 
 
 
According to GP1: 1H-pyrazole-3-carboxamide (256 mg, 2.30 mmol), caesium carbonate (751 mg, 2.30 
mmol) and diisopropyl (2-chloroethoxy)methylphosphonate 6 (662 mg, 2.56 mmol) in DMF. 
Chromatography (MeOH : DCM = 3 : 97) gave 21 as a clear oil (360.0 mg, 42 %). In spite of repeated 
chromatography, 21 could not be separated from a co-eluting product, which from the NMR data was 
believed to be a regioisomer. 
IR (CH2Cl2): max 3685, 3519 (N-H), 3402 (N-H), 2979 (C-H), 1686 (C=O), 1239 (P=O), 993 (P-O); δH (400 MHz, 
CDCl3) 7.50 (d, J = 2.4 Hz, 1H, H-5’), 6.79 (s, 1H, NH2), 6.76 (d, J = 2.4 Hz, 1H, H-4’), 5.79 (s, 1H, NH2), 4.63 (m, 
2H, CH(CH3)2), 4.30 (t, J = 4.8 Hz, 2H, H-3), 3.95 (t, J = 4.8 Hz, 2H, H-2), 3.68 (d, JPH = 8.3 Hz, 2H, H-1), 1.28 (d, 
J = 6.2 Hz, 6H, CH(CH3)2), 1.24 (d, J = 6.2 Hz, 6H, CH(CH3)2); δC (101 MHz, CDCl3) 164.1 (C=O), 146.4 (C-3’), 
132.1 (C-5’), 107.1 (C-4’), 71.5 (d, JPC = 10.1 Hz, C-2), 71.3 (d, JPC = 6.7 Hz, CH(CH3)2), 66.4 (d, JPC = 168.0 Hz, 
C-1), 52.7 (C-3), 24.2 (d, JPC = 3.7 Hz, CH(CH3)2), 24.1 (d, JPC = 4.5 Hz, CH(CH3)2); δC (162 MHz, CDCl3) 18.2; 
HRMS (ES): m/z found 334.1533 (M+ + H), C13H25N3O5P requires 334.1526 (M



































According to GP1: 1H-imidazole-4-carboxamide (290 mg, 2.61 mmol), caesium carbonate (850 mg, 2.61 
mmol) and diisopropyl(2-chloroethoxy)methylphosphonate 6 (750 mg, 2.90 mmol) were reacted in DMF. 
Chromatography (MeOH : DCM = 5: 95) gave 22 as a white solid (405 mg, 42 %). 
Mp: 92-96°C; IR (CH2Cl2): max 3518 (N-H), 3399 (N-H), 2979 (C-H), 1678 (C=O), 1584, 1236 (P=O), 993 (P-O); 
δH (400 MHz, Acetone) 7.69 (s, 1H, H-5’), 7.64 (s, 1H, H-2’), 7.14 (s, 1H, N-H), 6.56 (s, 1H, N-H), 4.65 (m, 2H, 
CH(CH3)2), 4.30 (t, J = 5.2 Hz, 2H, H-3), 3.94 (t, J = 5.2 Hz, 2H, H-2), 3.79 (d, JPH = 8.3 Hz, 2H, H-1), 1.27 (d, J = 
6.2 Hz, 6H, CH(CH3)2), 1.24 (d, J = 6.2 Hz, 6H, CH(CH3)2); δc (101 MHz, CDCl3) 165.1 (C=O), 138.4 (C-5’), 138.0 
(C-4’), 123.4 (C-2’), 72.7 (d, JPC = 10.6 Hz, C-2), 71.3 (d, JPC = 6.4 Hz, CH(CH3)2), 66.4 (d, JPC = 166.3 Hz, C-1), 
47.7 (C-3), 24.3 (d, JPC = 3.7 Hz, CH(CH3)2), 24.2 (d, JPC = 3.7 Hz, CH(CH3)2); δP (162 MHz, CDCl3) 23.5; HRMS 
(ES): m/z found 334.1525 (M+ + H), C13H25N3O5P requires 334.1526 (M
+ + H). 
 














According to GP1: 5-bromo-1H-1,2,4-triazole-3-carboxamide (12) (87 mg, 0.46 mmol), caesium carbonate 
(223 mg, 0.687 mmol) and diisopropyl (2-chloroethoxy)methylphosphonate 6 (177 mg, 0.687 mmol) were 
reacted in DMF at 100°C for 48 hours. Chromatography (ethyl acetate) afforded 23 as a clear oil (123 mg, 
65 %). 
IR (CH2Cl2): max 3508 (N-H), 3390 (N-H), 1708 (C=O), 1582, 1456, 1284 (P=O), 999 (P-O); δH (400 MHz, CDCl3) 
7.27 (s, 1H, N-H), 6.54 (s, 1H, N-H), 4.83 (t, J = 5.4 Hz, 2H, H-3), 4.65 (m, 2H, CH(CH3)2), 3.98 (t, J = 5.4 Hz, 2H, 
H-2), 3.71 (d, JPH = 8.3 Hz, 2H, H-1), 1.26 (d, J = 6.2 Hz, 6H, CH(CH3)2), 1.23 (d, J = 6.2 Hz, 6H, CH(CH3)2); δc 
(101 MHz, CDCl3) 157.8 (C=O), 147.8 (C-5’), 138.1 (C-3’), 71.4 (d, JPC = 6.6 Hz, CH(CH3)2), 70.6 (d, JPC = 10.8 
Hz, C-2), 65.8 (d, JPC = 167.4 Hz, C-1), 50.5 (C-3), 24.1 (d, JPC = 4.0 Hz, CH(CH3)2), 24.0 (d, JPC = 4.0 Hz, 
CH(CH3)2); δP (162 MHz, CDCl3) 18.4; HRMS (ES): m/z found 413.0577 (M
+ + H), C12H23BrN4O5P requires 



























A solution of dioxane and water (3 ml, 3 : 1) was thoroughly degassed by bubbling argon gas through it for 
30 minutes in a microwave reaction vessel to which was added 23 (60 mg, 0.15 mmol), lithium carbonate 
(22 mg, 0.29 mmol) and 1-ethynyl-4-fluorobenzene (35 mg, 0.29 mmol). The reaction vessel was then 
purged with argon, after which copper iodide (14 mg, 0.074 mmol) and tetrakis(triphenylphosphine) 
palladium(0) (17 mg, 0.015 mg), which were weighed out under argon, were then added. The reaction 
mixture was again purged with argon, sealed and then irradiated in a microwave reactor (100 °C, 150 W), 
with stirring, for 30 minutes. After the reaction mixture had cooled, 5% aqueous disodium 
ethylenediaminetetraacetate (EDTA) (10 ml) was added and the aqueous solution was then extracted with 
ethyl acetate (3 x 20 ml) and washed with water (10ml), after which the combined organic fractions were 
dried with magnesium sulphate and evaporated under reduced pressure. The resulting residue was then 
chromatographed (ethyl acetate) to afford 24 as a yellow oil (54 mg, 82 %). 
IR (CH2Cl2): max 3684, 3508 (N-H), 3390 (N-H), 2978, 2231 (C≡C), 1705 (C=O), 1234 (P=O), 994 (P-O); δH (400 
MHz, CDCl3) 7.56 (dd, JHH; HF = 8.4, 5.3 Hz, 2H, H-4’’), 7.27 (s, 1H, N-H), 7.05 (dd, JHH; HF = 8.4, 8.4 Hz, 2H, H-
5’’), 6.14 (s, 1H, N-H), 4.90 (t, J = 5.4 Hz, 2H, H-3), 4.68 (m, 2H, CH(CH3)2), 4.04 (t, J = 5.4 Hz, 2H, H-2), 3.74 
(d, JHP = 8.3 Hz, 2H, H-1), 1.29 (d, J = 6.2 Hz, 6H, CH(CH3)2), 1.27 (d, J = 6.2 Hz, 6H, CH(CH3)2); δC (101 MHz, 
CDCl3) 163.4 (d, JCF = 251.6 Hz, C-6’’), 158.3 (C=O), 146.5 (C-3’), 146.1 (C-5’), 134.3 (d, JCF = 8.6 Hz, C-4’’), 
117.5 (d, JCF = 3.4 Hz, C-3’’), 116.0 (d, JCF = 22.3 Hz, C-5’’), 89.1 (C-2’’), 79.3 (C-1’’), 71.4 (d, JCP = 6.6 Hz, 
CH(CH3)2), 70.9 (d, JCP = 10.6 Hz, C-2), 65.9 (d, JCP = 167.2 Hz, C-1), 50.6 (C-3), 24.2 (d, JCP = 3.7 Hz, CH(CH3)2 ), 
24.1 (d, JCP = 4.5 Hz, CH(CH3)2); δP (162 MHz, CDCl3) 18.4; HRMS (ES): m/z found 453.1712 (M
+ + H), 
C20H27FN4O5P requires 453.1703 (M
























The protected nucleotide 13 (200.0 mg, 0.60 mmol) was dissolved in DCM (4 ml) in a two-necked flask 
under nitrogen. Trimethylsilyl bromide (0.24 ml, 1.8 mmol) was then added dropwise at 0°C and the 
solution was stirred at room temperature for 12 hours. The reaction was monitored by TLC using water, 
acetic acid, 1-butanol and acetone (1:1:1:1). After the reaction reached completion, water (0.1 ml) was 
added and the reaction was stirred at room temperature for 10 minutes, before removing all solvents 
under vacuum in which residual water was removed azeotropically using toluene. The resulting oil was then 
taken up in a minimum volume of hot methanol and a small quantity of DCM was then added to the 
solution. The solution was allowed to cool to room temperature, resulting in 25 precipitating as a fine white 
powder (126.0 mg, 84 %). 
Mp: 206-208°C; IR (KBr): max 3397 (O-H), 3116 (N-H), 1701 (C=O), 1474, 1250 (P=O), 1013 (P-O); δH (400 
MHz, CD3OD) 7.58 (d, J = 7.9 Hz, 1H, H-6’), 5.61 (d, J = 7.9 Hz, 1H, H-5’), 3.96 (t, J = 4.9 Hz, 2H, H-3), 3.80 (t, J 
= 4.9 Hz, 2H, H-2), 3.74 (d, J = 8.8 Hz, 2H, H-1); δC (101 MHz, CD3OD) 167.3 (C-2’), 153.3 (C-4’), 148.7 (C-6’), 
102.3 (C-5’), 72.3 (d, JPC = 11.6 Hz, C-2), 67.8 (d, J = 163.9 Hz, C-1), 49.6 (C-3); δP (162 MHz, CD3OD) 18.5; 
HRMS (ES): m/z found 251.0423 (M+ + H), C7H12N2O6P requires 251.0427 (M
+ + H). 
 



















The protected nucleotide 14 (300 mg, 0.86 mmol) was dissolved in DCM (4 ml) in a two-necked flask under 
nitrogen. Trimethylsilyl bromide (0.34 ml, 2.58 mmol) was then added drop-wise at 0°C and the solution 
was stirred at room temperature for 12 hours. The reaction was monitored by TLC using water: acetic acid: 
1-butanol and acetone (1:1:1:1). After the reaction reached completion, water (0.1 ml) was added and the 
reaction was stirred at room temperature for 10 minutes, before removing all solvents under vacuum in 
which residual water was removed azeotropically using toluene. The resulting oil was then taken up in a 
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minimum volume of hot methanol and a small quantity of DCM was then added to the solution, which on 
cooling, resulting in the precipitation of 26 as a fine white powder (189.0 mg, 83 %). 
Mp: 179-181°C; IR (KBr): max 3489 (O-H), 2939 (C-H), 1684 (C=O), 1667 (C=O), 1246 (P=O), 1032 (P-O); δH 
(400 MHz, CD3OD) 7.43 (s, 1H, H-6’), 3.93 (t, J = 5.0 Hz, 2H, H-3), 3.79 (t, J = 5.0 Hz, 2H, H-2), 3.74 (d, JPH = 
8.9 Hz, 2H, H-1), 1.86 (s, 3H, H-7’); δC (101 MHz, CD3OD) 167.0 (C-2’), 153.0 (C-4’), 144.1 (C-6’), 110.6 (C-5’), 
71.9 (d, JPC = 11.7 Hz, C-2), 67.2 (d, JPC = 163.4 Hz, C-1), 48.8 (C-3), 12.1 (C-7’); δP (162 MHz, CD3OD) 18.9; 
HRMS (ES): m/z found 265.0581 (M+ + H), C8H14N2O6P requires 265.0584 (M
+ + H). 
 
General procedure for the de-alkylation of a diisopropyl protected acyclic nucleotide phosphonate 
derivative with trimethylsilyl bromide.92 (GP2) 
The diisopropyl protected acyclic nucleotide phosphonate was dissolved in DCM (3-4 ml) in a two-necked 
flask under nitrogen. An excess of trimethylsilyl bromide (3-6 eq) was then added drop-wise at 0°C and the 
solution was stirred at room temperature for 12 hours. After TLC (water: acetic acid: 1-butanol and acetone 
(1:1:1:1)) had shown the complete conversion of starting material to product, methanol was added to the 
reaction mixture and all the solvent was removed under reduced pressure and mild heating (ca 60°C), after 
which this process was repeated three times. The highly polar product was then extracted into distilled 
water (3 x20 ml) from DCM (1 x 30 ml) after which the inorganic fractions were evaporated under reduced 
pressure to yield the pure phosphonic acid as an amorphous solid or thick oil. 
 

















According to GP2: The protected nucleotide 15 (50 mg, 0.15 mmol) and TMSBr (0.1 ml, 0.771 mmol) 
reacted in DCM for 12 hours to afford 27 as an amorphous solid (34 mg, 91 %). 
Mp: 164-166°C [lit Mp: 167-168°C]; IR (KBr): max 3483 (O-H), 3313 (N-H), 2306 (C-H), 1684 (C=O), 1660 (N-H 
bend), 1250 (P=O), 998 (P-O); δH (400 MHz, CD3OD) 7.93 (d, J = 7.6 Hz, 1H, H-6’), 6.04 (d, J = 7.6 Hz, 1H, H-
5’), 4.07 (t, J = 5.2 Hz, 2H, H-3), 3.84 (t, J = 5.2 Hz, 2H, H-2), 3.75 (d, JPH = 8.7 Hz, 2H, H-1); δC (101 MHz, 
CD3OD) 161.6 (C-2’), 152.3 (C-6’), 149.1 (C-4’), 93.8 (C-5’), 71.0 (d, JPC = 11.2 Hz, C-2), 67.3 (d, JPC = 163.9 Hz, 
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C-1), 50.3 (C-3); δP (162 MHz, CD3OD) 18.63; HRMS (ES): m/z found 250.0581 (M
+ + H), C7H13N3O5P requires 
250.0587 (M+ + H). 
 
















According to GP2: The protected nucleotide 17 (85.0 mg, 0.256 mmol) and TMSBr (0.2 ml, 1.5 mmol) 
reacted in DCM for 12 hours to afford 28 as a dark yellow oil (59 mg, 93 %). 
IR (ATR): max 3361 (O-H), 3087 (N-H stretch), 3023 (N-H stretch), 1670 (N-H bend), 1659 (N-H bend), 1222 
(P=O), 1076 (P-O); δH (400 MHz, CD3OD) 7.56 (d, J = 7.3 Hz, 1H, H-6’), 6.13 (d, J = 7.3 Hz, 1H, H-5’), 3.78 (d, 
JPH = 8.4 Hz, 2H, H-1), 3.76 (t, J = 4.9 Hz, 2H, H-2), 3.68 (t, J = 4.9 Hz, 2H, H-3); δC (101 MHz, CD3OD) 164.7 (C-
2’), 156.9 (C-4’), 141.0 (C-6’), 99.6 (C-5’), 72.0 (d, JPC = 11.9 Hz, C-2), 67.2 (d, JPC = 163.7 Hz, C-1), 41.6 (C-3); 
δP (162 MHz, CD3OD) δ 20.4; HRMS (ES): m/z found 249.0745 (M



















According to GP2: The protected nucleotide 19 (195 mg, 0.669 mmol) and TMSBr (0.4 ml, 3 mmol) in DCM 
for 12 hours to afford 29 as a brown oil (137 mg, 99 %). 
IR (ATR): max 3349 (O-H), 2825 (C-H), 1242 (P=O), 992 (P-O); δH (400 MHz, CD3OD) 9.82 (s, 1H, H-4’), 8.90 (s, 
1H, H-3’), 4.70 (t, J = 4.9 Hz, 2H, H-3), 4.08 (t, J = 4.9 Hz, 2H, H-2), 3.81 (d, JPH = 8.8 Hz, 2H, H-1); δC (101 
MHz, CD3OD) 144.8 (C-4’), 143.2 (C-3’), 70.4 (d, JPC = 11.5 Hz, C-2), 67.1 (d, JPC = 163.0 Hz, C-1), 53.1 (C-3); δP 
(162 MHz, CD3OD) 18.6; HRMS (ES): m/z found 208.0479 (M
+ + H), C5H11N3O4P requires 208.0482 (M




















According to GP2: The protected nucleotide 20a (100 mg, 0.299 mmol) and TMSBr (0.15 ml, 1.2 mmol) 
reacted in DCM for 12 hours to afford 30 as a thick oil of fair purity (73 mg, 98 %). 
IR (ATR): max 3337 (N-H), 3112 (N-H), 2984 (C-H), 1703 (C=O), 1240 (P=O), 993 (P-O); δH (400 MHz, CD3OD) 
9.28 (s, 1H, H-5’), 4.64 (t, J = 4.9 Hz, 2H, H-3 ), 4.06 (t, J = 4.9 Hz, 1H, H-2), 3.81 (d, JPH = 8.8 Hz, 1H, H-1); δC 
(101 MHz, CD3OD) δ 160.4 (C=O), 153.7 (C-3’), 146.6 (C-5’), 70.9 (d, JPC = 11.5 Hz, C-2), 67.0 (d, JPC = 163.3 
Hz, C-1), 52.5 (C-3); δP (162 MHz, CD3OD) δ 18.9; HRMS (ES): m/z found 251.0535 (M
+ + H), C6H12N4O5P 
requires 251.0540 (M+ + H). 
 















According to GP2: The protected nucleotide 20b (60.0 mg, 0.179 mmol) and TMSBr (0.1 ml, 0.77 mmol) in 
DCM for 12 hours to afford 31 as a thick brown oil (40 mg, 89 %). 
IR (ATR): max 3376 (N-H), 3123 (N-H), 1688 (C=O), 1249 (P=O), 995 (P-O); δH (400 MHz, CD3OD) 8.25 (s, 1H, 
H-5’), 4.88 (t, J = 5.3 Hz, 2H, H-3), 4.04 (t, J = 5.3 Hz, 2H, H-2), 3.78 (d, JPH = 8.7 Hz, 2H, H-1); δC (101 MHz, 
CD3OD) 159.6 (C=O), 149.3 (C-5’), 147.7 (C-3’), 72.0 (d, JPC = 11.7 Hz, C-2), 66.8 (d, JPC = 163.4 Hz, C-1), 51.4 
(C-3); δP (162 MHz, CD3OD) 19.5; HRMS (ES): m/z found 251.0534 (M
+ + H), C6H12N4O5P requires 251.0540 




















According to GP2: The protected nucleotide 21 (163.0 mg, 0.488 mmol) and TMSBr (0.2 ml, 1.5 mmol) in 
DCM for 12 hours to afford 32 as a thick oil of fair purity (118 mg, 97 %). 
IR (ATR): max 3688 (O-H), 2952 (C-H), 1732 (C=O), 1248 (P=O), 997 (P-O); δH (400 MHz, CD3OD) 7.79 (d, J = 
2.3 Hz, 1H, H-5’), 6.77 (d, J = 2.3 Hz, 1H, H-4’), 4.42 (t, J = 4.9 Hz, 2H, C-3), 3.96 (t, J = 4.9 Hz, 2H, C-2), 3.73 
(d, JPH = 8.9 Hz, 2H, C-1); δC (101 MHz, MeOD) δ 167.0 (C=O), 146.5 (C-3’), 133.8 (C-5’), 107.6 (C-4’), 72.6 (d, 
JPC = 12.0 Hz, C-2), 67.2 (d, JPC = 163.7 Hz, C-1), 53.5 (C-3); δP (162 MHz, MeOD) δ 19.10; HRMS (ES): m/z 
found 250.0587 (M+ + H), C7H13N3O5P requires 250.0587 (M
+ + H). 
 
















According to GP2: The protected nucleotide 22 (306.0 mg, 0.916 mmol) and TMSBr (0.5 ml, 3.9 mmol) in 
DCM for 12 hours afforded 33 as a thick oil (216 mg, 94 %). 
IR (ATR): max 3325 (N-H), 3131 (N-H), 2917 (C-H), 1680 (C=O), 1232 (P=O), 997 (P-O); δH (400 MHz, CD3OD) 
9.09 (s, 1H, H-2’), 8.25 (s, 1H, H-5’), 4.55 (t, J = 4.8 Hz, 2H, H-3), 4.02 (t, J = 4.8 Hz, 2H, H-2), 3.83 (d, JPH = 8.8 
Hz, 2H, C-2); δC (101 MHz, CD3OD) 160.2 (C=O), 138.4 (C-4’), 129.2 (C-2’), 124.7 (C-5’), 71.6 (d, JPC = 11.7 Hz, 
C-2), 67.2 (d, JPC = 163.5 Hz, C-1), 51.0 (C-3); δP (162 MHz, CD3OD) 18.7; HRMS (ES): m/z found 250.0591 (M
+ 
+ H), C7H13N3O5P requires 250.0587 (M


































A solution of 26 (18 mg, 0.068 mmol), triethylamine (26 mg, 0.20 mmol), and pivaloyloxymethylchloride 
(103 mg, 0.681 mmol) was dissolved in acetonitrile (3 ml) and refluxed for 72 hours. The solvent was 
removed under reduced pressure and the remaining residue was dissolved in ethyl acetate (10 ml) and 
washed with a saturated solution of ammonium chloride (10 ml). The compound was further extracted with 
ethyl acetate (3 X 10 ml) after which the pooled organic fractions were dried with magnesium sulphate and 
evaporated. The crude product residue was then chromatographed (ethyl acetate) to afford 34 as white 
solid (25 mg, 75 %). 
Mp: 111-114°C; IR (CH2Cl2): max 3384 (N-H), 2965 (C-H), 1754 (C=O), 1708 (C=O), 1689 (C=O), 1239 (P=O), 
967 (P-O); δH (400 MHz, CDCl3) 9.09 (s, 1H, N-H), 7.13 (s, 1H, H-6’), 5.68 (dd, Jgem = 9.5, J HP = 5.1 Hz, 2H, H-
1”), 5.65 (dd, Jgem = 9.5, JHP = 5.1 Hz, 2H, H-1”), 3.88 (t, J = 4.6 Hz, 2H, C-3), 3.85 (d, JHP = 7.7 Hz, 2H, C-1), 3.79 
(t, J = 4.6 Hz, 2H, C-2), 1.89 (s, 3H, CH3), 1.21 (s, 18H, H-3’’); δc (101 MHz, CDCl3) 176.9 (C-2’’), 164.4 (C-2’), 
151.1 (C-4’), 141.8 (C-6’), 110.3 (C-5’), 81.8 (d, JCP = 6.1 Hz, C-1’’), 71.5 (d, J = 9.8 Hz, C-2), 65.7 (d, J = 166.3 
Hz, C-1), 48.1 (C-3), 38.8 (C(CH3)3), 26.9 (C-3’’), 12.2 (CH3); δP (162 MHz, CDCl3) 20.6; HRMS (ES): m/z found 
493.1946 (M+ + H), C20H34N2O10P requires 493.1951 (M
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